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Abstract
Treatments for dry age-related macular degeneration and
Stargardt disease: a systematic review
Norman Waugh,1* Emma Loveman,2 Jill Colquitt,2 Pamela Royle,1
Jian Lee Yeong,3 Geraldine Hoad4 and Noemi Lois3,5
1Division of Health Sciences, University of Warwick, Coventry, UK
2Effective Evidence, Waterlooville, UK
3Ophthalmology, Royal Victoria Hospital, Belfast, UK
4Macular Society, Andover, UK
5Wellcome-Wolfson Centre for Experimental Medicine, Queens University, Belfast, UK
*Corresponding author Norman.Waugh@warwick.ac.uk
Background: Age-related macular degeneration (AMD) is the leading cause of visual loss in older people.
Advanced AMD takes two forms, neovascular (wet) and atrophic (dry). Stargardt disease (STGD) is the
commonest form of inherited macular dystrophy.
Objective: To carry out a systematic review of treatments for dry AMD and STGD, and to identify
emerging treatments where future NIHR research might be commissioned.
Design: Systematic review.
Methods: We searched MEDLINE, EMBASE, Web of Science and The Cochrane Library from 2005 to
13 July 2017 for reviews, journal articles and meeting abstracts. We looked for studies of interventions
that aim to preserve or restore vision in people with dry AMD or STGD. The most important outcomes are
those that matter to patients: visual acuity (VA), contrast sensitivity, reading speed, ability to drive, adverse
effects of treatment, quality of life, progression of disease and patient preference. However, visual loss
is a late event and intermediate predictors of future decline were accepted if there was good evidence
that they are strong predictors of subsequent visual outcomes. These include changes detectable by
investigation, but not necessarily noticed by people with AMD or STGD. ClinicalTrials.gov, the World
Health Organization search portal and the UK Clinical Trials gateway were searched for ongoing and
recently completed clinical trials.
Results: The titles and abstracts of 7948 articles were screened for inclusion. The full text of 398 articles
were obtained for further screening and checking of references and 112 articles were included in the final
report. Overall, there were disappointingly few good-quality studies (including of sufficient size and duration)
reporting useful outcomes, particularly in STGD. However we did identify a number of promising research
topics, including drug treatments, stem cells, new forms of laser treatment, and implantable intraocular lens
telescopes. In many cases, research is already under way, funded by industry or governments.
Limitations: In AMD, the main limitation came from the poor quality of much of the evidence. Many
studies used VA as their main outcome despite not having sufficient duration to observe changes. The
evidence on treatments for STGD is sparse. Most studies tested interventions with no comparison group,
were far too short term, and the quality of some studies was poor.
Future work: We think that the topics on which the Health Technology Assessment (HTA) and Efficacy
Mechanism and Evaluation (EME) programmes might consider commissioning primary research are in
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STGD, a HTA trial of fenretinide (ReVision Therapeutics, San Diego, CA, USA), a visual cycle inhibitor, and
EME research into the value of lutein and zeaxanthin supplements, using short-term measures of retinal
function. In AMD, we suggest trials of fenretinide and of a potent statin. There is epidemiological evidence
from the USA that the drug, levodopa, used for treating Parkinson’s disease, may reduce the incidence of
AMD. We suggest that similar research should be carried out using the large general practice databases in
the UK. Ideally, future research should be at earlier stages in both diseases, before vision is impaired, using
sensitive measures of macular function. This may require early detection of AMD by screening.
Study registration: This study is registered as PROSPERO CRD42016038708.
Funding: The National Institute for Health Research HTA programme.
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Plain English summary
The macula is the most sensitive part of the eye, responsible for detailed vision such as for reading.Age-related macular degeneration (AMD) is the most common cause of visual loss in older people.
There are two forms of AMD: ‘wet’ and ‘dry’. This report looks only at dry AMD.
The commonest cause of macular damage in young people is Stargardt disease (STGD). There have been
no effective treatments for dry AMD or STGD, although progression in AMD can be slowed by taking
the nutritional supplement used in the Age-Related Eye Disease Study (AREDS) 2 trial, containing lutein,
zeaxanthin, vitamins and zinc.
Our aim was to review all the evidence on treatments for dry AMD and STGD in order to identify treatments
that look most promising for research by the UK National Institute for Health Research (NIHR) programmes.
We reviewed all the relevant research studies. The quality of the studies was very variable. We noted that
some claims for treatments with no good evidence to support them.
There are some promising treatments for dry AMD including stem cell transplantation, new laser treatments
and drugs. Research is under way on some of these, so we think that the NIHR might wish to prioritise
drugs such as atorvastatin, fenretinide and levodopa.
For STGD, we think that the NIHR might wish to consider a trial of fenretinide to reduce damage to the
macula and a pilot study of the nutritional supplements, lutein and zeaxanthin, to see if they protect
the macula.
It could be useful for research studies to look for changes earlier in the diseases before vision is affected.
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Scientific summary
Introduction
Age-related macular degeneration (AMD) is a progressive degenerative disease of the retina, in which the
macula is most affected. It is the commonest cause of blindness in the UK. It affects mainly older people.
Advanced AMD takes two forms, wet and dry, both of which can lead to visual loss. Wet AMD, also called
exudative or neovascular age-related macular degeneration (nAMD), is characterised by the development
of abnormal new vessels [choroidal neovascularisation (CNV)]. Dry AMD refers to the progressive demise of
retinal pigment epithelium (RPE) and photoreceptor cells (visual cells) of the retina resulting in geographic
atrophy (GA). This report is concerned only with dry AMD, including progression to wet AMD, but not
treatment of wet AMD or previously treated inactive wet AMD.
The first signs of AMD are the accumulation of yellowish deposits in the retina, called drusen. AMD goes
through various stages, called early, intermediate and advanced. Advanced dry AMD is characterised by
atrophy of the central retina (the macula) – it wastes away and patches of the retina and vision are lost.
The central most detailed vision is lost, making it difficult to drive, read or recognise faces.
Stargardt disease (STGD) is a recessively inherited disease, wherein a defective gene has to be inherited
from both parents. The disease is caused by mutations in the ABCA4 gene, but different mutations are
involved, and the age at onset varies according to the mutations, from childhood to adulthood. It affects
mainly young people, often starting in late teens or early 20s. Older age at onset is associated with slower
progression. STGD appears to be the commonest inherited retinal dystrophy.
There were two aims for this review. The first was to provide an up-to-date systematic review of treatments
for dry AMD and STGD. The second aim was to identify treatments that were sufficiently promising for the
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) and Efficacy Mechanism
and Evaluation (EME) programmes to consider commissioning primary research.
Methods
We carried out a systematic review of treatments for dry AMD and STGD, using the standard search and review
methods, looking first for systematic reviews and randomised trials, but with no restriction on study design
because we were aware from scoping searches that many treatments were reported only by observational
studies. We searched MEDLINE, EMBASE, Web of Science and The Cochrane Library from 2005 to 13 July 2017
for reviews, journal articles and meeting abstracts. Searches were limited to English language. The Association
for Research in Vision and Ophthalmology (ARVO) website was also searched for meeting abstracts.
References of reviews were checked for relevant studies. ClinicalTrials.gov, the World Health Organization
search portal and UK Clinical Trials gateway were searched for ongoing and recently completed clinical trials.
The methodological quality of the included studies was assessed using criteria based on those recommended
by the Cochrane Collaboration and US National Institutes of Health.
The titles and abstracts of 7948 articles were screened by two reviewers and checked by a third. The full
texts of 398 articles were obtained for further screening and checking of references, and 112 articles were
included in the final report.
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Principal findings: age-related macular degeneration
Physical treatments
Newer forms of laser treatment show promise but a large trial, the Laser Intervention in Early Stages of
Age-Related Macular Degeneration (LEAD) trial, from a world centre of excellence in Melbourne, VIC,
Australia, is ongoing (anticipated completion date June 2018), so we suggest waiting for their results.
Implantable telescopic lenses also show promise, but a NIHR EME study is under way (Efficacy of the
Telescopic Mirror Implant for Age-related Macular Degeneration: The MIRROR Trial) in advanced AMD.
There is insufficient good-quality evidence to recommend the use of, or further research in, acupuncture,
microcurrent stimulation or treatment with ozone.
There is some evidence on rheopheresis but the largest trial showed no benefit; most studies reporting
positive results were small with only modest effect sizes and mostly uncertain risks of bias, and treatment
would be inconvenient to older people. Therefore, we do not see rheopheresis as a research priority.
The evidence for the use of blue-light-filtering intraocular lenses after cataract extraction is currently
insufficient to justify their routine use, but further research is under way.
Cell therapies
Two very small case series of cell transplantation were identified. Improvements in visual acuity (VA) were
found in over half of treated eyes. The evidence base is still very sparse, but this seems a promising
development and further research is under way.
Drug treatments
We think there is sufficient evidence to justify a trial of a potent statin, such as atorvastatin 80 mg daily.
Fenretinide (ReVision Therapeutics, San Diego, CA, USA) is a visual cycle inhibitor that may reduce the
deposition of lipofuscin. One trial, with an unclear risk of bias, and written up by the manufacturer’s staff
as a ‘proof of concept’ study, had mixed results. Progression of GA was little different overall, but was less
in the subgroup that responded best to the drug. Progression to wet AMD was halved by fenretinide.
There were higher rates of adverse events with fenretinide. Overall, we think a trial in early dry AMD to
slow progression might be considered.
An impressively large retrospective study from the USA found that people taking levodopa (L-dopa) were
less likely to develop AMD, and that if they did develop it, it was about 7 years later than among people
not taking L-dopa. Further research is needed, perhaps using one of the large UK general practice-based
databases, in order to assess whether a trial assessing its use in treating AMD could be justified.
Large trials of lampalizumab are under way (sponsored by the manufacturer), so no new research is
indicated in the meantime.
There is a little evidence of benefit from glatarimer acetate, but with only some shrinkage of drusen in two
studies that had unclear risks of bias. The evidence is too sparse to justify NIHR research at present.
One small study reported benefit from oral prednisolone but it scored poorly on quality assessment so
there is insufficient evidence to justify its use. If steroids were to be used, a localised one would seem
better. The results of a trial of an implanted steroid, fluocinolone (Alimera Sciences, Alpharetta, GA, USA),
are awaited (NCT00695318).
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For nine drugs, there was some evidence showing no or very little benefit, or even harm, so we do not
recommend further consideration. They are alprostadil, eculizumab, dorzolomide, OT 551 eye drops,
sirolimus, tandospirone, trimetazidine, visaline and emixustat (Acucela, Seattle, WA, USA).
Nutrients
There are many studies of nutritional supplements but some had too few participants, were of poor
quality, were of too short duration or were of combinations of compounds, making it difficult to assess
the relative contributions of each. Supplements used include lutein and zeaxanthin, in combination or
individually, or combined with a variety of other minerals and/or vitamins: omega-3 fatty acids, folic acid,
various vitamins, ginkgo biloba, curcumin (from turmeric), saffron and zinc. The first AREDS trial showed
the benefit of supplements in patients with intermediate or advanced AMD, which persisted for 7 years,
with a modest but useful slowing of progression. It could mean that 30% of people expected to progress
to advanced AMD over a 5-year period would not. The trial did not have enough power to confirm, or not
confirm, effects in the earliest stages. The AREDS 2 trial showed that beta-carotene should be replaced
by lutein and zeaxanthin, and that the dose of zinc could be reduced. We therefore think that there is
already good evidence that the AREDS 2 supplement should be used for patients meeting the AREDS 3
and 4 categories.
Saffron extracts have been reported to show some benefits in VA and might justify further research.
There is currently insufficient evidence to recommend any other nutritional supplements.
Principal findings: Stargardt disease
At present, the most promising treatments for STGD appear to be:
l Prevention of lipofuscin accumulation. Several drugs may have potential, including fenretinide,
deuterated vitamin A (ALK-001; Alkeus Pharmaceuticals, Boston, MA, USA) and emixustat. Early trials
of ALK-001 and emixustat are under way. Fenretinide has shown promise in dry AMD and we think a
trial in STGD may be justified. A vignette has been written for the HTA programme.
l Gene therapy is at an early stage, but a study (StarGen NCT01736592) is under way in Oregon
and Paris.
l Cell transplantation to replace the RPE has been tried in one small study in only nine people with
STGD, but looks promising. Further research is under way.
There are three other possible interventions that seem worth further research. One is light reduction with
glasses or contact lenses, as reported in one very small trial in which progression in the light-protected eye
was reported to be less in four out of the five participants. Second, there is a plausible rationale for the
benefits of lutein and zeaxanthin supplementation to protect the macula (perhaps especially the fovea)
but insufficient evidence.
The evidence for the third comes, so far, only from animal work, in which fenofibrate appears to have
some activity as a visual cycle inhibitor. Fenofibrate is an old, cheap and safe drug used for lipid-lowering,
but is currently being trialled in diabetic retinopathy, in which it has shown some benefit in past studies.
Limitations: age-related macular degeneration
The main limitation came from the poor quality of much of the evidence. Many studies were of too
short duration. Many studies used VA as their main outcome despite not having sufficient duration to
observe changes.
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Limitations: Stargardt disease
The evidence on treatments for STGD is sparse. Most studies tested interventions with no comparison
group, were far too short term and the quality of some studies was poor. There has been very little
research into the treatment of STGD compared with AMD.
Outcomes in future research
Visual acuity is often preserved until a late stage in patients with AMD and in those with late-onset STGD.
We would like to see interventions at earlier stages, when people may have few symptoms, as it is likely that
treatment at earlier stages would be more effective. Research at earlier stages of AMD may require earlier
identification, for example by optometrists at annual eye examinations. The most important outcomes are
those that matter to patients: distant and near VA, contrast sensitivity, reading speed, ability to drive,
adverse effects of treatment, health-related quality of life, progression of disease and patient preference.
Central visual loss is a late event, especially in atrophic AMD, and predictors and early biomarkers of future
central visual loss, such as macular sensitivity, should be sought for use in clinical trials if there is good
evidence that they are strong predictors of subsequent visual outcomes. These will include changes
detectable by investigation, such as by microperimetry, but not necessarily by people with AMD. These
biomarkers might make it feasible to reduce the length of follow-up, and possibly sample sizes, in clinical
trials, and might speed to discovery of new treatments.
One possibility is dark adaptation, which may be an early sign of developing AMD. Several studies have
reported that dark adaptation may be impaired in AMD before best corrected VA is affected.
So another recommendation is for research into predictors of later visual outcomes which can be used in
trials of early interventions, starting with a systematic review of predictors and biomarkers, and then
longitudinal population-based cohort studies.
Conclusions
Taking into account the considerable amount of research that has been done or is under way, we suggest
that, in AMD, the NIHR programmes should consider:
l a trial of a potent statin
l a trial of fenretinide.
In STGD, we suggest:
l a trial of fenretinide
l a proof of concept trial of lutein and zeaxanthin supplements.
We also suggest that there should be an epidemiological study into the relationship between treatment
with L-dopa (for Parkinson’s disease) and the incidence of AMD. This may be more within the remit of
the MRC.
Study registration
This study is registered as PROSPERO CRD42016038708.
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Chapter 1 Introduction to age-related macular
degeneration
Age-related macular degeneration (AMD) is a progressive degenerative disease of the retina in whichthe macula is most affected.1 It is the commonest cause of blindness in the UK and it affects mainly
older people.
Age-related macular degeneration goes through various stages, called early, intermediate and advanced.
The first signs are yellowish deposits in the retina called drusen. Then abnormalities in the colour of the
retina develop: paler areas called hypopigmentation, and darker areas with hyperpigmentation. Advanced
AMD takes two forms, wet and dry, both of which lead to visual loss. Advanced dry AMD is characterised
by atrophy of the retina – it wastes away and patches of retina and vision are lost. Because the patches
were thought to resemble countries on a map, it became called ‘geographic atrophy’ (GA). The central
most detailed vision is lost, making it difficult to drive, read or recognise faces.
Wet AMD, also called exudative AMD, is characterised by the development of abnormal new vessels [choroidal
neovascularisation (CNV) and retinal angiomatous proliferation (RAP)]. It is now treated with drugs that inhibit
a compound called vascular endothelial growth factor (VEGF), so they are called ‘anti-VEGF drugs’. They
include bevacizumab (Avastin, Roche), ranibizumab (Lucentis, Novartis, Basel, Switzerland) and aflibercept
(Eylea, Bayer). The AMD sections of this report are concerned with treatments for only dry AMD, at all stages,
from prevention of early changes progressing to advanced AMD, both dry and wet, and treatment of advanced
dry AMD. As part of the background, we also look at some epidemiological studies of risk factors for AMD.
Prevalence
The prevalence of AMD increases with age.2 Owen and colleagues3 reported an overall prevalence of
advanced AMD in 2007–9 of 2.4% in the over 50s rising to 12.2% in the over 80s. The estimated number
of people with advanced AMD in the UK was 513,000, about 2.4% of the population aged ≥ 50 years,
with just over half (1.3%) having dry AMD. In the UK, there are about 2.6 million people with early AMD.
The Bridlington Eye Assessment Project (BEAP) showed that 38% of those aged > 65 years have no sign
of AMD, 54% have early AMD, 2.8% have intermediate AMD and 4.5% have advanced AMD. The
prevalence of advanced AMD rises with age, from 2.1% in those aged 65–70 years, to 7.5% in those
aged 80–85 years, and 16% in those aged > 85 years.4 Visual acuity (VA) is often maintained at 6/9 or
better in most eyes before the development of GA. AMD is by far the commonest cause of blind and
partial sight certifications in the UK, accounting for about 59%.5
We have an ageing population with more people living longer; therefore, more people will live to develop
AMD. They may otherwise be fit with a good quality of life, and so visual loss may have a dramatic effect
in their remaining years.
We need to distinguish rates and numbers. The most recent meta-analysis of the prevalence of AMD in
Europe, by Colijn and colleagues6 from the EYE-RISK consortium and the European Eye Epidemiology (E3)
consortium, concludes that the prevalence of advanced AMD is now declining, perhaps because of
healthier lifestyles. However, the number of people with any AMD will almost double.
Impact
Age-related macular degeneration causes central visual loss leading to gaps on items on which the eye
naturally focuses, such as words on pages, bus numbers, faces and television. Vision becomes distorted,
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colours can fade and adaptation to dark can be impaired. Driving may become impossible. Visual
impairment increases the risk of falls and injuries and can lead to depression and social isolation. Getting
out and about safely, for example to go shopping, may become difficult. Independent living may become
impossible. Sight loss is a leading cause of suicide among older people.7
Age-related macular degeneration reduces quality of life. Brown and colleagues8 assessed the quality of life
among patients with mild [VA of 20/20 to 20/40 in the better-seeing eye (BSE)], moderate (VA 20/50 to
20/100 in BSE), severe (≤ 20/200) and very severe AMD (≤ 20/800). They used the time trade-off method,
which asks how much of remaining life would be given up in return for perfect vision.
Patients scored their quality of life as:
l 0.83 with mild AMD (similar to having moderate angina)
l 0.68 with moderate AMD (similar to life following a moderate stroke, or having AIDS)
l 0.47 with severe AMD (similar to end-stage renal failure on dialysis)
l 0.40 with very severe AMD – a 60% loss of quality of life (similar to being bedridden after a major
stroke or advanced prostate cancer with intractable pain).
Aetiology
The causes of AMD are not known. Risk factors include age, genetic predisposition, exposure to light,
race, smoking, overweight and obesity, and diet.9–11 High fat diets and obesity increase the risk, whereas
antioxidant nutrients protect. In the Danish Inter99 study, Munch et al.12 found that among people aged
30–60 years, macular drusen of > 63 µm was associated with physical inactivity, higher waist measurements
(in men) and higher serum triglycerides (in women).
Chakravarthy and colleagues13 carried out a systematic review of risk factors for AMD, drawing on
18 cohort and six case–control studies. They found that cigarette smoking and a family history of AMD
showed strong associations, and that there were moderate but consistent associations with risk factors
for cardiovascular disease such as higher BMI, hypertension and higher plasma fibrinogen.
Smoking greatly increases the risk of AMD. The European Eye Study14 reported that current smokers
had 2.6 times the risk of wet AMD and 4.8 times the risk of advanced dry AMD (GA) as opposed to
non-smokers. The Melbourne Collaborative Cohort Study15 looked at patterns of diet, and found that diets
rich in fruits, vegetables, chicken and nuts and low in red meat were associated with a lower prevalence
of advanced AMD. Interestingly, they divided foods by method of cooking and noted that steamed fish
conferred a lower risk than fried fish, probably reflecting broader dietary patterns. An earlier paper from
the same study16 had reported that high red meat and processed red meat intake increased the risk of
AMD, but that higher chicken intake reduced it. A third paper17 reported that higher trans-unsaturated fat
intake was associated with increased prevalence of late AMD. Higher olive oil intake (> 100 ml/week) was
associated with an odds ratio (OR) of 0.48 [95% confidence interval (CI) 0.22 to 1.04] compared with an
intake of < 1 ml/week.
In a recent review, Zhu and colleagues18 provide a high-quality review of fish consumption and the incidence
of AMD, with a meta-analysis of eight prospective cohort studies from the USA (n = 4), Australia (n = 2),
Ireland (n = 1) and the Netherlands (n = 1). Some of the studies adjusted for a wide range of confounding
variables, others for only a few. The incidence was reduced by 24% overall (OR 0.76, 95% CI 0.65 to 0.90,
I2 = 50%; but heterogeneity in effect size not direction). Fish consumption is not clearly defined in the review
but a diagram of the dose–response relationship shows that the reduction in OR increases with frequency,
with once a week consumption reducing the risk by only 11% (RR 0.89, 95% CI 0.83 to 0.96). However,
after an increase to three times a week, the relative risk (RR) plateaus at the 0.76 level.
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High intake of dietary salt has also been suggested as a contributory cause.19 This could be mediated
through its effect on blood pressure. The Complications of Age-related Macular Degeneration Prevention
Trial (CAPT) research group reported that, compared with people who had normal blood pressure, those
with definite hypertension (defined as a systolic blood pressure of ≥ 160, diastolic blood pressure of ≥ 95,
or on treatment) had 1.55 times the risk of wet AMD and 1.86 times the risk of GA.20
Low-dose aspirin (100 mg on alternate days) taken for 10 years had no significant effect compared with
placebo, with the hazard ratio (HR) for developing new AMD of 0.82 (95% CI 0.64 to 1.06).21 Heavy
alcohol consumption (more than three standard drinks per day) was reported by Chong et al.22 to increase
the risk of early AMD.
The prevalence varies among ethnicities, with the frequency of late AMD highest in white people, and
lowest in Africans.10 This is partly due to varying genetic susceptibilities.
The presence of some genes increases susceptibility, particularly the complement factor H (CFH) gene, which
is linked to the complement pathway, part of the immune system, and the Age-Related Maculopathy
Susceptibility Gene 2 (ARMS2). These two genes are involved in > 60% of cases of advanced AMD.10
Conversely, some genes such as some variants of the apolipoprotein E gene, which regulates lipid and
cholesterol transport in the central nervous system, appear to be protective. The mechanism underlying the
protection may be via better transport of cholesterol and other metabolites out of the cells in the retinal
pigment epithelium (RPE).
The structure of the eye
The sclera
The outer layer of the eyeball is the sclera, which forms part of the supporting wall of the eye. It is the
‘white of the eye’ and it surrounds most of the eye. However at the front of the eye, it is replaced by the
cornea, which is transparent and allows light through.
The choroid
Inside the sclera, the next layer at the back of the eye is the choroid, which is the vascular layer of the eye,
composed of blood vessels and connective tissue. There are sublayers within the choroid, including the
choriocapillaris and Bruch’s membrane. The choriocapillaris consists of the capillaries that provide oxygen
and nutrients to the retina.
Bruch’s membrane
Bruch’s membrane is the innermost part of the choroid, in contact with the retina. The innermost part of
Bruch’s membrane is formed by the basement membrane of the RPE, which transmits waste products of
metabolism from the photoreceptors (PRs) in the retina into the blood vessels in the choroid. The RPE and
the choroid provide nourishment to the retinal PR cells.
Bruch’s membrane gets thicker with age, and this slows the transport of metabolites. With ageing, lipids
accumulate in Bruch’s membrane. The conduction of fluids (hydraulic conductivity – the ability to let fluids
pass) through the membrane is reduced.23,24 It is thought that oxidative change in the lipids may trigger an
inflammatory process, including activation of complement. Reduced transport of nutrients into the retina
and reduced transport of waste products of metabolism out of it may trigger a release of VEGF in an
attempt to provide more blood supply, and this may lead to the development of abnormal new blood
vessels in wet AMD. The RPE has a symbiotic relationship with the choriocapillaris; if the RPE is lost, then
the choriocapillaris closes down. This is believed to be the result of reduced production of VEGF by the RPE.
There is a large variation in thickening of Bruch’s membrane with age. Lommatzsch et al.23 suggest that half
of the thickening is due to natural ageing and half is due to other factors, such as genetic susceptibility and
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environmental factors. In early AMD, there is thickening of Bruch’s membrane due to lipid and protein
deposits (drusen).25
The retinal pigment epithelium
The RPE lies between Bruch’s membrane and the PRs. Boulton and Dayhaw-Barker26 provide a good
review of its functions, which include transport of ions, fluid and metabolites; support for the visual cycle;
clearance of debris; protection against light and free radicals; and production of growth factors. The RPE
changes with age. In AMD, accumulation of lipofuscin in the RPE can damage it.
The retina
The retina contains the PR cells, rods and cones, and it is only 0.5 mm thick. Retinal pigmentation is partly due
to the presence of melanin in the RPE. There is more melanin in the macula so it appears darker.26 Melanin is
protective but the amount of melanin falls with age, and one effect is to reduce antioxidant potential.26
The macula
The macula is an oval area near the centre of the retina, only 5.5 mm across. It is the most sensitive part of
the retina. At the centre of the macula is the fovea. The macula is responsible for high acuity and colour
vision. The macula is yellowish in colour due to the macular pigments.
Macular pigments
These consist of lutein, zeaxanthin and meso-zeaxanthin, which are found in high concentration in the
macula and are known as macular pigments. The first two are obtained from the diet, and meso-zeaxanthin
is formed in the macula from lutein. The levels are measured as macular pigment optical density (MPOD).
Their distributions in the retina vary, with meso-zeaxanthin dominating in the centre of the macula and
lutein at the periphery. Carpentier et al.27 provide an overview, with points including:
l Adipose tissue may compete with the retina for uptake of lutein and zeaxanthin so obesity may
lower MPOD.
l Macular pigments protect the retina from the effects of blue light.
l In the USA, the combined intake of lutein and zeaxanthin is about 2 mg per day.
l Higher intakes appear to reduce the risk of AMD.
l Taking supplements increases MPOD when that is low and some studies report improvements in
visual function.
Lutein and zeaxanthin are members of the xanthophyll family. Most lutein and zeaxanthin comes from
vegetables with highest concentrations, dark leafy vegetables such as spinach and kale, and egg yolk and
maize. These carotenoids have antioxidant effects, protecting the RPE from oxidative stress. Increasing
dietary intake leads to an increase in macular levels. A Dutch trial28 showed increases in VA and improvement
in dark adaptation.
However, Stevens et al.29 from Aston University reported that among 158 patients recruited via the Macular
Society helpline, those with AMD consumed a daily average 3.3 mg of lutein and zeaxanthin (text – table
says under 2 mg/day), which is well below the 10 mg recommended after the AREDS 2 study.30 Many
patients were not eating vegetables such as spinach and kale, but a control group of people without AMD
had better intake.
Pathology
Drusen are small yellow or white accumulations of extracellular material that build up between Bruch’s
membrane and the RPE. Drusen come in two main forms: hard and soft. Most people > 40 years have a
few small hard drusen, but if they are more numerous or if they are larger, they may be the start of
macular degeneration.
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Small drusen (< 63 µm) are considered by Holz et al.11 not to be associated with progression to AMD,
but to be a non-specific change due to ageing. However, drusen volume31 or size32 are strong predictors
of progression to GA or wet AMD.
Reticular pseudodrusen
Reticular pseudodrusen (RPD) are a specific phenotype of early AMD first described by Mimoun et al.33
as a yellowish interlacing network in the outer macula of AMD patients, best visualised under blue light.
Other terms that have been used for RPD are subretinal drusenoid deposits, reticular macular disease and
reticular drusen.
Arnold et al.34 reported RPDs typical predominant location between the upper edge of the fovea and the
supero-temporal arcade. The fundus autofluorescence (FAF) findings of RPD and its common association
with RAP were first noted by McBain et al.35 and Lois et al.36 and subsequently supported by others.37
The prevalence of RPD was initially reported to be 0.7% in the Beaver Dam Eye study38 and 1.95% in the
Blue Mountains Eye study.39 The 15-year incidences were 3% and 4%, respectively. Later studies utilising
multimodal imaging have reported a higher prevalence of the condition [4.9% in the Rotterdam study40 and
13.4% in the Alienor (Antioxydants, Lipides Essentiels, Nutrition et Maladies OculaiRes) study41]. This could
be attributed to the fact that the former studies only utilised colour fundus photography (CFP) to detect RPD
but the latter used newer imaging technologies. Known risk factors for RPD include age and female gender.38–41
Reticular pseudodrusen are associated with all stages of AMD as well as being more prevalent in late
AMD.42–46 The prevalence of RPD in early AMD was reported to be 8.4% in the AREDS study,47 36–54%
in neovascular age-related macular degeneration (nAMD) and ranging from 29% to 92% in GA.42 The
Beaver Dam Eye study reported that eyes with RPD are at a sixfold higher risk of progressing to late AMD
within 5 years than eyes with indistinct soft drusen but no RPD.38 The Blue Mountains Eye study reported a
fourfold increased risk.39 Gil and colleagues48 studied the fellow eyes of patients with unilateral wet AMD
and found that 58% had RPD, and that RPD increased the risk of progression compared with patients
without RPD.
Fellow eyes of patients with unilateral wet AMD are known to have a higher risk of progression to late
AMD.47,49 Studies in this group have shown that presence of RPD is an independent and additional risk
factor (when combined with drusen and pigmentary changes) for progression to late AMD in the fellow
eye.46,48,50,51 Eyes with RPD tend to progress to GA50,51 but some studies have also reported a higher risk
of wet AMD.34,44 In patients with established GA, Marsiglia et al.52 reported that eyes with RPD have a
higher rate of progression than eyes without RPD.
Reticular pseudodrusen have been reported to cause significant deterioration in rod function,42 although
central VA is preserved, as reported by Hogg et al.50 using the Smith-Kettlewell low luminance acuity test
and by Steinberg et al.53 using microperimetry. Compared with areas with no pathologic morphology,
areas with RPD demonstrated a large and sharp decrease of scotopic sensitivity while there was only a mild
decrease in photopic sensitivity.53 Other studies have shown that RPD are associated with reduction in
photopic sensitivity when compared with healthy controls or people with typical drusen.54–56 Ooto et al.57
suggested that in order to truly reflect a patient’s visual function, other parameters, such as contrast sensitivity
and mesopic sensitivity, should be measured along with VA, as RPD are associated with deterioration in both.
Corvi et al.58 compared MPOD in patients with RPD and people without AMD, and reported lower levels.
They also reported reduced best corrected visual acuity (BCVA) and retinal sensitivity. After 3 months
supplementation with lutein 10 mg/day and zeaxanthin 2 mg/day, the mean MPOD in the RPD group
improved to the same levels as in the control group. However, no significant improvements were seen in
BCVA or retinal sensitivity. This may be because changes in function take longer to accrue. In the CREST
study, Nolan and colleagues59 found that MPOD increased by 3 months but that changes in contrast
sensitivity took 12 months to reach statistical significance.
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Pigmentation
Melanin in the choroid is protective against oxidative damage, and a reduction in pigment in the eye may
increase the risk of developing AMD.
Retinal hypopigmentation results in paler areas and is usually associated with loss of the RPE cells. Conversely,
hyperpigmentation can occur in early AMD. Neither change is specific to AMD. Another pigment, lipofuscin,
appears harmful. It is composed of lipids and protein. A major component is a retinoid A2E (N-retinyl-N-
retinylidene ethanolamine) which is a by-product of the visual cycle.
The ‘visual cycle’
Light reaching the photoreceptors in the retina triggers the conversion of the light-sensitive retinoid
11-cis-retinal into a different form, 11-cis-retinol, thereby generating an electrical signal to the brain. The trans
form is then converted back to the cis form in the RPE and then returns to the photoreceptors, completing the
visual cycle. If the two molecules of the trans form combines with one of the lipids (phosphatidilethanolomine)
in the RPE, A2E is formed, and this can impair RPE function. Because the edges of patches of GA are thought
to have A2E accumulation [as reflected in increased autofluorescence (AF)], reducing that accumulation may
be one target of drug treatment.
Oxidative stress
Oxidative stress is defined by Betteridge60 as a disturbance in the balance between the production of
reactive oxygen species (free radicals) and antioxidant defences. The retina has a very high metabolic rate,
reflected in high oxygen consumption, and has a high concentration of polyunsaturated fatty acids and
exposure to light, which, if coupled with inadequate levels of antioxidants, can make it very susceptible to
oxidative stress. Yehoshua and Rosenfeld61 report that the evidence for cumulative oxidative damage being
the cause of AMD has been growing, but that a mechanism for it is not yet known.
Barnett and Handa62 suggest that oxidative stress can affect the immune system, turning it from a protective
to a pathological response, and can also lead to chronic inflammation.
The immune system
Ambati and colleagues63 have reviewed the immunology of AMD. In brief, they consider that overactivity in
the alternative pathway of the complement system is involved in the development of AMD. This is associated
with the genetic susceptibility via a variant of the CFH gene, known as CFH (402His), which causes a greater
than normal complement response to retinal injury. Ambati and colleagues63 suggest that in individuals with
‘a complement hyperinflammatory phenotype’ there is an over-reaction to cellular damage in the retina.
Anderson, Hageman and colleagues64 first described the role of inflammation in AMD, and put forward
the hypothesis that drusen were the result of local immune-mediated processes and the junction of the
RPE and Bruch’s membrane.
The pathological role of the complement system has led to trials of drugs to inhibit that system.
Age-related macular degeneration
Classification (Macular Research Classification Committee 2013):65
1. Normal ageing – people with small drusen (< 63 µm), also termed drupelets, should be considered to
have normal ageing changes with no clinically relevant increased risk of late AMD developing.
2. Early AMD – medium drusen (≥ 63 to < 125 µm), but without pigmentary abnormalities thought to be
related to AMD.
3. Intermediate AMD – large drusen or with pigmentary abnormalities associated with at least medium drusen.
4. Late AMD – neovascular (wet) AMD or GA (advanced dry AMD).
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In this report, we use the term dry AMD to cover all stages from early AMD to GA.
Early and intermediate AMD is characterised by drusen, and/or by changes in pigmentation.25 However,
most people with drusen will not progress to severe visual loss and drusen may cause only mild or no
visual symptoms. Up to 80% of people > 60 years have some drusen. Hard drusen are well-defined
yellowish deposits with little risk of progression.
Soft drusen are larger, not well demarcated and are associated with a high risk of progression to late AMD.
They may become larger and merge over time and can lead to RPE detachments, called drusenoid RPE
detachments. They may disappear, but this is usually associated with atrophy of the outer retina. Drusen are
associated with thinning of the overlying RPE. Fleckenstein and colleagues66 consider that GA is the natural
end stage of soft drusen. A key component of drusen is amyloid beta,67 which is a waste product.
The underlying processes include locally intensive metabolism, oxidative stress, chronic inflammation,
a pathological immune response and lipofuscin accumulation.9 Lipofuscin is considered toxic.
In atrophic AMD, there may be a single patch of atrophy or several. Over time, the patches may get bigger
and may merge. The foveal centre (the area responsible for central vision) is lost last as atrophy occurs
around the centre of the macula first before expanding into the fovea, which is the very centre of the
macula. This potentially gives time for treatment before the central vision is lost.
Vision is lost from atrophic patches and the gaps in vision are called scotomas.
The atrophy is due to loss of the RPE, outer layers of the retina and the underlying choriocapillaris.11,66
On optical coherence tomography (OCT), GA appears as a flat patch where the retinal has withered away.
A total of 20% of people with legal blindness have lost central vision due to GA. It tends to be of similar
extent in both eyes66 but patients can have GA in one eye and wet AMD in the other, and can also have
both GA and wet AMD in the same eye, if late dry AMD turns to wet AMD.
Geographic atrophy is also seen in patients treated with anti-VEGF drugs for wet AMD.35,68 In both the
Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)69 and Inhibition of VEGF in
Age-related choroidal Neovascularisation (IVAN)70 trials (of ranibizumab vs. bevacizumab in wet AMD) it
was observed that about one-fifth of patients developed GA after 2 years of anti-VEGF treatment.71 This
GA appeared to be clinically similar to the GA that is seen in dry AMD and may occur because VEGF is
required for the maintenance of the choriocapillaris by the RPE.
Progression and natural history
Data on natural history studies are important because natural history may be the only comparator for some
interventions reported in observational studies.
Wet AMD will develop in 10–15% of people with intermediate AMD.72 In the AREDS trial, the average
time to atrophy was 5–6 years in people with large drusen and hyperpigmentation, but 2.5 years in those
with hypopigmentation.
Most people with AMD are at the early stage,2 as shown in Table 1.
The KORA (Cooperative Health Research in the Region of Augburg) study from South Germany reported
features of AMD in people < 50 years.73
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The Geographic Atrophy Study by Sunness et al.74,75 reported that GA enlarged at 2.6 mm2 per year over a
median follow-up of 4.3 years, in 212 eyes in 131 patients, mean age 78 years. However, there was a very
wide range of progression rates from none to almost 14 mm2 per year. They noted a high concordance in
rates of enlargement between eyes.
The Geographic Atrophy Progression Study,76 in patients with a mean age of 77 years, found that the GA
enlarged by an average of 1.85 mm2 over 12 months, based on AF, and this was slightly higher based
on CFP.
The Beaver Dam Study77 found a progression rate of 1.3 mm2 per year in 53 eyes of 32 patients (mean age
about 81 years) over 5 years.
The AREDS trial group reported progression of 1.7 mm2 per year in 251 eyes of 181 patients (mean age
70 years) over a median follow-up of 6 years.
The FAM (Fundus Autofluorescence in age-related Macular Degeneration) study78 reported a similar
progression rate of 1.75 mm2 per year (mean) or 1.52 mm2 per year (median) in 195 eyes of 129 patients
(mean age 74 years), but over a median follow-up of only 1.8 years. They also reported a wide range of
progression rates. They used FAF to determine areas of GA.
Decision problem
The questions for this review include:
1. Can treatment of early AMD prevent or slow progression to advanced forms (wet or dry)?
2. Can any treatments improve, or slow deterioration in, GA?
3. Can any treatments prevent GA progressing to wet AMD?
As our aim is to identify interventions that might have reached a stage where they could be assessed by
the NIHR programmes [mainly Efficacy Mechanism and Evaluation (EME) and Health Technology
Assessment (HTA)], we are not interested in –
l rehabilitation methods such as external low visual aids
l diagnostics
l research still at basic science stage, such as in vitro, including cell work, or methods of carriage of gene
therapies into cells using viral carriers
l treatments with some evidence of efficacy in animal studies but not yet tested in humans. Such
research might fall within the remit of the Medical Research Council (MRC) Translational Research
Programme.
TABLE 1 Prevalences of dry AMD by age and stage
Age (years) Drusen Advanced dry AMD
65–69 M 9.7%, F 9.8% M 0.5%, F 0.1%
70–74 M 12.5%, F 17.3% M 0.6%, F 1.0%
75–79 M 18.7%, F 18.1% M 1.9%, F 1.2%
≥ 80 M 23.3%, F 28.9% M 1.4%, F 5.8%
All ages > 65 15.4% 1.2%
F, female; M, male.
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Potential treatments might be divided into the following groups:
1. Treatments where proof of concept in humans has already been achieved but where research is needed
to evaluate clinical efficacy, and which might be suitable for the EME programme.
2. Treatments where there is evidence that shows they can be effective, but where further research is
needed to establish the clinical effectiveness and cost-effectiveness for the NHS in comparison with the
current best alternative. Such research falls within the remit of the HTA programme.
3. Interventions where there is sufficient evidence of lack of benefit, so that no further research is justified.
4. Interventions where there is no good evidence of any benefit and on which no money should be spent.
Identifying these may help people who see unjustified claims or adverts.
Outcomes
The most important outcomes are those that matter to patients: VA, contrast sensitivity, adverse effects
of treatment, reading speed, ability to drive, health-related quality of life, progression of disease and
patient preference.
However, VA loss is a late manifestation of AMD and not a good primary outcome in most trials, especially
when the treatment is aiming at prevention of visual loss before it occurs. Early AMD may cause minimal
or no symptoms. VA depends only on the centre of the fovea but this tends to go last in atrophic AMD
and many patients have large areas of atrophy and experience considerable problems before the fovea
goes. Reading and seeing faces of people can be extremely difficult and the ability to drive may be lost.
Progression of dry AMD is slow, and so it could be years before a trial could show a decline in vision.
Therefore, predictors or biomarkers of future decline can be accepted if there is good evidence that they
are strong predictors of subsequent visual outcomes. These will include changes detectable by investigation,
but not necessarily by people with AMD, including:
l Rod function, which may not correlate with VA as central VA acuity (as measured using VA charts)
depends on foveal function, and the fovea is cone rich. But rod function is one of the earliest
abnormalities detected in people who will later develop GA in AMD.
l Macular pigment density, because it appears to be protective.
l Integrity of the RPE layer, as determined by FAF and OCT.
l Drusen volume and number. Disappearance of drusen may be a sign of developing GA.
l Macular sensitivity, which can be measured by microperimetry.
l Dark adaptation.
Both photopic and scotopic vision need to be considered. Scotopic vision refers to low levels of light such
as in near darkness.
One issue is the clinical significance of changes in VA. In past evaluations, for example of the anti-VEGF
drugs, a clinically significant difference in VA has usually been considered as a change of ≥ 10 letters.
Changes of < 5 letters are not regarded as clinically relevant as may indicate normal variability. Changes of
5–9 letters are not regarded as clinically useful but might be regarded a valuable outcome to investigate if
seen in a short-term study, suggesting that a larger or longer trial is justified.
In dry AMD, no change (which could be lack of deterioration) could be regarded as clinically meaningful if
observed over a long enough period.
Microperimetry
Microperimetry can detect changes in macular sensitivity in patients with early AMD and normal VA.79
Macular sensitivity measured using microperimetry focuses on the central macula instead of the entire
visual field.80–83
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Testing is performed either with a modified Humphrey Field Analyser or with a microperimeter.83
There is limited evidence of the reproducibility of microperimetry in patients with AMD, but current studies
have suggested that it provides consistent and reproducible readings.84–86
Early AMD patients have rod sensitivity loss87 and impaired rod-mediated parameters of dark adaptation,88
which worsen as AMD progresses. The association between early AMD changes and macular sensitivity
was further established by the observation that a correlation existed between altered AF signal and
reduced macular sensitivity.79,89 In GA, macular sensitivity was reduced in areas of increased fundus AF
signal at the junctional zone of areas of atrophy.90 However, this observation has not yet been proven to
be a predictor of GA enlargement over time.90
Current evidence suggests that macular sensitivity is a valuable biomarker for early AMD and microperimetry
has proven to be an easy and reliable test to measure it. It is not widely used in clinical practice, but has
been used in clinical trials to evaluate the effects of treatments on macular sensitivity.91–96
Review methods
For reasons of space, we summarise methods here. Further details are provided in Appendix 1, including
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.
Search strategies
MEDLINE, EMBASE, Web of Science and The Cochrane Library were searched from 2005 to 13 July 2017
for reviews, journal articles and meeting abstracts. Searches were limited to English language.
Initial searches of all databases were undertaken in June 2016 and updated searches were run in June
2017 to check for any articles added in the previous year. The Association for Research in Vision and
Ophthalmology (ARVO) website was also searched for meeting abstracts.
References of reviews were checked for relevant studies and clinical experts were also consulted for any
other relevant literature.
Studies were selected for inclusion through a two-stage process using predefined and explicit criteria. Titles
and abstracts of 7948 articles from the full literature search results were screened independently by two
reviewers to identify all citations that appeared likely to have met the inclusion criteria, and checked by a
third. The full texts of 398 articles were obtained for further screening and checking of references and 112
articles were included in the final report.
ClinicalTrials.gov, the WHO search portal and UK Clinical Trials gateway were searched for ongoing and
recently completed clinical trials.
Full details of the search strategies are in Appendix 1.
Inclusion and exclusion criteria
Participants
People with a confirmed diagnosis of dry AMD or Stargardt disease (STGD).
Interventions
Any interventions that aim to preserve or restore vision in dry AMD or STGD.
INTRODUCTION TO AGE-RELATED MACULAR DEGENERATION
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Exclusions
To avoid overlap, we excluded studies on some interventions being reviewed in the NICE guideline process
(e.g. smoking cessation, diagnostic technologies, monitoring and review, and rehabilitation support).
Outcomes
These are as above.
Design
We placed no restriction on study design so included randomised controlled trials (RCTs), controlled clinical
trials (CCTs) with a concurrent control group, and observational studies. This was partly so that we could
assess the evidence base for treatments that might be advocated without a sufficient evidence base.
Systematic reviews were assessed for quality and summarised if they met quality criteria. Reviews were also
used as a source for identifying primary studies, and for identifying studies published before 2005 that
seemed relevant, such as earlier studies of included treatments.
Study selection and data extraction
Studies published as abstracts or conference presentations were only data extracted and included if
sufficient details were presented to allow an appraisal of the methodology and the assessment of results to
be undertaken. If such details were not available, key points from abstracts were summarised in the text.
Data were extracted by one reviewer using a standard data extraction form and checked by a second
reviewer. At each stage, any disagreements between reviewers were resolved by consensus or, if
necessary, by arbitration by a third reviewer.
Quality assessment strategy
The methodological quality of primary research studies was assessed using criteria based on those
recommended by the Cochrane Collaboration and National Institutes of Health (NIH), National Heart,
Lung and Blood Institute (NHLBI) (for further details, see Appendix 1). Quality criteria were applied by one
reviewer and checked by a second reviewer, with any differences in opinion resolved by consensus or by
arbitration by a third reviewer.
The quality of systematic reviews was assessed using the Centre for Reviews and Dissemination (CRD)
checklist, with reviews assessed as good if four or more criteria were met.
Method of data synthesis
Studies were synthesised through a narrative review with tabulation of results of included studies. Formal
synthesis through meta-analysis was not possible because studies were not of sufficient quality and were
heterogeneous in terms of participant characteristics, outcomes and study design.
References
Trials and other studies listed by National Clinical Trial (NCT) numbers are available on the ClinicalTrials.gov
website (https://clinicaltrials.gov/) by searching using NCT number. This website is a service of the US NIH.
Changes to the protocol
An outline protocol was registered on PROSPERO at an early stage. (This is mandatory for reviews
commissioned by the HTA programme). However, during the systematic review, the protocol evolved over
time, as agreed by the funder. The main change was to include additional outcomes, or predictors of
outcomes, because of the awareness that many studies were relying on VA, which is a late outcome.
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Quantity of evidence
We included 108 primary studies reported in 112 articles (see Figure 2). Of 104 dry AMD studies, there
were 26 of pharmacological treatments, 30 in physical therapies, 3 of cell transplants and 45 of nutritional
supplements. There were four studies in Stargardt’s, two of physical therapies and two of nutritional
supplements. Two studies had subgroups of people with dry AMD and Stargardt’s97,98 making a total of six
studies in STGD.
An overview of the study characteristics can be seen in Report Supplementary Material 6. There was a
range of study designs, with 60 RCTs and CCTs, 24 cohort studies and cross-sectional studies, 13 single-arm
before-and-after studies, 5 case–control studies, and 6 case series. Many studies had small sample sizes,
the durations of intervention and follow-up were often short, and there were differences in the outcomes
reported. We reported all outcomes of relevance if they were reported by the authors of each study. Further
details are provided in Chapters 2–6. Baseline characteristics of participants are summarised in Report
Supplementary Material 6. There was generally poor reporting of baseline characteristics across the studies.
The risks of bias of RCTs and CCTs and quality of non-randomised studies are summarised in Report
Supplementary Material 6. The overall quality of each study is reported within the results chapters of this report.
Details of methods and quality assessments are in Appendix 1. Report Supplementary Material 1–5 contain
data extraction and quality assessment tables and can be downloaded as separate files from the HTA
programme website (URL: www.journalslibrary.nihr.ac.uk/programmes/hta/150910/#/documentation).
Report Supplementary Material 6 has a list of excluded studies, most of which were excluded because they
were on wet AMD or basic science, or were superseded by later studies.
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Chapter 2 Stargardt disease
Background
Stargardt disease is caused by inheritance of a faulty gene: the ABCA4 gene. Genes are in pairs, one
inherited from the father and one from the mother. If abnormal ABCA4 genes are inherited from both
parents, then the disease will occur. Because of these abnormal genes, a build-up of waste material from
metabolism called lipofuscin occurs in the retina. This material should be cleared away but because of the
disease it is not and damages the retina, and some of the retinal cells die. This causes loss of vision, but
the amount of loss varies. There are many different forms of the faulty gene and, as a result, some people
have more severe disease than others.
The German ophthalmologist Karl Stargardt described this condition in 1909 (see Fishman99 for a historical
review). It has also been called fundus flavimaculatus and, luckily, it is quite rare. The prevalence is often
quoted to be about 1 in 10,000,100 which is compatible with a recent UK study of incidence101 carried out
under the auspices of the British Ophthalmological Surveillance Unit (BOSU). The BOSU study reported an
incidence of 1.1 to 1.3 per million population (all ages), based on 81 new cases reported to BOSU over a
12-month period. The median age at onset was 27 years, range 5–64 years, with a female majority of
61%. The BOSU authors note that not all patients with STGD have only macular disease, and that a
minority have wider retinal involvement, with both central and peripheral visual loss. They therefore
suggest that it be referred to as a retinal disease rather than a macular one.
Stargardt disease leads to atrophy of the RPE but it appears that once atrophy is established and the RPE
is lost, the choriocapillaris may be lost to a greater degree than is observed in GA in AMD. Giani et al.102
found that areas of atrophy in STGD demonstrated hypofluorescence on indocyanine green angiography,
whereas in AMD they were hyperfluorescent, suggesting a loss of the choriocapillaris in STGD.
Pellegrini and colleagues103 used a new imaging technique, OCT angiography, in addition to indocyanine
green angiography, to study the choriocapillaris in patients with AMD and STGD. They found areas
of ‘dark atrophy’ in 65% of patients with STGD but in none of the patients with AMD and GA.
If this is the case, then RPE transplantation at this late stage may not be able to improve function.
Transplanted RPE would be unlikely to survive because of lack of nourishment if there is no choriocapillaris.
The defective ABCA4 gene in STGD encodes a protein involved in the visual cycle, which is found in PR
cells but nowhere else in the body. Many mutations in this gene have been identified. Some cause
retinopathies other than STGD. There is a similar disease (referred to as STGD-like disease) caused by a
dominant gene, the ELOV1 gene.
As reported in the BOSU study,101 STGD often affects people in their 20s but the onset can occur at any age. The
loss of vision is usually slowly progressive but can be more rapid when the condition develops in younger people.
Lambertus et al.104 report a cohort of early-onset STGD with mean age at onset of 7 years (range 1–10 years).
VA declined rapidly. This early-onset group represents the more severe end of the STGD spectrum.
A very large study from Gerald Fishman’s group in Chicago105 reported data from 361 patients. At presentation:
l 22% were aged ≤ 20 years, of whom 13% had VA 20/40 or better
l 41% were aged 21–40 years, with 22% having VA 20/40 or better
l 31% were aged 41–40 years, with 28% having VA 20/40 or better
l 6% were > 60 years.
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This study reported that the younger the patient at presentation, the shorter the time to go from VA
≥ 20/40 to ≤ 20/200. Patients aged < 20 years at diagnosis with VA ≥ 20/40 took a median of 7 years to
reach ≤ 20/200, whereas the median times for such progress were 22 years and 29 years for those initially
seen who were aged 21–40 years or 41–60 years, respectively. The authors note an implication for research
studies in that, given that progress often takes decades, intervention studies need a long follow-up before
there can be certainty about prevention of progression.
The ProgStar group also reported an older age at onset group in which progression is slower.106 Lambertus
et al.104 from Nijmegen, the Netherlands, defined late-onset STGD as age at onset of > 45 years, plus at
least one ABCA4 mutation. They report a case series of 47 patients followed for a median of almost
5 years. The time to mild visual impairment averaged 2.7 years, the time to moderate impairment was
10.2 years and the time to severe impairment was 11.4 years.
Lambertus et al.104 also report that there is a higher frequency of asymmetric progression in late-onset STGD.107
In 29% of patients, atrophic areas encircled the fovea but did not involve it. There was considerable variation
in effects on VA. Some patients had eventual foveal involvement without a preceding foveal-sparing stage.
van Huet and colleagues108 also report a group of patients (13 out of 198 with STGD) who had foveal
sparing in at least one eye. All were confirmed to have an ABCA4 mutation. As in the study by Lambertus
et al.,104 they were later onset (mean age 52 years, range 32–67 years), with only three developing symptoms
before the age of 45 years. Progression was slower than in younger onset patients. van Huet et al.108 suggest
that people with foveal sparing may therefore be particularly suitable for trials because therapies may have
more time to take effect, but results of such trials might only be applicable to this subgroup.
Lois et al.109 classified patients with STGD into three groups based on functional loss. People can have
loss of macular function, loss of peripheral cone function in addition to macular function, or loss of both
peripheral cone and rod function in addition to macular function. This last form is extremely severe.
The earlier the age at onset, the more likely the disease is to be more severe.
l Group 1: dysfunction confined to the macula
l Group 2: macular and generalised cone electroretinography (ERG) abnormalities
l Group 3: macular and both generalised cone and rod ERG abnormalities
These groups may represent distinct phenotypes of STGD with different prognoses. In a study of 59 patients,
all with central visual loss at baseline, with mean follow-up of 10.5 years,110 progression varied as shown in
Table 2.
In those with normal full-field ERG at baseline, only 20% showed clinically significant progression. However,
all those with abnormal full-field rod dysfunction on ERG progressed.
This study showed that the groups were not just at different stages but had different forms of STGD.
Another study, with only 12 patients, showed that the different groups had different progression rates,
with areas of atrophy at the macula enlarging at a faster pace and new areas of atrophy at the macula
developing more frequently in group 3.111
TABLE 2 Stargardt disease. Progression by group
Group Proportion at baseline Median age (years) at onset ERG deterioration
1 46% 25 22%
2 29% 20 65%
3 25% 14 100%
STARGARDT DISEASE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Childhood onset has a poorer prognosis. Fujinami et al.110 from Moorfields Hospital reported that in a
series of 42 patients diagnosed at median age of 8.5 years,110 childhood-onset STGD was associated with
severe visual loss, probably associated with more severe variants in the ABCA4 gene.
A characteristic of STGD is deposition of A2E (a major component of lipofuscin) in the RPE. The accumulation
of A2E can be reduced by isotretinoin, which is an inhibitor of retinal dehydrogenase and rhodopsin
regeneration. Fenretinide (ReVision Therapeutics, San Diego, CA, USA) also reduced the accumulation of
A2E and lipofuscin in RPE cells in the mouse model of STGD, the ABCA4 knockout mouse (ABCA4–/–)
(reviewed by Lu et al.112). The ABCA4–/– mice model of STGD has been used to validate hypotheses about
how ABCR, the protein codified by the ABCA4 gene, functions in the retina. The mice have also been used
to demonstrate the impact of light on the accumulation of lipofuscin in the retina – when the ABCA4
knockout mice were raised in the dark, the accumulation of lipofuscin was prevented.113
Aleman and colleagues114 noted that in macular degenerations associated with ABCA4 mutations, the fovea
is often spared until late. They hypothesised that this might be due to the macular pigment concentration,
which may reduce the build up of lipofuscin and that, if so, lutein and zeaxanthin supplements might slow
progression. Their intervention study is described later.104
Fundus autofluorescence has also been proposed as a good way to determine progression and monitor
response to treatment111,115 and a recent study from the Progression of Atrophy Secondary to Stargardt
Disease (ProgStar) study group116 supports this.
There are three main ways of trying to treat STGD:
l prevent the harmful accumulation of lipofuscin
l gene therapy (to give the retina a new ABCA4 gene to replace the faulty ones)
l cell transplantation to replace the dead cells with new ones.
Quantity and quality of research
Reviews
One recent review of treatments for STGD has been published by Lu et al.112 It claims to be systematic but
no details of methods are given, and not all therapies were covered. Three other non-systematic reviews
were identified.100,117,118 A very thorough report from the National Horizon Scanning Centre (NHSC)119 was
found, covering all inherited retinal conditions, based on extensive searches and discussions with experts.
All these reviews were used to check for references, including to ongoing research. The NHSC report119
was particularly useful.
Lu et al.112 conclude that the most promising drug treatments for STGD are drugs that reduce lipofuscin
accumulation, such as deuterated vitamin A (ALK-001; Alkeus Pharmaceuticals, Boston, MA, USA),
fenretinide (Sirion Therapeutics, Tampa, FL, USA) and A1120, a non-retinoid RB4 antagonist.
A more recent review by Tanna and colleagues120 provides a detailed review of diagnostic methods but
adds little on treatments. Lambertus et al.104 have also reported ways of monitoring progression of STGD,
focusing on late-onset STGD.
Studies
Four studies and two subgroup analyses of studies included people with STGD. The interventions in these
studies were microcurrent stimulation (MCS) (two studies),97,121 light protection (one study),122 RPE
transplantation (one study)123 and nutritional supplements (two studies).124,125
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Microcurrent stimulation
In this treatment, very small electrical currents (800 µA) are applied to the eyelids, eyebrow or cornea.
Two studies including a total of 15 people (11 treated, 4 placebo) assessed the effects of electrical
stimulation. One of these was a RCT by Röck and colleagues.121 The RCT was a small three-arm
comparison of two doses of transcorneal electrical stimulation and a sham comparator applied weekly for
6 weeks; the duration of follow-up was unclear. There were four participants in each group and the mean
age of participants was 40 years. The study was undertaken in Germany and received commercial funding.
The RCT had an unclear risk of selection bias.121
Röck and colleagues121 included patients with logarithm of minimum angle of resolution (logMAR) VA
0.02–0.9. The eye with the worse VA was selected as the study eye. Although there was a small improvement
in BCVA in the group given stimulation at 150% of the electrically stimulated evoked phosphene potential,
and a deterioration in the 66% stimulation group and placebo group, the mean change in BCVA at follow-up
was not significantly different among groups (Table 3). Mean intraindividual changes were also not significantly
different between the three groups. No adverse events (AEs) were reported.
The other study was of a subgroup of three patients with STGD from a study by Kondrot,97 which also
included people with dry AMD and other eye conditions (see Chapter 3). This study involved 3 days of a
mixture of ‘alternative’ treatments, which means that it would not be possible to say which, if any, was
effective. There was no external funding but participants paid US$3000 to have the treatment. The timing
of assessment of results is not clear but may have been at the end of the course. The study scores poorly
on quality assessment (see Report Supplementary Material 1).97 The mean age was not reported.
Kondrot97 reported that in the three people with STGD, there were improvements in acuity of 6.6 letters
and in contrast sensitivity of 3.67 letters after 3 days of mixed treatment. No statistical analyses were
presented. There was also reported visual field ‘expansion’ in all six eyes. The author does not claim
that the benefits were due only to microcurrent, but simply states that ‘In this article, I demonstrated
that certain natural interventions given in a short period can reverse eye disease and improve vision’.
He suggested a trial with a control group.
Adverse events were not reported.
TABLE 3 Results of microstimulation
Röck 2013121
Röck 2011126
RCT; unclear ROB Sham, n= 4
Stimulation
66%, n= 4
Stimulation
150%, n= 4 p-value
BCVA change, logMAR, mean (SE) +0.03 (0.01) +0.03 (0.01) –0.02 (0.01) 0.07
Kondrot97 (B+A study; PQ) Mixed treatment including MCS, n= 3 (6 eyes)
Acuity improvement, ETDRS chart, mean 6.6 letters (range 2–13)
Contrast sensitivity improvement, mean 3.67 letters (range 0–10)
B+ A, before and after; ETDRS, Early Treatment in Diabetic Retinopathy Study; PQ, poor quality; ROB, risk of bias (selection);
SE, standard error.
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An observational study (NCT01790958) in 50 patients with various eye conditions, including STGD, was
reported to be under way in Hawaii with an end date December 2012, but no results have been posted.
Summary of microstimulation
The small RCT by Röck and colleagues,121 with an unclear risk of bias, did not find any statistically
significant benefit from MCS. We found no good evidence that MCS worked.
Light protection
Molecules can exist in different forms, called cis- and trans-isomers. In the visual cycle, light converts
11-cis-rhodopsin to the all trans form. This is then recycled back to the cis-form through a number of
stages in which the ABCR protein is involved. The ABCR protein is encoded by the ABCA4 gene, which is
defective in STGD. This results in the harmful compound, A2E, being produced and accumulating as the
main component of lipofuscin in the RPE.
Exposure of the retina to light therefore stimulates production of A2E and the rationale of light therapy is
to reduce the light reaching the retina in order to reduce the formation of A2E.
Light protection has been tried. The theory is that in people with STGD, light exposure may lead to more
lipofuscin accumulation. So reducing incoming light might help to reduce the amount of lipofuscin and
the damage caused. There is evidence from mice with STGD that darkness protects the eye.
One study of five participants by Teussink et al.122 assessed the effects of light exposure protection using a
black contact lens covering > 90% of light in the visible spectrum, worn on the better eye during waking
hours for a year.122 The other eye acted as a control. The study was undertaken in the Netherlands.
Follow-up assessments were undertaken at a mean of 17.8 months. The study was assessed as poor quality
(see Report Supplementary Material 1). Funding was from a non-commercial source. The mean age of
participants was 22.6 years, and three were male. The BCVA at baseline was provided only for individual
participants. Further details are provided in Report Supplementary Material 1.
Teussink and colleagues122 included people with typical clinical symptoms associated with STGD and at
least one ABCA4 mutation. BCVA in the treated eye was reported only for individual participants and no
mean value was provided. In four out of the five patients, progression was less in the light-protected eye.
The study reported that BCVA was stable in all but one patient during the study period. No participants
developed atrophy and there were no AEs reported.
Summary of light protection
One very small study reported reduced progression in the light-protected eye in four out of five participants.
So although the evidence base is very weak, and we need a proper trial, we could recommend that people
with STGD should wear sunglasses or dark contact lenses to protect their retinas from light exposure.
Retinal pigment epithelium transplant and stem cells
Two publications from a small before-and-after study in STGD conducted in the USA were identified.98,123
Schwartz and colleagues98,123 recruited nine participants with STGD, and the eye with the worst vision was
treated. A single treatment of subretinal transplantation of human embryonic stem cells (hESCs) derived
RPE with 12 weeks of immune suppression was assessed. Median follow-up was 22 months. The study
was assessed fair quality. Funding was from both commercial and non-commercial sources. Mean age was
50 years and 44% of participants were male. Baseline VA ranged from 20/200 (severe vision loss) to hand
motion (near blindness). The STGD study, now completed, was registered as NCT01345006 and sponsored
by the Astellas Institute for Regenerative Medicine (Malborough, MA, USA).
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Schwartz and colleagues98,123 included people with end-stage STGD, peripheral visual field constriction and
BCVA 20/400 or worse in the study eye. Unfortunately, three patients with STGD developed cataracts in
the treated eyes, and one suffered from a post-surgical endophthalmitis. Of the other five patients, VA
had improved by a median of 12 letters at 12 months, whereas the improvement in the untreated control
eyes was only 2 letters. In two of the patients who developed cataracts, vision improved by 6 or 7 letters
during cataract progression, and further after cataract removal. Quality of life, assessed by the National
Eye Institute Visual Function Questionnaire-25 (NEIVFQ-25) improved for general vision, peripheral vision,
near activities, distance activities and mental health (Table 4). Other outcomes are reported in Report
Supplementary Material 1.
An update was presented at the 2017 American Academy of Ophthalmology meeting when 10 patients
had a mean follow-up of 3 years with no serious side effects, with some gaining > 10 letters.127
Adverse events
There were no AEs specifically from the cellular therapy (e.g. acute transplant rejection or abnormalities in
retinal vascular or choroidal circulations) but one patient developed an endophthalmitis following surgery,
which was a potentially devastating complication.
Summary of retinal pigment epithelium transplantation
One small before-and-after study98,123 found improvements in VA in most of the nine eyes after 12 months,
whereas there was little change in the untreated fellow eyes. Improvements in quality of life were also noted.
Discussion
The NHSC report119 discussed the prospects for RPE cell transplants, quoting expert opinion doubts about
the effectiveness of hESC-derived RPE cells. This was on the grounds that most people with STGD may
need replacement of both RPE cells and PRs, if the treatment is undertaken at a late stage of disease,
when PR cells may be already lost and permanent damage to the choriocapillaries may have taken place.
Indeed, the early clinical trials referred to above selected patients with very advanced STGD. The treatment
could potentially be more promising if the disease were to be treated at an earlier stage and this could be
done provided that the risks of the treatment were small.
TABLE 4 Results for stem cell transplantation98,123
Schwartz et al.98,123 (before and after; FQ) RPE transplant (7 patients with 12-month follow-up)
VA (ETDRS) (12 months) improved by
≥ 15 letters 3 eyes
11–14 eyes 0 eyes
≤ 10 letters (stable) 3 eyes
Worsened
10 letters 1 eye
NEIVFQ-25 change from baseline
General vision, median Change at 12–52 weeks: +20.0
Peripheral vision, median Change at 12–52 weeks: +12.5
Near activities, median Change at 12–52 weeks: +8.3
Distance activities, median Change at 12–52 weeks: +12.5
Mental health, median Change at 12–52 weeks: +9.4
ETDRS, Early Treatment Diabetic Retinopathy Study; FQ, fair quality.
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Research in progress
Research in collaboration with Ocata Therapeutics (formerly Advanced Cell Technology, now part of
Astellas) has been under way at Moorfields since 2012.
NCT02445612 is the long-term (15 years, to 2029) follow-up of the NCT01345006 study by Schwartz et al.
described above.
NCT02941991 is a 5-year follow-up study in Moorfields and Newcastle of people treated with hESC RPE
cells, due to complete data collection in December 2019. The sponsor is the Astellas Institute for
Regenerative Medicine.
NCT01469832 was called ‘Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem
Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With STGD Macular Dystrophy (SMD)’.
It was being carried out in Moorfields, Newcastle and Edinburgh, aiming to end by 2015. It was sponsored
by Astellas Institute for Regenerative Medicine. NCT02941991 looks to be a continuing follow-up, which is
due to end in 2019. The entry for NCT01469837 has disappeared from Clinical trials.Gov.
NCT01625559 is a small study in Korea aiming to recruit three patients. No details have been added recently.
NCT02749734 aims to recruit 15 patients in China (Southwest Hospital) for a 12-month study.
Two stem cell studies are reported to be under way, called Stem Cell Ophthalmology Treatment Study (SCOTS)
I and II, which are sponsored by MD Stem Cells. These are being carried out in nine different eye diseases, and
involve injecting bone marrow cells (from the hip) into the eye by different routes. There is no control group.
SCOTS I (NCT01920867) is due to end in August 2017. The start date for SCOTS II (NCT03011541) was
January 2016 and end date will be 2020. The sites are Florida (Retinal Associates of South Florida) and Dubai
(Al Zahra Hospital). A couple of single case reports have been published, but not in STGD, except for a case
report from another centre of a retinal detachment following stem cell transplantation in a SCOTS I patient
(Leung et al.128). Media reports are that patients are being charged $20,000 for the treatment.129
NCT02903576 is under way in São Paulo, Brazil, recruiting 18 patients with STGD and AMD, and due to
end in 2018.
Many of the studies registered on ClinicalTrials.gov are not trials, and patients should be aware that
registration does not mean approval by scientific authorities. Several who saw an entry for NCT02024269
had adipose tissue cells injected into their eyes. Kuriyan and colleagues130 report on the resulting visual
loss. The patients were charged for the treatment and the ‘trial’ registration has been withdrawn.
Nutritional supplements
Two studies assessed the effects of nutritional supplements in people with STGD.114,125
In a before-and-after study, Aleman and colleagues114 included nine people with STGD with foveal fixation
and known or suspected disease-causing mutations in the ABCA4 gene. The study received non-commercial
funding. The study was of fair quality and the mean age was 32 years, range 14–56 years. Follow-up
assessments were undertaken immediately after the intervention period.
Baseline VA ranged from 20/20 to 20/50. The selected patients had relatively spared foveal function in at
least one eye. Patients had reduced MPOD compared with normal eyes, and foveal thickness was reduced
in patients compared with controls. The mean increase from baseline in foveal MPOD after 6 months of
treatment with lutein 20 mg daily was reported to be statistically significant (p < 0.001) at 2 degrees and
5 degrees. MPOD correlated with serum lutein and nearly all patients had increases in serum lutein, but
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only 63% had increases in MPOD. There were no significant differences in foveal sensitivity between
MPOD responders and non-responders, and there were no differences in logMAR VA.
Other outcomes are reported in Report Supplementary Material 1, including subgroups for those classified as
responders and those as non-responders. AEs were not reported in the study by Aleman and colleagues.114
The retina has a high concentration of omega-3 fatty acids and, in particular, of docosahexaenoic acid
(DHA). Querques and colleagues125 hypothesised that DHA supplements might protect the retina. In their
case series, 20 participants with late-onset STGD (defined as > 18 years, but mean age was 45 years,
range 27–72 years) received DHA supplementation for 6 months. VA improved in only four patients, and
only slightly (e.g. 20/25 to 20/20). The study quality was fair. The funding source was not reported. BCVA
at baseline was only reported for individual patients. Other results are reported in Report Supplementary
Material 1.
No AEs were recorded by Querques and colleagues.125
A trial (NCT00420602) appears to be under way in Utah, in STGD3, using over-the-counter DHA/
eicosapentaenoic acid (EPA) dietary supplementation with 1000 mg/day DHA/EPA. There is also a trial
registered of DHA as having been done in Maryland (NCT00060749) but no results have been posted.
NCT03927515 (details first posted September 2017) will be a trial of omega-3 fatty acids versus placebo
(sunflower oil) called MADEOS – MAcular DEgeneration Omega-3 study. The primary outcome is given as
VA after 24 weeks, which seems very short.
NCT01278277 is a trial of saffron supplements (20 mg once a day) versus placebo, being carried out in
30 people by Falsini and colleagues in Rome, due to end December 2017. The primary outcome is ERG
after 6 months.
Too high a vitamin A intake may be harmful. Sofi et al.131 found that in 24 patients with STGD, those with
low vitamin A intake (< 600 µg RAE per day) had better visual function, but there were only four such
patients. There is support from the work of Radu et al.132 who showed that in the STGD mice model
(ABCA4–/–), vitamin A supplementation led to increased accumulation of lipofuscin in the RPE.
Summary of nutritional supplementation
One small short-term study of lutein supplementation failed to find a beneficial effect on VA and dark-adapted
sensitivity.114 A trial of DHA supplementation found only slight improvement in VA in 4 out of 20 people after
6 months of treatment.125 It should be noted that treatments may be effective without improving vision if they
prevent further deterioration, but this could only be shown by longer-term RCTs.
We suggest an exploratory EME study of lutein and zeaxanthin in STGD. There is theoretical support for
them being of value in protecting the centre of the macula, through protection of visual cycle products
from photo-oxidation, and hence reducing accumulation of the toxic A2E. Aleman and colleagues114 found
that the eyes of those with STGD have lower MPOD than normal eyes and about half the serum levels of
the carotenoids, compared with a control group, despite similar dietary intakes. That study was published
in 2007. No trials of carotenoid supplements are registered on ClinicalTrials.gov.
We suggest an EME ‘proof of concept’ trial using sensitive measures of retinal function rather than changes
in VA. MPOD and VA would be measured, but the aim would be to recruit people before vision was
significantly impaired to determine whether functional loss could be delayed or prevented. So the study
should use macular microperimetry or multifocal ERG to test macular function, reading vision and reading
speed, visual-related quality of life and AF. The power of the study would be increased by recruiting faster
progressors in STGD, which would probably allow some outcomes to be determined after shorter follow-up,
perhaps 1 year. Because treatment would be systemic, both eyes will be treated (so no possibility of using
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one eye as treated and one eye as control) and, therefore, adequate controls would be required. It would be
essential that all patients (treated and controls) are similar with regard to characteristics known to affect
speed of progression of disease as well as genotype, which could be achieved by a large enough trial,
and/or by stratified randomisation. Although genotyping may pose problems if mutations on the ABCA4
gene are not found in both alleles. A matched placebo would be required to reduce the risk of the control
group self-treating with supplements.
Gene therapy
The status of gene therapy in STGD was reviewed in 2015 by Aurichio et al.133 and in 2016 by Dalkara
et al.134 Aurichio et al.133 note that the major problem is the size of the ABCA4 coding sequence (6.8 kb)
and expression of the ABCA4 gene/protein exclusively in PR cells; therefore, the vectors need large carrying
capacity and ability to transduce PR cells. Vectors with efficient PR transduction, such as adenoviruses,
cannot carry more than 4.7 kb. However, the gene can be split in two halves and loaded on two vectors.
Adeno associated virus appears safe and has been trialled in Leber congenital amaurosis (with some increase
in vision). This approach seems promising but unproven. Aurichio et al.133 report some success in a mouse
model of STGD with ABCA4 transgene expression for up to 8 months with improved dark adaptation and
reduced lipofuscin accumulation.
Dalkara and colleagues134 report proof-of-concept studies in mice, wherein subretinal injection of a
lentivirus vector carrying the human ABCA4 gene was followed by reduced A2E and lipofuscin levels.
Lentivirus can carry larger genes (8–10 kb).
A Phase I/II trial (NCT01367444) started in 2011 in Oregon and Paris with lentivirus carriage, with the
equine infectious anaemia virus (StarGen, Oxford Biomedica) in humans, sponsored by Sanofi, and will test
a range of doses. It aims to report results in 46 patients in 2018. No interim results have been published
but a press release in 2013 reported that the first dose caused no safety problems.135
A second trial (NCT01736592) began in 2012 and aims to follow up patients for 20 years. Results at 48 weeks
were presented at ARVO 2017, but so far show no difference in VA between treated and untreated eyes.136
A third trial (NCT01367444) is registered as being under way in three US centres and Paris. The Sanofi
product is known as SAR422459.
Drug treatments
Our review found no evidence of any drug yet having been shown to be effective in STGD.
Soraprazan
Soraprazan is a proton potassium-competitive acid-blocker developed for use in dyspepsia, but discontinued
for that use. It was granted orphan drug status by European Medicines Agency (EMA) for use in STGD in
Germany in November 2013.137 An orphan designation is not a marketing authorisation, but only approval
for investigation. The EMA noted that no trials had been started.
The EMA document provides an accessible explanation of how soraprazan might work:138
Soraprazan is expected to be able to enter the cells of the retina, where it attaches to the abnormal
deposits that damage the retina cells. Soraprazan is thought to cause the deposits to break up and
partly dissolve. The broken-down deposits can then be expelled by the cell’s own natural mechanisms,
reducing their build-up and the damage to the cell.
Reproduced with permission from © European Medicines Agency, 2013138
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Isotretinoin
This was reported in a review by Battaglia Parodi et al.139 to delay visual loss in STGD but to have adverse
effects including liver toxicity. The evidence comes from the mouse model (ABCA4–/–), in which it reduced
A2E and lipofuscin granules, but at a dose too high for human use.
Dobesilate
Dobesilate has been reported in a single case history95,140 to improve VA 4 weeks after a single injection,
but with no changes in fundus photography, fluorescein angiography or foveal thickness. Dobesilate is an
inhibitor of fibroblast growth factor.
4-methylpyrazole
A placebo controlled trial (NCT00346853) of 4-methylpyrazole was conducted in Utah in healthy adults to
see if it would improve dark adaptation. Jurgensmeier et al.141 reported that there were no significant
differences after six intravenous (i.v.) injections and they concluded that further trials in humans were
not justified.
ALK-001
This compound is C20 deuterated vitamin A. In deuterated compounds, hydrogen is replaced by
deuterium (deuterium is an isotope of hydrogen which has a neutron in the nucleus, as in ‘heavy water’).
In the retina, vitamin A has a tendency to ‘dimerise’, which means that two vitamin A molecules join
together. The combined compound is A2E, which is a major component of lipofuscin. Deuterated vitamin A
is much less likely to dimerise, and so the deposition of A2E in lipofuscin is reduced by about 80% in a study
in mice by Charbel Issa and colleagues.142 For a recent review of rationale and of animal studies, see Saad
and Washington 2016.143
The rationale for use is that ALK-001 interferes with the vitamin A processes that lead to the formation
of A2E and lipofuscin accumulation. A Phase I trial assessed safety in healthy volunteers (NCT02230228)
and a Phase II trial is under way, called TEASE – Tolerability and Effects of AKL-001 on Stargardt disease
(NCT02402660), which aims to recruit 50 patients followed for 24 months. The sponsor is Alkeus
Pharmaceuticals, Boston, MA, USA.
Fenretinide
Fenretinide is a synthetic form of vitamin A. Administration leads to reduced levels of retinol binding
protein (RBP) which, in turn, leads to decreased levels of vitamin A in the eye and reduced accumulation of
the toxic A2E. Safety concerns (angiosarcomas) have been raised following research in mice (see Lu et al.112
for review) but it has been used in a large study144 of 246 patients with dry AMD in two doses: 100 mg
and 300 mg (see Chapter 5). Adverse reactions were common in a group with a median age of 79 years,
and 17% of the lower-dose group and 20% of the high-dose group stopped the drug, compared with
6% on placebo. It may be worth a trial in STGD, in a much younger and fitter population. We have not
found any such trial on Clinicaltrials.gov. It has been trialled in many cancers and other diseases so safety
data are available in younger age groups.
LBS-500
This drug (www.linbioscience.com/Pipeline/LBS008)145 from Lin BioSciences (Taipei City, Taiwan) is expected
to work in a similar way to fenretinide by reducing RBP4. It was granted orphan drug status by the Food
and Drug Administration (FDA) for STGD, and a Phase I trial will be carried out in the USA in collaboration
with Columbia University, supported by NIH.146
A1120
This was originally developed for type 2 diabetes (to improve insulin sensitivity) but was ineffective.
However, it competes with vitamin A for binding on to RBP and reduces accumulation of A2E and
lipofuscin in a mouse model of STGD.147 We have not found any human studies in STGD.
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Emixustat
A Phase II pharmacodynamic study (NCT03033108) started in January 2017, which will look at safety
and retinal responses to flashes of light (measured by electroretinogram), and was sponsored by Acucela
(Seattle, WA, USA). There will be three different doses but no placebo group. Data collection is due to end
in December 2017.
Fenofibrate
A very recent conference abstract by Moiseyev and colleagues148 has reported that fenofibrate may be a
visual cycle inhibitor, and, if so, may have potential to decrease the accumulation of A2E in STGD.
Fenofibrate has been used for many years in hyperlipidaemia, but is currently of interest in diabetic
retinopathy. An unexpected finding from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes)
trial149 was a reduction in progression of diabetic retinopathy. The LENS (Lowering Events in Non-proliferative
retinopathy in Scotland) trial150 of fenofibrate to reduce progression of diabetic retinopathy is under way,
funded by the HTA programme.
Full publication of the study by Moiseyev and colleagues148 is awaited, and further pre-clinical research is
probably required before clinical trials can start. However, fenofibrate is an old, cheap and safe drug so if it
is proven to be a visual cycle inhibitor, then a trial in STGD (and dry AMD) would be justified.
Avacincaptad pegol
Avacincaptad (Zimura, Ophthotech, New York, NY, USA) is a C5 complement inhibitor or anti-C5 aptamer.
A trial (NCT03364153) in STGD is due to start in December 2017, aiming to recruit 120 patients. An earlier
smaller trial, NCT00950638, does not seem to have been published yet.
Another trial (NCT02686658) is under way in the USA and Hungary. The aim is to recruit 300 people
to three arms: two doses of the drug and sham. It is due to end in December 2018.
There is another Zimura registration on the EU Clinical Trials Register, EUCTR2015-003991-56-HU, for a
trial with a target of 900 patients, but without any sites mentioned, although the ‘HU’ implies Hungary.
Prevention of Stargardt
Sohrab and colleagues151 report a single case in which a man with STGD and his wife, who was a
carrier but unaffected (i.e. heterozygous, carrying only one copy of the responsible gene), had IVF and
pre-implantation diagnosis to identify an embryo with a normal maternal allele before implantation.
The child was born healthy and will be an unaffected carrier.
Summary and conclusions
The evidence on treatment of STGD is sparse. We found only one RCT and it had only 12 patients. Most
studies did not have a control group, were far too short term (did not last long enough to determine the
effect and potential side effects of the treatment), and the quality of some studies was poor. There has
been very little research into the treatment of STGD compared with that of AMD.
In prevention of lipofuscin accumulation, several drugs may have potential. Early trials of ALK-001 and
emixustat (Acucela, Seattle, WA, USA) are under way. Fenretinide has shown promise in dry AMD and we
think that a trial in STGD may be justified. We have not found any. We have not found any trials of A1120
in humans with STGD.
Gene therapy is at an early stage, but a study (StarGen NCT01736592) is under way in Oregon and Paris.
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Cell transplantation to replace the RPE has been tried in one study in only nine people with STGD, but
looks promising. RPE transplants may not be suitable for all people with STGD because other parts of the
eye (the choriocapillaris, which provides the blood supply) can be affected and RPE cells will not replace
those. There is also an issue of timing – if the cells are given at a very late stage then they may not be of
benefit if other cells that are needed, such as those in the choriocapillaris or even PR cells, are already lost.
There is a plausible rationale for the benefits of lutein and zeaxanthin supplementation but no evidence.
Nutritional supplements have been used in one short study wherein people with STGD were found to have
lower levels of macular pigments than people without the condition.114 There were no changes in vision.
Although this could be seen as negative result (no improvement), it may suggest a beneficial effect (no
progression) but the study was really too small and too short to determine whether lutein supplements
help. There are plausible theories that lutein (and zeaxanthin, another type of macular pigment) could slow
progression, and we think that a longer and larger trial should be considered.
One supplement that should not be taken is vitamin A. There are some data from basic laboratory research
suggesting it would cause harm in people with STGD by increasing lipofuscin in the retina.
Two key aspects will be the stage at which intervention is undertaken and case selection. Some treatments
may be potentially suitable for an earlier stage and others for a later stage.
It is very important that outcome measures of trials are carefully selected. If function is lost, it may not be
recoverable and thus vision may not improve. In inherited retinal diseases, main outcomes should include
prevention of functional and structural deterioration (rather than improvement) as measured by best
corrected vision, or ERG, or prevention of enlargement of atrophy on AF or prevention of loss of structure
by OCT.
It is important that a clear definition of STGD is used for inclusion in the studies. Unfortunately, in many
patients, mutations in the ABCA4 gene are identified in only one allele, so a confirmed genetic diagnosis
may not be made in all cases. Some studies included patients in whom only one mutation was identified.
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Chapter 3 Physical treatments for age-related
macular degeneration
In this chapter we examine the evidence for seven interventions. There are considerable problems withsome of the evidence that we have, or that we do not have, with one concern being publication bias.
For example, we have one trial of acupuncture that reports benefit.152 We do not know how many
negative unpublished acupuncture trials there may be. This problem also applies to other interventions,
and we note elsewhere that some registered trials have never been reported.
Acupuncture
Quantity and quality of research
Reviews
The American Academy of Ophthalmology153 reviewed the evidence published from January 1970 up to
March 2007 on the safety and effectiveness of acupuncture, and concluded that there was insufficient
evidence to justify its use. They found no relevant articles in MEDLINE, but found two articles from an
internet search, from a journal not indexed in MEDLINE. Both articles were non-randomised case series.
We therefore focused on publications in later years.
Studies
One before-and-after study conducted in Austria with 328 participants was identified.152 Acupuncture
was delivered twice a day, 5 days per week for 2 weeks. The study was assessed as poor quality and the
funding source was not reported (Table 5). Mean age was 77.4 years [standard deviation (SD) 8.6 years].
VA was reported as the percentages of lines correctly read from 3 m [22%, interquartile range (IQR) 0–5%]
and from 40 cm (45%, IQR 20–67%).
TABLE 5 Results of acupuncture in dry AMD
Krenn et al.152 (before and after; PQ) Acupuncture, n= 328
Median (IQR) VA reading from 3-m distance (% lines correctly read) Baseline 22 (0–55)a
2 weeks 33 (0–66)a
Median (IQR) VA reading from 40-cm distance (% lines correctly read) Baseline 45 (20–67)a
2 weeks 66 (50–82)a
Vision at 3 m (%)
Improved 44.2
Stable 51.5
Worsened 4.3
Vision at 40 cm (%)
Improved 88.4
Stable 8.8
Worsened 2.7
PQ, poor quality.
a Estimated from figure in Krenn et al., 2008.152
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Results
Consecutive patients with dry AMD (details of stage not given), as diagnosed by their ophthalmologist,
were included. After 2 weeks of acupuncture, the median VA at 3-m distance and at 40-cm distance
improved in 44.2% and 88.4% of participants, respectively. Vision at 3 m and at 40 cm worsened in 4.3%
and 2.7% of participants, respectively. No statistical analyses were presented.
Summary
One large before-and-after study found improvement in vision after 2 weeks of acupuncture; however,
no statistical analyses were presented and the study was assessed as low quality.
Registered studies
The study NCT02255981 aims to use acupuncture to treat 33 patients in Columbia with unspecified
macular diseases. With no control group, it is unlikely to be helpful.
Blue-light-filtering intraocular lenses
Mechanism of action
The outer layer of the retina has an abundant supply of oxygen from the choriocapillaris and oxidative
damage, triggered by the effects of light, is a risk. Several studies have shown that people most exposed
to sunlight, like fishermen, have a higher risk of AMD (see Cuthbertson review154). The risk may be higher
in people who are both exposed to sunlight and have low antioxidant levels.155
The structure of the human eye reduces penetration of harmful light. Protective mechanisms include the
structure in front of the retina (especially the lens), various enzymes and the macular pigments lutein and
zeaxanthin, which absorb blue light.
Cataract surgery is common in older people and the natural lens is replaced by an artificial one – an
artificial intraocular lens (IOL). These can be protective only against ultraviolet radiation (UVR) or against
both UVR and blue light. The argument against additional blue-light-filtering appears to be based on the
effects on vision in poor light (scotopic vision) and circadian rhythms and sleep. Scotopic vision declines
with age and is reduced by blue-light-filtering IOLs.
People with artificial lenses are described as ‘pseudophakic’. People who still have their own lens are
called phakic.
There are several uncertainties:
l Are people more at risk of AMD after cataract removal?
l If so, do blue-light-filtering IOLs prevent AMD?
l In people with existing AMD, do blue-light-filtering IOLs reduce or prevent progression?
Quantity and quality of research
Reviews
Four good reviews of blue-light-filtering IOLs were found (Cuthbertson et al.,154 Davison et al.,156
Henderson and Grimes157 Lai et al.158) but they could not be described as systematic.
The reviews came to different conclusions. Cuthbertson and colleagues154 consider that evidence is lacking
on whether blue-light-filtering IOLs are beneficial, and that only large long-term studies could provide
evidence. They made no recommendation. Davison and colleagues156 conclude that blue-light-filtering
IOLs should be used even without definite proof of protection against AMD. They conclude that such IOLs
have no significant proven harms, can reduce glare and could be protective against the development and
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progression of AMD in pseudophakic eyes. They admit that definite proof of protection against AMD
is lacking.
Henderson and Grimes157 conclude that there is no evidence that definitively demonstrates that blue-light-
blocking IOLs have any effect on AMD. However, the evidence that they have disadvantages compared
with UVR-only blocking IOLs is weak. Henderson and Grimes157 argue that the likelihood of any further
RCTs being done to assess the effect on AMD is very low and that blue-light filters should be used because
it is very likely that they would protect the eye.
Writing early in 2014, Lai and colleagues158 provide another non-systematic but useful review. They note
that yellow-tinted, blue-light-filtering IOLs reduce blue-light irradiance of the retina by 62–82%, whereas
clear UV-blocking IOLs reduce it by 43–64%; these ranges reflect the variation across studies. They also
note that epidemiological studies of the association between light exposure and the development of AMD
are conflicting. They suggest that there are at least two reasons for this. First, it is difficult to retrospectively
quantify lifetime light exposure in people with and without AMD. Second, the development of AMD
depends on many factors, including genes, smoking and diet. For example, Fletcher and colleagues155
found that the risk of AMD was increased only in those with low antioxidant levels. Lai and colleagues158
conclude that uncertainties remain over both the association between cataract surgery and the risk of
AMD, and the value of blue-light-filtering IOLs after cataract surgery.
Chew and colleagues,159 from the AREDS study, found no definite effect of cataract surgery on the risk of
progression of AMD. Their patients received clear UV-blocking IOLs. In a later study, available only as an
ARVO abstract160 with data from AREDS 2, they again report no increase in progression of AMD after
cataract extraction. Indeed, fewer eyes developed AMD after cataract surgery than eyes that did not have
cataracts removed.
In a recent update, Downes,161 who was one of the authors of the Cuthbertson review,154 noted that
there was little new research on whether the risk of AMD or of progression among those who had it was
increased after cataract surgery.
However, since the previous reviews were written, several new studies on choice of IOL have been published.
Studies
Four studies were included.
Pipis and colleagues162 from Germany assessed progression in 66 eyes, 27 with a blue filter and 39 with a
non-blue filter at 1 year, non-randomised, in people with pseudophakia and GA. Funding sources were
not reported. GA progression was measured using spectral domain OCT and automated software analysis.
At 1 year, progression was statistically significantly less in eyes with a blue-light filter than eyes with a
no-colour filter [0.72 mm2 (SD 0.39 mm2) vs. 1.48 mm2 (SD 0.88 mm2); p = 0.002]. AEs were not reported.
The Pipis study162 was assessed as poor quality because on the NIH risk-of-bias checklist it was unclear how
participants were selected, the sample size was not justified, the outcome assessors were not blinded to
the intervention, and potential confounding variables were not adjusted for.
Nagai and colleagues163 reported a similar study in which they compared 52 eyes with blue-light-filtering
(yellow-tinted) IOLs and 79 eyes with standard UV-filtering (colourless) IOLS. The groups were not randomised.
They recorded FAF, GA and any wet AMD at baseline (cataract removal) and 2 years later. No abnormal AF
was observed in the blue-light-filtering group but it developed or increased in 15% of the colourless IOL group
(p= 0.0016) (Table 6).
Chong and colleagues,165 in a study available only as an abstract, carried out a study in 128 people who had
cataracts removed from both eyes. The study could not be assessed as good quality because of lack of
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detail. They implanted a standard clear UV-light-filtering IOL in one eye and a blue-light-blocking IOL in the
other. They found no significant difference in the progression of AMD after a mean follow-up of 26 months,
but no detailed results were presented. The authors recommend longer follow-up but it is not clear whether
they intend further publications.
Lavric and Pompe164 report the results of a study in 30 people having bilateral cataracts removed, with a
UV-only light-filtering IOL placed in one eye and a blue-light-filtering IOL in the other. They report that
after at least 2 years, there was no significant difference in proportions developing early signs of AMD.
Other studies
A study reported by Łak and colleagues166 is in Polish and so only the English abstract is available to us. Forty
eyes of 20 patients had cataracts extracted, with a standard IOL in one eye and a blue-light-filtering IOL in
the other. After 18 months, they concluded that there was no protection from blue-light-filtering IOLs.
Brockmann and colleagues167 have noted that available blue-light-filtering IOls may vary in the protective
characteristics, but that most mimic the protection of the natural lens.
Summary
The evidence is mixed. The Davison156 and Henderson157 reviews make a good case for routine use of
blue-light-filtering IOLs. The Pipis trial162 provides some support for a reduction in progression but scores
poorly on quality. The Chong,165 Lavric164 and Łak166 studies, which have a stronger design with patients
having standard IOLs in one eye versus blue-light-filtering ones in the other, report no differences, but two
(Chong165 and Łak166) are available only as abstracts. The adverse effects on scotopic vision and sleep
disturbance do not seem to be clinically significant.
However, a very large trial is under way, called the CLOCK-IOL colour study. Nishi and colleagues168 from
Nara in Japan report that they plan to randomise 1000 patients after cataract surgery to a standard IOL or
a blue-light-blocking IOL, with AMD one of the primary outcomes, assessed first after 1 year but with
follow-up planned for up to 20 years. The protocol has been published.168 The trial is registered on the
University Hospital Medical Information Network as UMIN000014680.169
TABLE 6 Result of blue-light filter studies
Study and outcome Intervention Comparator p-value
Pipis et al.162 Blue-light filter, n= 39 eyes No blue filter, n= 27 eyes
Retrospective cohort; PQ
GA progression in 1 year (mm2),
mean (SD)
0.72 (0.39) 1.48 (0.88) p = 0.0002
Nagai et al.163 Blue-light filter, n= 52 eyes Colourless lens, n= 79 eyes
Cohort study; FQ
Abnormal FAF development or
increase in size or density, n (%)
over 2 years
0 12 (15.2) 0.0016
Abnormal FAF decrease, n (%) 3 (5.8) 2 (2.5) NR
Wet AMD or GA development 1 (1.9) 9 (11.4) 0.042
Lavric and Pompe164 Blue-light-filter IOL, n= 30 eyes UV-filter IOL, n= 30 eyes
Cohort study; PQ
Signs of early DRAMD (e.g. drusen
or RPE changes), n (%)
5 (17%) over 32 months (SD 8) 5 (17%) over 34 months (SD 8)
FQ, fair quality; PQ, poor quality; NR, not reported.
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Rheopheresis
Rheopheresis, also called haemopheresis, is a procedure in which blood is removed from the body, passed
through a filter to remove the larger molecules, and then returned into the bloodstream. It is similar to renal
haemodialysis. The patient’s entire blood volume is filtered over a 2- to 4-hour session. In the largest trial,
eight treatments were given over 10 weeks. Blood is taken from one arm, filtered, and reinfused into the
other arm. The filtration removes only larger molecules, including immunoglobulins such as immunoglobulin
M (IgM), fibrinogen, von Willebrand factor and low-density lipoprotein (LDL) cholesterol. About half of
these are removed. Smaller molecules, such as albumin and high-density lipoprotein (HDL) cholesterol,
are not extracted.
Mechanism of action
Brunner and colleagues170 suggest that a key feature in AMD is impaired choroidal perfusion, and that
reduction of plasma viscosity can improve this. However, reduced viscosity may be more important in the
retinal circulation where vessels are smaller (3–10 µm compared with 20–40 µm in the choroidal capillaries).
Perfusion pressure may be more important than viscosity as choroidal vessels are wider, fenestrated and
have lower pressure than retinal vessels.171,172
Quantity and quality of research
Reviews
One non-systematic review by Pulido and colleagues173 was identified (see Report Supplementary Material 2).
It concluded that:
Rheopheresis treatment shows strong promise as a viable clinical option for patients suffering from the
dry form of AMD in terms of minimizing vision loss, vision restoration, and overall quality of life factors.
Pulido and colleagues173
However, this was based largely on the interim results of the Multicenter Investigation of Rheopheresis for
Age-related macular degeneration (MIRA) trial,174 of which Dr Pulido was an investigator, and the final
results showed no overall benefit.
Studies
Eight studies of haemopheresis were identified. Five studies were RCTs: Koss 2009,175 Pulido 2006,176
Brunner 2000,170 Rencova 2015177 and Swartz.178 The RCTs randomised 168 patients to haemopheresis
and 132 as controls, but the largest174 was bigger than all the rest put together, with 104 randomised to
haemopheresis. Two were CCTs (non-randomised) (Blaha 2013179 and Studnicka 2013180) and one was a
large retrospective cohort study from the Rheonet Registry.181
Further details are given in Report Supplementary Material 2.
The studies were conducted in the Czech Republic (n = 3),116,179,180 Germany (n= 3)170,175,181 and the USA
(n= 2).174,178 In all but one study170 participants received between 8 and 10 treatments. Duration of follow-up
was between 20 weeks and 3.5 years (some participants in the Brunner study continued treatment and were
followed up to 4 years). One RCT175 had a low risk of bias, with four of the Cochrane risk of bias criteria graded
low and three high. The remaining RCTs were assessed as having uncertain risk of selection bias;170,176–178 and
the CCTs were assessed as at high risk of selection bias.179,180 The retrospective cohort study was assessed as
poor quality.181 Five studies had small sample sizes (< 22 participants per arm). Where reported, mean age
ranged between 64 and 76 years and studies typically had a greater proportion of women than men. BCVAs at
baseline were reported in six studies. The funding source was not reported by two of the studies,163,164 three
received commercial funding158,162,168 and three received non-commercial funding.165–167
Two studies182,183 used rheophoresis in combination with plasma exchange and selective adsorption.
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The earliest studies (not included above) came from a group in Cologne. In 1995, Brunner and colleagues184
reported that in a series of 10 patients with ‘various macular diseases’ (no details given so not an inclusion),
haemophoresis (which they called membrane differential filtration) reduced plasma viscosity by 15% by
removing the large molecules. The largest reductions (measured the day after treatment) were in IgM (down
to 33% of pre-treatment level), alpha-2-macroglobulin (30%), LDL (33%) and cholesterol (33%) but there
were also reductions in HDL cholesterol (62% of pre-treatment level) and IgG (59%). VA was reported to
improve by at least one Early Treatment Diabetic Retinopathy Study (ETDRS) line in 7 out of the 10 patients
the day after treatment, but no details of baseline or final VA are given.
A second case series from 1996182 reported that a combination of plasma exchange, selective adsorption
and membrane differential filtration improved VA by at least one ETDRS line 24 hours after treatment
in 11 out of 17 patients (15 out of 31 eyes) with AMD (about half with wet AMD and results not given
separately). One ETDRS line is not usually considered a clinically important change.
Brunner and colleagues 2000170 randomised 40 people with AMD in at least one eye, of whom 22 had dry
AMD (based on the presence of drusen, pigment clumping, areolar atrophy) and VA 20/160 to 20/32, to
membrane differential filtration with five sessions over 21 weeks. Mean age was 71 years. At follow-up
(11 months for treated group, 12 for controls) there was deterioration in VA in both groups. The change
was not significantly smaller in the haemopheresis group than for the controls (Table 7).
In a longer-term case series with 20 participants with dry AMD (available only as an abstract),183 Brunner
and colleagues reported significant improvements in BCVA 1.9 lines at 2 years and 1.2 at 3 years but not
at 4 years follow-up, after combined plasma exchange, selective adsorption and filtration.
Koss and colleagues175 included 43 people with advanced AMD (wet or dry) in the non-study eye but not
in the study eye. For inclusion, patients had to be between 45 and 85 years old, with AMD (no details,
but confirmed by fluorescein angiography and fundus photography) in both eyes, and to have had dry
AMD in the study eye. Study eyes had to have BCVA 0.1–0.8 determined with the use of the ETDRS
charts. Treatment was 10 sessions over 17 weeks. At 7.5 months there was a statistically significant
difference in the change in BCVA between the two groups favouring haemopheresis (see Table 7).
Although not statistically analysed, there were higher proportions demonstrating improvement in VA
and lower proportions demonstrating deterioration in the haemopheresis groups than the control group.
At 25 months, about half of the patients were retested (others did not return after the end of the trial).
The rheophoresis patients had lost an average of 1.7 lines and the controls had lost an average of 3.1
lines. By 25 months, four control patients and two haemopheresis patients had developed wet AMD.
A pilot study in Utah does not appear to have been published in full, but only as a conference abstract.
Swartz and Rabetoy178 included 30 people with non-exudative AMD characterised by large soft drusen and
VA 20/40 – 20/100 in one eye. They were randomised to three groups: rheophoresis, sham rheophoresis
(blood moved from arm to arm through tubing but not filtered) and controls. No mean baseline values for
BCVA by group were reported but the improvement at 20 weeks was reported to be greater (+1.9 ETDRS
lines in active group and +1.3 lines in controls) in those treated with rheopheresis than the two control
groups, although no statistical testing was undertaken. The sham group appeared to do better than the
control group and it was suggested that this might be because large molecules adhered to the tubing.
Lane 2004185 wrote an article for Eurotimes (www.eurotimes.org, a journal of ESCRS – European Society
for Cataract and Refractive Surgery) in which he interviewed experts in the field. He describes the Utah
pilot by Swartz and Rabetoy178 as ‘the FDA pilot study’, and states that the unexpected sham result was
the reason why FDA did not wish to include it in what was expected to be the definitive study of
rheophoresis, the MIRA trial, approved by FDA.
The MIRA trial by Pulido et al.174 was a RCT with 216 people with dry AMD in the study eye with ≥ 10
drusen and BCVA 20/32 to 20/125. GA was allowed as long as it covered less than three disk areas.
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TABLE 7 Results of rheopheresis studies
Koss 2009175 Rheopheresis, n= 22 Control, n= 21 p-value
Change in BCVA, 7.5 months, ETDRS lines,
mean (95% CI)
0.63 (0.28 to 0.99) –0.31 (–0.64 to 0.02) Difference
0.9 (0.2, 1.7),
p= 0.014
Pulido 2006,174 Pulido 2005176
RCT; unclear ROB Rheopheresis, n= 104 Placebo, n= 69 p-value
Mean logMAR ETDRS VA at 12 months (SD) 0.02 (0.213) 0.02 (0.20) p= 0.977
Brunner 2000170
RCT; unclear ROB
Membrane differential
filtration, n= 20 Control, n= 20 p-value
Change in VA at follow-up, ETDRS lines,
mean (SD), approximately 11 months
–0.21 (2.4) –1.83 (2.9) Difference
1.6, p= 0.06
Swartz and Rabetoy 1999178
RCT; unclear ROB Apheresis, n= 10
No
filtration,
n= 10
No
treatment,
n= 10 p-value
BCVA mean change (logMAR) ETDRS chart
lines
1.9 1.3 0.6 Not reported
Rencova 2015177
RCT; unclear ROB Rheopheresis, n= 12 Control, n= 12 p-value
BCVA, ETDRS letters, median (95% CI),
2.5 years
79.0 (57.3 to 83.4) 72.5 (23.4 to 83.1) p= 0.021
Drusenoid pigment epithelial detachment,
mm2, mean (SD)
0.71 (1.27) 9.19 (9.51) p< 0.001
Blaha 2013179
CCT; high ROB
Rheohaemopheresis,
n= 37 Control, n= 34 p-value
BCVA (95% CI) at 2.5 years, Snellen lines 0.68 (0.35 to 1.00) 0.52 (0.25 to 0.80) p= 0.09
Studnicˇka 2013180
Rheohaemopheresis,
n= 19 Control, n= 18 p-value
Mean BCVA (95% CI) at 3.5 years,
Snellen lines
CCT; high ROB
0.79 (0.41 to 1.0) 0.7 (0.32 to 0.87) p= 0.125
Mean (SD) DPED, mm2 4.13 (3.84) 6.69 (4.2) p= 0.015
Klingel 2010181
Retrospective cohort; PQ AMD, eyes, n= 428 Controls, eyes, n= 85 p-value
% of eyes with improvement in VA
(difference of ≥ 0.1 log Mar)
42 26 p< 0.01
% of eyes with loss in VA
(difference of ≥ 0.1 log Mar)
17 40 p< 0.01
BCVA, best corrected visual acuity; PQ, poor quality; ROB, risk of bias (selection).
DOI: 10.3310/hta22270 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 27
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
Wet AMD was excluded. The mean groups were well matched at baseline. Quality assessment was mixed,
with risks of selective reporting, incomplete outcome data, and allocation concealment unclear. Baseline
VA was quite well matched. The interim results based on the first 43 patients (28 rheopheresis and
15 controls) were promising.186 At 12 months, 16% of the rheopheresis group, but none of the controls,
had improved VA by ≥ 3 lines. A total of 58% of the rheopheresis group achieved VA 20/40 or better
compared with 14% of the controls. However, it should be noted that numbers are small as 14% of the
controls is two patients. A total of 29% of the controls (four patients) lost 3 lines of vision compared with
5% of the rheopheresis group.
However in the final analysis, Pulido and colleagues174,176 found no statistically significant difference
in VA between groups at 12 months (see Table 7). Many patients entered into the trial did not meet the
inclusion criteria, and 37% of the treated patients had to be excluded. Reanalysis after removing them
did show a statistically significant difference between arms but only of 0.09 lines, which is not clinically
relevant. The authors concluded that ‘At best this was a flawed study in that 37% of the treated cases did
not meet inclusion criteria, and at worst there was no evidence of effect.174
A case series (not an inclusion because it is not published) with a similar intervention to MIRA was
carried out in Canada, called Prospective Evaluation of visual functioning with Rheopheresis treatment
for age-related macular degeneration in Canada (PERC). The only reports we have found so far are a
conference abstract by Wong and colleagues187 from the 2006 ARVO meeting and presentations by
members of OccuLogix (San Diego, CA, USA) reported in Primary Care Optometry News (www.healio.com/
optometry) and in business media news. The abstract provided little detail but an Occulogix press release
reports that the PERC results were presented at the American Society of Retinal Specialist 2005 annual
meeting, and that 12 out of the 30 PERC patients gained ≥ 1 line of vision, with 16 being unchanged and
two losing 1 line of vision or more.188
The Rencova 2015 RCT177 included 38 people with dry AMD. Recruits had high-risk, dry AMD with soft
drusen, confluent soft drusen and drusenoid pigment epithelium detachment (DPED). Baseline BCVAs were
74 letters in both groups. Median BCVA was higher in the haemopheresis group than the control group at
2.5 years (79 vs. 72.5 letters) and the DPED area as measured by fundus photography was significantly
smaller in the haemopheresis group (see Table 7). A higher proportion of participants in the haemopheresis
group demonstrated improvement in DPED area and fewer demonstrated deterioration compared with the
control group (Report Supplementary Material 2). This study has a possible overlap of participants from
Blaha179 and Studnicˇka,180 which are reported next.
Blaha and colleagues 2013179 included 38 people with AMD in both eyes, confirmed in one or both eyes by
fluorescein angiography and fundus photography, with soft drusen, confluent soft drusen and DPED. There
were 34 control patients. At 2.5 years there were no statistically significant differences between groups in
BCVA (see Table 3). Higher proportions of participants had improvement and lower proportions had
deterioration in VA in the haemopheresis groups than the control group, although it is unclear whether or
not this was analysed on the whole sample (Report Supplementary Material 6). No participants progressed
to wet AMD.
In a non-randomised (but with some controls) study from the same centre, Studnicˇka and colleagues
2013180 included 19 patients with bilateral soft drusen and, in 17 patients, DPED. No GA is mentioned.
Baseline BCVA was 0.74 (95% CI 0.34 to 1.0). At 2 years’ follow-up, there was a significant difference
between groups in BCVA, but at 3.5 years, no significant difference was seen (see Table 7). DPED area
was smaller in the haemopheresis group than the control group. Two eyes in the haemopheresis group
and six eyes in the control group developed CNV.
Klingel and colleagues 2010181 included in their large retrospective cohort study from the Rheonet Registry
people with dry AMD, soft drusen, pigmentary abnormalities and VA between 0.1 – 0.63. Dry AMD was
not defined, but did not include people with just soft drusen. Mean BCVA was not reported. They compared
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results in 428 eyes of 279 patients treated with rheophoresis, with those in 85 eyes of 55 patients who were
deemed suitable for rheophoresis but not treated for various reasons (poor vascular access, no reimbursement,
unwilling to be treated), but no comparison of the baseline data from treated and untreated groups is given,
so we cannot say whether like was compared with like. The study was more about safety and adverse effects.
Significantly more eyes improved in the haemopheresis group and significantly more eyes deteriorated in the
control group (see Table 7).
Combinations of rheophoresis and other interventions
Two studies182,183 used rheophoresis in combination with plasma exchange and selective adsorption.
Brunner et al.182 reported in a case series in 1996 that a combination of plasma exchange, selective
adsorption and membrane differential filtration improved VA by at least 1 line, 24 hours after treatment
in 11 out of 17 patients (15 out of 31 eyes) with AMD (about half with wet AMD and results not given
separately). A single ETDRS line is not usually considered clinically important.
In a longer-term case series with 20 participants with dry AMD (available only as an abstract), Widder and
colleagues183 reported significant improvements in BCVA 1.9 lines at 2 years and 1.2 at 3 years but not at
4 years follow-up, after combined plasma exchange, selective adsorption and filtration.
A small trial by Kamami-Levy and colleagues189 is as yet available only as an abstract from ARVO 2014.
Patients were randomised to rheopheresis (n = 10) or controls (n = 11). The control intervention, if any, is
not specified. After 24 months there were no statistically significant differences in VA or atrophic area.
Adverse events
Adverse event rates were low in three studies (0%, Studnicˇka 2013;180 2%, Koss 2009;175 5%, Blaha
2013;179) (for specific events see Report Supplementary Material 2). However, Pulido 2006174 reported that
during the period of follow-up, 34% of haemopheresis participants and 28% of control participants
experienced an AE, with serious AEs in 24% of treated participants. Few details are given of what these
serious AEs were. No serious AEs recorded by Brunner 2000.170 In the study by Klingel 2010,181 0.24% of
people with dry AMD experienced retinal bleeding (Table 8). AEs were not reported in the Rencova177 or
Swartz178 studies.
Summary
Seven intervention studies, with unclear risk of bias in four170,174,176–178 and poor quality in two,190,191 were
included. Only one study (Koss192) was thought to have a low risk of selection bias. Results were mixed,
with statistically, but not really clinically, significant effects of haemopheresis on VA reported in only three
studies, all of which included very small numbers of patients. The studies that did not show differences
between groups in BCVA included Pulido,174 with by far the largest numbers, and Studnicka 2013180 and
Blaha 2013179 with longer periods of follow-up.
Overall, the results do not provide a strong case for the value of haemopheresis on VA. The two studies
from Germany by Koss et al.192 and Brunner et al.170 reported statistically significant differences, and
Lane179 reports that the largest German medical insurance company, Deutsche Kranken-Versicherung AG,
agreed to fund rheopheresis. The largest study, the MIRA trial by Pulido et al.,174 was deemed to be
negative and we could not find any FDA approval for the treatment on the FDA website. One interesting
feature, reported by Brunner and colleagues,170 was that the effect of rheophoresis persisted for much
longer than the reduction in viscosity, implying that a relatively short period of reduced viscosity could have
longer-lasting effects.
The practicality and acceptability of having older people attend for 2- to 4-hour sessions, about 10 times a
year, would have to be considered.
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A related technology is HELP (heparin-induced extracorporeal lipoprotein precipitation). A study, NCT01840683,
was registered in 2013 to be carried out at the Canadian Centre for Advanced Eye Therapeutics, a private
company in Mississauga, Ontario, Canada. Some results were published by Ali and Armogan in Retina Today
(Sept/October 2008, 72–75). After eight HELP sessions, VA was reported to have improved by at least 1 line in
just over half of 33 eyes of 19 patients, and by ≥ 3 lines in 15% (about 5 patients). Drusenoid macular thickness
was reduced in over half the eyes. No full publications were found, but there is a conference abstract.193
Conclusion: given that most positive studies were small, that they mostly had uncertain risks of bias, that
effect sizes were modest, that the largest one was negative and that treatment would be inconvenient to
older people patients, we do not see rheopheresis as a research priority.
Microcurrent stimulation
Electrical current stimulation with transcutaneous electrical nerve stimulation (TENS) is commonly used in
medicine to relieve musculoskeletal pain.194 Recently there has been interest in using minute amounts of
electrical stimulation, termed MCS, in an attempt to improve or restore vision in dry AMD.
The MCS uses electrical stimulation to nerve fibres via cutaneous electrodes at a much lower current
that TENS.194 These are attached to a controller (microcurrent stimulator), which delivers a fixed current,
commonly of between 50 and 500 µA, with biphasic waveform at various frequencies set by the therapist.194
MCS was first used for evoking phosphenes (visual perceptions induced by stimuli other than light) in early
visual prostheses for blind patients.195 A minimum of 150 µA seems to be needed to elicit phosphenes in
patients with AMD so that is the minimum current used.
One study described below, by Anastassiou and colleagues,196 used 30–50 µA above the minimum.
Sehic and colleagues197 suggest that the optimum level may vary among retinal diseases. Clinically, MCS
can be applied via various routes, namely transpalpebral, transorbital, transcorneal, subretinal, epiretinal,
TABLE 8 Adverse events with rheopheresis
Koss 2009175 Rheopheresis, n= 25 (%) Control, n= 22 (%)
Any AE 2.1
AE requiring treatment 0.8 4.5 (not treatment
related)
Serious AE 0
Pulido 2006,174 Pulido 2005176 Rheopheresis, n= 129 (%) Placebo, n= 69 (%)
AE requiring intervention during day of treatment 24.0 5.8
AE during follow-up (after treatment phase) 34.4 27.5
AE requiring intervention during follow-up (after treatment phase) 30.3 27.5
Blaha 2013179
Rheohaemapheresis,
n= 37 (%) Control, n= 34 (%)
Any AE 5.4
Any AE requiring intervention 1.0
AE resulting in treatment termination 0
Klingel 2010181 AMD, n= 833 (%)
Retinal bleeding 0.24
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transchoroidal and direct stimulation of the optic nerve or brain.197 The most common MCS delivery method
currently used in AMD studies is the transpalpebral approach.196,198,199
The mechanism of action is not understood and many suggestions have been made. Current thinking on
the mechanism of action of MCS comes from studies on experimental animal models, summarised in a
narrative review by Sehic et al.197 The main mechanisms proposed are neuroprotective, increasing cellular
activity, improving cellular permeability, increasing nerve conduction velocity, reducing inflammation and
increasing blood flow to the retina.194,197
Electrical stimulation may have a neuroprotective effect on retinal ganglion cells by increasing expression of
brain-derived neurotrophic factor, ciliary nerve trophic factor (CNTF) and of Bcl-2 (family of proteins involved
in the regulation of apoptosis) by Müller cells.197 An anti-inflammatory action may be achieved through
inhibition of microglial secretion of interleukin-1β and tumour necrosis factor α.197 Electrical stimulation can
also increase intracellular calcium influx, thus causing neuronal depolarisation and increased cyclic adenosine
monophosphate levels.197 It was also demonstrated that retinal proteins associated with cellular signalling
and neuronal transmission are up regulated with MCS.197 In a study involving 10 healthy volunteers,
Kurimoto et al.200 found that transcorneal MCS increased choroidal blood flow. Although it is not clear
whether or not the investigators were masked to the treatment allocation, if this finding were to be
reproduced in other studies it could offer further support to the potential beneficial effect of MCS in
AMD196,198,201 as inadequate choroidal perfusion appears to play a role on the pathogenesis of this
disease.201,202 Another potential mechanism by which MCS could affect the retina is by its potential effect
in the RPE, for which there is evidence from in vitro research on cells alone.203
In brief, if it works, the mechanism(s) are not known but there are possibilities.
Quantity and quality of research
Reviews
The American Academy of Ophthalmology Taskforce194 on complementary therapy assessment published a
systematic review in 2004. The review concluded that there was no strong evidence to demonstrate the
effectiveness of MCS for AMD. It only included three studies: Michael and Allen 1993,204 Allen 1998205 and
Wallace 1997.206 The review did not identify any serious adverse effects on health but did comment that
there might be a significant cost associated.
The Task Force advised patients considering the treatments to ask the following questions of the providers:
l Is the treatment being provided as part of a FDA-authorised study?
l What are the results and benefits compared with a control group?
l What other treatment options are available and how do they compare?
l Is lifelong treatment with MCS necessary to maintain benefits?
These seem useful questions.
Studies
Six studies including 213 participants were identified (203 treated, 10 given placebo). One study207 and
one subgroup97 were in STGD207 and are reported in Chapter 2. A number of studies included eyes with
other retinal conditions. Data on these were not extracted. One study was a RCT by Anastassiou et al.
2013.196 Four studies were single-arm before-and-after studies: Shinoda 2008,199 Chaikin 2015,198 Kondrot
2002208 and Kondrot 2015.97 One case series reported two substudies.204,205 The studies were conducted in
Japan (n = 1), Germany (n = 1) and the USA (n = 4). The duration of treatments varied between 3 days
and 3 months, where reported. In two studies, participants were also given nutritional supplements.97,204
Follow-up was between 3 days and 24 months. The RCT196 was assessed as having unclear risk of selection
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bias and a risk of outcome detection bias. One of the before-and-after studies199 was of fair quality.
The remaining studies were of poor quality10,97,198,204,208 (see Report Supplementary Material 2).
In the RCT and prospective before-and-after studies, the sample sizes were small as each had < 30 participants.
The retrospective study included 70 participants with dry AMD.97 Mean ages ranged from 76 to 83 years.
The funding sources were not reported. In one study, participants paid US$3000 to have the treatment.
Results
Anastassiou and colleagues 2013196 included 22 people with dry AMD, no neovascular disease and VA
between 25 and 45 letters. Details of the stage of AMD were not given. At 6 months, there was no
statistically significant difference in the change in VA, contrast sensitivity or macular sensitivity (Table 9).
However, they did report an improvement in VA after 1 week, an improvement of > 10 letters in three
patients at 4 weeks, and an increase in contrast sensitivity at 4 weeks. Anastassiou and colleagues 2013196
concluded that transpalpebral electrostimulation led to a temporary increase in visual function in some
patients, but that further research was needed.
Shinoda and colleagues 2008199 included people with wet or dry AMD (wet not reported here). The
inclusion criteria for dry AMD imply that GA was present. The study was graded as fair on the NIH
checklist but it was very small, containing only seven patients with dry AMD. They reported a statistically
significant improvement in the number of ETDRS letters in the dry AMD group from 39.8 to 42.9
(p = 0.04) after 4 weeks (see Table 9). However, they conclude that the limitations of the study (small
numbers, short follow-up and the absence of a control group) means that it cannot be used to justify the
use of MCS. They recommend a larger RCT with longer follow-up.
The Kondrot 2002208 study was graded as very poor quality, achieving only one positive answer out of
12 items on the NIH checklist. Kondrot 2002208 treated people with dry AMD (no details are given) with a
combination of MCS, vitamins and nutritional supplements (details of those not given), starting with a pilot
of 10 patients. There was no loss of vision, change in Amsler grid or change in intraocular pressure (IOP)
in the first group of 10 patients, so the study was then expanded to treat 56 eyes of 28 patients with
no control group. Before treatment, the range of VA was 20/25 to 1/400. After treatment, up to 1-year
follow-up, the range of VA was reported to be between 20/20 and 3/800. The proportion of participants
with improvement of VA was 66% and the range of improvement was mean 0.48 lines, range 0–2.5 lines.
No other outcomes were reported. Dr Kondrot suggested that a double-blind study was desirable to
address the possible placebo effect.
Chaikin and colleagues 2015198 included six people with wet and 25 with dry AMD (details not provided).
MCS was given by the palpebral route, for 35 minutes once a week, for an average of 4.8 sessions
(range 2–10). We report only results in dry AMD. There was no control group. The study was graded poor,
achieving only four out of 12 items on the checklist. At 3 months, treated eyes showed an improvement in
logMAR VA (see Table 9). There was a sharp improvement in the first week, continuing in the first month,
followed by a levelling off. The authors stated that the mean letter change from baseline was statistically
significant (p = 0.012), although a figure in the publication suggests this was not significant (p = 0.059).
There was improvement in VA (defined as a gain of ≥ 1 letter) in 52% of eyes and deterioration in 28%.
The authors cautiously conclude that the short follow-up and small numbers, the training effect of
repeated VA testing and the lack of masking of the VA testers mean that long-term efficacy is unproven.
They encourage further studies including a control arm with sham treatment. They conclude that if further
studies supported the positive results from their study, that the treatment would be an easy one to
administer in offices or at home.
In a large retrospective before-and-after study, graded poor on quality assessment, of a package of
alternative treatments (i.v. nutrition, oxidative therapy, MCS and ‘syntonic light therapy’) combined with
a stress reduction programme and a detoxification programme, Kondrot 201597 reported a 5.5-letter
improvement in VA at follow-up (likely immediately following 3 days of treatment) (see Table 9).
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Improvement of < 1 line was apparent in 35.7%, 1–2 lines in 37.9% and > 2 lines in 15.7%. There was
also an improvement in contrast sensitivity of 3.8 letters (Report Supplementary Material 2). However,
given the combination of therapies, no conclusions on MCS stimulation can be reached.
In one publication, two linked studies of MCS in people with dry AMD (no further inclusion criteria)
were reported, one of which had two separate cohorts of 12 and 34 patients, all patients treated, with
no controls.204,205 In the first study there was a decrease in VA after 2–7 years’ follow-up (see Table 9).
In the second study, few results were reported; there was a mean loss of 3 letters of VA in cohort 1,
and a mean gain of 8.5 letters in cohort 2. Few other results were reported (see Report Supplementary
TABLE 9 Results of MCS studies
Anastassiou et al. 2013196
RCT; unclear ROB Microstimulation, n= 12 Placebo, n= 10 p-value
VA, change letters at 6 months 4.1 –1.0a p = 0.3
Contrast sensitivity change, number of
optotypes at 6 months
1.5 0a p = 0.9
Macular sensitivity, change dB at 6 months 0.1b –0.8a p = 0.4
Shinoda 2008199
Prospective B+A; FQ Dry AMD, eyes n= 7
Mean (SE) ETDRS
p-value change from baseline at 4 weeks
42.9 (4.9)
p= 0.0401
Kondrot 2002208
Prospective B+A; PQ Microstimulation, n= 28
Per cent of eyes with improvement of acuity
at possible 1-year follow-up
66
Range of improvement, lines of VA 0 to 2.5 lines
Chaikin 2015198
Prospective B+A; PQ
Frequency specific MCS,
dry AMD eyes= 25
VA, logMAR, change from baseline (95% CI)
at 3 months
(n= 7) –0.1 (–0.2 to –0.01)c
Kondrot 201597
Retrospective B+A; PQ Dry AMD, n= 70 (140 eyes)
Acuity improvement, ETDRS chart, mean
letters, at possible 3 days’ follow-up
5.5
Contrast improvement mean letters 3.8
Michael 1993,204 Allen 1998205
Case series; PQ Study 1, n= 25
Study 2, cohort 1,
n= 12
Study 2, cohort 2,
n= 34
Mean numbers of letter change in VA, both eyes –0.3 NR NR
Loss of letters of VA, mean by eye NR 3 NR
Gain of letters of VA, mean by eye NR NR 8.5
B+ A, before and after; dB, decibels; FQ, fair quality; PQ, poor quality; ROB, risk of bias (selection) NR, not reported;
SE, standard error.
a Estimated from figure in Anastassiou et al. 2013.196
b Text states 0.1 increase, figure appears to demonstrate approximately –0.4 change.
c Estimated from figure in Chaikin 2015.198
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Material 2). In addition to electrotherapy, a nutrition extract of taurine, rutin and bilberry was administered
in the second study by Allen et al.205 There was no control group.
Adverse events
Anastassiou et al.196 reported that there were no adverse effects of treatment. Shinoda et al.199 reported
that there were no ocular or systemic complications except in one participant who developed contact
dermatitis on eye lids, which was treated as a serious AE. It is not clear from the publication if this was in a
dry AMD patient. Three studies did not report AEs.97,198,208
A pilot study (not included above) with 17 patients from Mumbai by Natarajan et al.209,210 reported improvements
in VA after MCS treatment with the ScyFIX device (Chanhassen, MN, USA; http://www.scyfix.org/.) Natarajan
et al.210 recommend a RCT with long-term follow-up.
Summary
The American Academy of Opthamology Taskforce concluded there was no strong evidence on the
effectiveness of MCS stimulation, but it preceded many of the studies listed above. The studies reported
mixed results of MCS. Follow-up was generally short and sample sizes small. In the RCT there were
no significant benefits of treatment. In the before-and-after studies and the case series, results were
difficult to interpret owing to differences in measures, time points, small samples, study quality and a
lack of statistical analysis. In addition, in the case series, participants were given long-term nutritional
supplements. In the immediate to short term following treatment, there may be some improvement in VA,
but most authors expressed caution and suggested RCTs. Few studies reported other outcomes.
Overall, the evidence base for MCS is weak. Despite this, we note that Nova Oculus Partners (Indian Wells,
CA, USA), manufacturers of an ‘electrotherapeutic device’ to treat dry AMD (unspecified), are hoping to
get International Organization for Standardization (ISO) certification worldwide.211
A device is being marketed by ScyFIX for ‘microcurrent neuromodulation’. It has a Conformité Européene
(CE) mark in Europe. The manufacturer claims that microcurrent neuromodulation has been shown to be
effective.212 In their submission to the FDA, ScyFIX cite a study by Wallace 1997206 who reported treating
43 patients with dry AMD with microcurrent (200 µA for 20 minutes for 36 sessions) after which 54%
improved by 1–4 Snellen lines.212
ScyFIX212 also cite a paper by Paul (undated) which claims a 72% success rate in AMD after microcurrent
and nutritional treatment. They also cite a presentation by Halloran and Reader213 (Fourth Annual
Symposium on Biologically Closed Electrical Circuits 1997) in which improvement in visual field
function was reported to be 4.61 decibels, and in VA 0.98 lines. The treatment was part of a package
of treatments, including some described as applied kinesiology, neurolymphatic deep stimulation,
deep tissue acupressure, colour-shape identification therapy and nutritional supplements.
Current research
We have identified five trials in ClinicalTrials.gov (accessed 16 April 2017).
NCT01600300 aimed to do a feasibility trial of the Tesmac device versus sham Tesmac (Acuity Medical
International, Minneapolis, MN, USA). The completion date was 2004 but no results have been posted.
The Tesmac device is now owned by The Eye Machine (Indian Wells, CA, USA).214
NCT00804102: the study details mention a range of eye diseases including dry AMD but the only publication
posted was on retinitis pigmentosa. However, the research group includes Röck from Tubingen, so this may
have been the Röck 2013121 study described in Chapter 2.
NCT0170958 was an observational study in AMD, STGD and retinitis pigmentosa, led by Papastergiou in
the Retinal Institute in Hawaii. No results have been posted. Completion date was 2012.
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NCT02699216 is listed as currently recruiting in the Du Bois Vision Clinic, PA, USA, but expected
completion date was December 2016. It will assess with the Novo Oculus device (The Eye Machine).
NCT02540148 was to be another trial of the Novo Oculus device against sham treatment, but is listed as
not yet recruiting. The details were provided by The Eye Machine Canada (Indian Wells, CA, USA) but have
not been updated since 2015.
We are aware of proposals for a further study of MCS being planned by Oxford Bioelectronics. A leaflet in
February 2017 said they would be embarking on a pilot study to establish safety and clinical acceptability
of the device as a treatment for dry AMD, and that if successful, a clinical trial for regulatory approval of a
bioelectronic treatment would follow.
It is not clear if the pilot will have any control patients. If it does not, it will contribute little new. However,
the proposal for a full clinical trial, if that is a RCT, is welcome. No further details were on the company
website (www.oxfordbioelectronics.com/amd/; accessed 31 July 2017).
Lasers
Laser photocoagulation treatment of early age-related macular degeneration
Prophylactic laser photocoagulation has been proposed to prevent progression of early AMD.
Mechanism of action
Gass215 first reported drusen regression with application of laser photocoagulation remote to the area of
drusen in 1971. A review by Cukras and Fine noted several studies that suggested that the laser need not
be applied directly to the drusen.216 Subsequent smaller RCTs217–220 have showed positive results favouring
laser photocoagulation in terms of drusen regression, improvement in VA and similar or fewer incidences
of CNV than with the fellow untreated eyes.
In order to maintain photoreceptor health, healthy RPE and Bruch’s membrane are required to aid diffusion
of nutrients from the choroidal circulation. In old age, the hydraulic conductivity between the RPE, Bruch’s
membrane and the choroid decreases due to accumulation of hydrophobic debris in the RPE and Bruch’s
membrane.221 In addition, matrix metalloproteinase (MMP), an enzyme responsible for degradation of
extracellular matrix in the Bruch’s membrane and thus keeping the Bruch’s membrane thin, decreases in
ageing.221 These processes seem to occur earlier in eyes with AMD.
The mechanism(s) by which laser photocoagulation may help to remove drusen deposition is still poorly
understood. It has been proposed that laser irradiation rejuvenates Bruch’s membrane by leading to a
transient increase of MMP-2 and MMP-9 and by stimulating RPE migration 4–7 days after laser exposure.221,222
It has been observed that laser photocoagulation enhances clearance of debris by choroidal phagocytic cells
that have been seen protruding from the choroidal endothelium extending its processes towards Bruch’s
membrane.222 These subsequently leads to a thinner Bruch’s membrane, increasing hydraulic conductivity and
egress of water and debris.221 Utilising Fourier OCT, Huang et al.223 demonstrated reduction in perifoveal RPE
elevation compared with controls after applying barely visible laser photocoagulation in a horseshoe-shaped
area temporal to the fovea. In a more recent review,224 it was stated that thermal induced stress of the RPE
results in production of heat shock proteins that aid in repairing damaged tissues and increased apoptotic
threshold of RPE cells to thermal, inflammatory, oxidative or hypoxic injury.
Laser photocoagulation as a therapeutic modality to clear drusen and increase the hydraulic conductivity of
Bruch’s membrane has been performed either at threshold (visible burns) or at subthreshold (invisible/barely
visible burns) levels. One of the earliest RCTs, the Choroidal Neovascularisation Prevention Trial (CNVPT)225,226
utilised threshold argon laser photocoagulation by applying either three rows of fundoscopically visible
burns in a horseshoe-shaped manner or two concentric rings with identical settings, both of which were
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applied no closer than 750 µm from the fovea. Although significant drusen reduction was detected, there
was a significant increase in incidence of CNV.225,226 This result was mirrored in the Drusen Laser Study,227
which also applied laser at threshold levels.
From the CNVPT, Kaiser et al.228 showed that the increased incidence of CNV appears to be related to the
laser intensity used. It was postulated that with thermal lasers, excessive heat is spread to the overlying
photoreceptors after being absorbed by the RPE, causing thermal damage.221,224 The intense heat could
also rupture Bruch’s membrane and promote CNV formation.224,228 In addition, lateral spread to adjacent
RPE occurs and causes damage beyond the specified laser spot diameter, giving an enlarged scar.224 As a
result, this could potentially lead to a visually significant GA if the fovea is involved.229
In order to minimise damage to the adjacent structures while stimulating the RPE, subsequent studies used
laser at subthreshold levels by reducing the duration of laser exposure. As a result, no burns are caused.
Although two studies230,231 utilising this laser modality showed an increase in incidence of CNV, a recent
Cochrane review222 showed that there was no significant difference between threshold and subthreshold
laser treatment in terms of CNV or GA progression.
Although most RCTs have shown significant drusen reduction in treated eyes when compared with
controls, this did not improve functional outcomes for patients. In fact, Virgili et al.222 pointed out in
their Cochrane review that prophylactic laser treatment (both threshold/subthreshold) did not affect VA,
contrast sensitivity and reading ability when compared with untreated eyes. However, this review did not
include the newer studies using micropulse or nanosecond (2RT) lasers. It was postulated that despite
utilising subthreshold laser treatment, structures adjacent to the RPE (the intended target) still suffered
collateral thermal damage from heat conduction due to the use of conventional continuous wave lasers.224
Hence, micropulse and nanosecond lasers, which allow further reduction of duration of exposure, may
provide improved outcomes.
In subthreshold diode micropulse lasers, multiple micropulses of laser energy (100–300 microseconds of
exposure) are delivered; the laser is only ‘on’ for microseconds and then there is an ‘off’ time that prevents
the increased heat that takes place using conventional lasers. ‘On’ and ‘off’ episodes are repeated while the
treatment is being applied. To apply micropulse laser spots, users typically start with a test spot in continuous
wave mode to determine the power required to create a barely visible threshold burn. When this is achieved,
the laser is switched to the micropulse mode to create a subthreshold burn.224 Brader and Young224 concluded
in their review that SDM laser treats the RPE selectively without neurosensory retinal damage while better
preserving the electrophysiological function than conventional lasers.
Nanosecond laser is delivered in a single pulse with a pulse duration of 3 nanoseconds and a spot size of
400 µm. Again, test shots are applied to get a threshold burn before reducing the power by 20% to
achieve a subthreshold treatment end point.232 A subsequent study233 showed that nanosecond laser was
very specific to the RPE, with no damage seen in the adjacent neurosensory retinal or Bruch’s membrane.
At the laser sites, it was observed that adjacent RPE cells enlarged and extend to reform the disrupted RPE
monolayers in both the human and animal models. From the animal model, RPE cells around the borders
of laser treatment sites were observed to be undergoing active cell proliferation. In addition, the immune
response around the subthreshold laser sites was milder than threshold laser, reducing the risk of PR
damage. The authors also observed that nanosecond laser induced thinning of the Bruch’s membrane by
remodelling the extracellular matrix through increased expression of the MMP-2 and MMP-3 genes in the
RPE. These observations have further reinforced the proposed mechanisms by which laser photocoagulation
induce drusen regression as outlined above.
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Quantity and quality of research
Reviews
We identified one good-quality systematic review from the Cochrane Eyes and Vision Group222 and four
non-systematic reviews by Brader and Young,224 Geneva,234 Cukras and Fine 2007216 and Hsu et al.
2005.235 The Cochrane review concluded that, although drusen area can be reduced, laser treatment is not
associated with improved outcomes for patients. The RCTs included in the Cochrane review had a low risk
of bias. Studies of laser treatment appear to include people with drusen, before GA develops.
The other reviews came to similar conclusions, but covered different topics. The earliest by Hsu et al.235
noted that laser treatment had sometimes been reported to increase the risk of dry AMD progressing to
wet AMD. Brader and Young224 reviewed subthreshold diode laser studies and concluded that there was
only low evidence of efficacy but that the treatments given varied and were mostly not micropulsed. They
also noted that one study by Friberg et al. 2006230 had been stopped prematurely because of an increased
risk of wet AMD. Cukras and Fine216 concluded that the benefits of laser therapy were unproven.
Most prophylactic laser studies are in two high risk groups:
1. Bilateral intermediate AMD where one eye is treated and the other is the control.
2. Unilateral wet AMD where the non-wet eye receives laser.
Studies
The Cochrane review included only RCTs. We identified seven non-RCT studies, including 439 patients
undergoing laser therapy. The Huang223 and Prahs236 studies were CCTs, and the Guymer232 and Ivandic237
studies were prospective cohort studies. There was one retrospective cohort study by Luttrull et al.,96
one before-and-after study by Merry et al.238 and one case series with a randomised element by Figueroa
et al.239 The studies were conducted in China (n = 1), Germany (n = 2), the USA (n = 1), Australia,
Canada and Spain (n = 1). Between one and nine treatments were applied across the studies, with
average follow-up ranging from 1 month to 8 years. The Huang223 and Prahs236 CCTs were assessed as
having a high risk of bias. Three of the other studies were assessed as poor quality.96,237,239 In the Figueroa
et al.239 trial section, most items on the Cochrane risk of bias checklist could not be completed because
of lack of detail. The Ivandic237 study had positive answers for only 5 out of the 14 items on the NIH
checklist. The Guymer232 study was assessed as fair to good, getting positive answers on 9 out of the
14 NIH checklist items and three negatives. The Merry238 study were assessed as poor quality, partly on
some weak criteria (unclear if all eligible patients met criteria, small sample, no blinding, unclear loss
to follow-up) and partly because details were not given for several items. Funding source was not
reported by five of the studies,96,223,237–239 one received non-commercial funding236 and one received both
non-commercial and commercial funding232 (see Report Supplementary Material 2). The Prahs236 and
Merry238 studies had small numbers of recruits receiving laser treatment. Where reported, mean age
ranged from 62 to 78 years across the studies and 30–45% of participants were men.
Results
Key results from these studies can be seen in Table 10.
Figueroa and colleagues 1997239 included two cohorts of people: (1) bilateral confluent soft drusen and
pigmentary changes (eyes were randomised to treatment or no treatment) and (2) high-risk drusen in
one eye and choroidal neovascular membrane in fellow eye (where the eye with dry AMD was lasered). A
green argon laser was used, and 0.1 seconds and 160-µm spot sizes. Light grey-white take was considered
the end point for the treatments. Drusen disappeared in 45 out of 46 patients during an average of
3.5 months and untreated drusen (located far from laser scars) disappeared in 43 out of 46 patients during
an average of 8.6 months (cohort not stated). Initial improvement in VA was seen in 33% of patients in
cohort 1, but this was lost after 3 years’ follow-up in half of these. After an average of 3 years’ follow-up,
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TABLE 10 Results of laser studies
Figueroa et al., 1997239
Case series and RCT; PQ
Cohort 1, n= 30
Intervention, 30 eyes
Cohort 1, n= 30
Control, 30 eyes
Cohort 2, n= 16
32 eyes
Choroidal neovascular membrane developed,
n/N (%)
0/30 eyes 1/30 (3.3) eyes
p= 0.5 vs.
intervention cohort 1
3/16 (18) patients
Improvement in Snellen VA ≥ 1 line, after
subfoveal drusen disappearance
10/30 (33.2) patients 5/16 (31.25) patients
Snellen VA, 3 years
Improved ≥ 1 line 5/30 (16.6) eyes 0/30 eyes 5/16 (31.25) patients
No change 10 (33.3) eyes 15 (50) eyes –
Deterioration ≥ 1 line (due to cataract
progression)
15 (50) eyes 15 (50) eyes –
Guymer et al., 2014232
Prospective cohort; FQ Laser, n= 50 eyes No laser, n= 50 eyes p-value
Mean change from baseline in BCVA, ETDRS
letters
–0.1 0.8 Not reported
Improved by ≥ 5 letters, n (%) 8 (16) 4 (8)
Lost ≥ 5 letters, n (%) 7 (14) 4 (8)
Reduction in drusen area (%) 44 22
Increase in drusen area (%) 24 18
Ivandic et al., 2008237
Prospective cohort; PQ Laser, n= 193 eyes
People without cataracts
VA (%)
Improved overall 97.3a
By one row Snellen 19.8
By two rows 37.0
By three rows 19.2
By four or five rows 8.2
By six rows 4.1
By seven rows 0.7
Unchanged 2.7
People without cataracts
VA (%)
Improved overall 94.5a
By one row Snellen 24.7
By two rows 41.2
By three rows 13.7
By four or five rows 8.8
By six rows 3.8
PHYSICAL TREATMENTS FOR AGE-RELATED MACULAR DEGENERATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
17% of eyes in cohort 1 and 31% of participants in cohort 2 had at least 1-line improvement in VA,
compared with none of the untreated eyes. No statistical analyses were presented.
Guymer and colleagues 2014232 included 50 people with bilateral intermediate AMD, excluding those with
evidence of GA or presence of CNV. They describe their study as a pilot. Only one eye was treated. They
used an ultra-low energy nanosecond laser aiming at ‘retinal rejuvenation therapy’: 12 spots around the
macula, 400-µm diameter spots, 3-nanosecond pulse length, 532-nm wavelength. This was estimated to
give 1000 times less radiant exposure than conventional macula thermal lasers. At 12 months’ follow-up, a
treatment effect was seen in both treated and untreated eyes; BCVA improved by at least 5 letters in 16%
and 8% of eyes, and drusen area was reduced in 44% of treated and 22% of untreated eyes, but p-values
were not reported.
TABLE 10 Results of laser studies (continued )
Ivandic et al., 2008237
Prospective cohort; PQ Laser, n= 193 eyes
By seven rows 1.6
Unchanged 0.5
People without cataracts 5.5
VA (%)
Prahs 2010236
CCT; high ROB Treated eyes, n= 6
Untreated eyes,
n= 6 p-value
Mean atrophic area, mm2 (range) at baseline 6.3 (1.5–14.9) 6.4 (0.9–15.4) NR
Mean atrophic area, mm2 (range) after
12 months
9.2 (3.1–16.4) 8.3 (1.4–16.8) Not reported
Mean (SD) progression rate, mm2 per year 3.0 (2.8) 1.9 (1.6) Not reported
Merry 2016238
Before and after; FQ
Photobiomodulation,
n= 24, 42 eyes
Change in BCVA letter score at 3 months + 5.14
p < 0.001
Change in CS 1.5 cycles per degree
(log-CS) at 3 months
+ 0.080
p = 0.056
Change in CS 3.0 cycles per degree
(log-CS) at 3 months
+ 0.166
p = 0.016
Change in CS 6.0 cycles per degree
(log-CS) at 3 months
+ 0.10
p = 0.036
Change in drusen volume (mm3) at
3 months
–0.029
p = 0.021
CS, contrast sensitivity; FQ, fair quality; PQ, poor quality; ROB, risk of bias (selection).
a p< 0.00001 from baseline. PERG, pattern ERG.
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Guymer’s proposed explanation for the improvement in untreated eyes is that laser to one eye exposes the
drusen to the immune system. She suggests that the exposure starts the immune system cleaning up of
drusen in both eyes.240 Another possible explanation is that laser treatment breaks up the drusen and
triggers an inflammatory response.
Ivandic and colleagues 2008237 included all stages of AMD (dry and wet forms with or without cataracts)
and a VA ≤ 20/20. They applied low-level laser treatment: four sessions semi-conductor laser diode,
continuous emission at 780 nm, spot diameter of 3 µm. They reported a statistically significant increase in
VA by study end (not defined, assume 4 weeks, no data presented; p < 0.00001) for patients undergoing
laser treatment, whereas there was no change in a small control group with no treatment.
In a retrospective pilot study, Luttrull and colleagues96 recruited 108 people (158 eyes) with high-risk AMD
(presence of multiple large, diffuse, or bilateral macular drusen; macular pigment disturbance; extrafoveal
or subfoveal GA; and/or CNV in the fellow eye). The laser used was diode micropulse laser at subthreshold
levels. Follow-up was 1 month after one course of panmacular laser treatment. Snellen VA was unchanged
(data not reported, p = 0.75, includes eight participants with inherited PR degeneration) but several
secondary outcomes, pattern ERG (an early indicator of retinal dysfunction) and visual function (measured
using central vision analyser and automated microperimetry) improved.
Huang and colleagues 2011223 allocated one eye to laser treatment and one eye to control in 10 people
with bilateral soft drusen. Treatment was with argon green laser: 514 nm, 100 spots, 200-µm spot size,
0.1-second duration, at 55 m to 100mW, to give barely visible spots. After at least 8 years’ follow-up,
soft drusen in the treated eyes were reduced (although new drusen had appeared), whereas soft drusen
had increased ‘significantly’ in the untreated eyes (presented in figures only). BCVA did not reduce
‘significantly’ in either eye, and at 2-year follow-up there was no difference in retinal contrast sensitivity.
No CNV occurred during the study.
Prahs et al.236 treated one eye of each of six patients with bilateral GA with laser therapy (described as
‘selective retinal therapy’) while the other eye served as control. The laser used was neodymium-doped
yttrium lithium fluoride (Nd:YLF), 527 nm, 200-ns pulse duration, 30 pulses at 100 Hz. After 1 year, the
mean GA area and progression rate (mm2 per year) were slightly higher in the treated eyes, but statistical
analyses were not reported.
Merry and colleagues 2016238 included 42 eyes of 24 people with dry AMD, with AREDS grades 2 (21%),
3 (48%) or 4 (with GA but no CNV, 31%) and a BCVA letter score of 50 (logMAR 1.0, Snellen 20/200)
or better. They used low-level laser therapy, with three wavelengths: yellow 590 nm, red 670 nm and
near-infrared 790 nm. They describe their approach as ‘photobiomodulation’, thought to act by biostimulation
of PRs, increasing blood flow and stimulating cellular functions. It differs from earlier forms of laser therapy
that created thermal effects. NCT00940407
Three months after laser treatment in all affected eyes, there was an increase in mean BCVA letter score
(5.14 letters; p < 0.001) and an increase in contrast sensitivity that was statistically significant at 3.0 and
6.0 (but not 1.5) cycles per degree (see Table 10). A reduction in drusen volume was also found (p = 0.021),
but there was no difference in other outcomes. No new wet AMD or GA developed during the study.
An abstract from the RANZCO 2011 conference by Beaumont and colleagues241 reported a study of
subthreshold laser photocoagulation of large drusen in AMD in 121 patients in which one eye was treated
and the other acted as control. After a mean of 5.5 years’ follow-up, wet AMD had developed in 4% of
treated eyes and 8% of untreated eyes. GA developed in 10% of treated eyes and 7% of control eyes. In
eyes which developed neither wet AMD nor GA, drusen had resolved in 57% of treated eyes and partially
resolved in 34%. In control eyes, most drusen were unchanged. However, the overall results did not reach
statistical significance.
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One small study by Scalinci and colleagues242 from Bologna, Milan and Rome reported that
photobiomodulation with a device called mnemosline (Mnemosline, Vicenza, Italy), which provided pulsed
light at 650 nm for 10 minutes twice a day, 5 days a week for 3 months, was associated with modest
improvements in BCVA, pattern ERG and retinal sensitivity. Only an abstract is available and no statistical
significance analysis is provided. The authors call for a larger trial.
Adverse events
Guymer and colleagues 2014232 reported dot haemorrhage in one patient. Three studies reported no
AEs occurred.96,236,237
Summary
The Cochrane review of RCTs with a low risk of bias concluded that although laser treatment can reduce
drusen area, it is not associated with improved outcomes for patients. Seven additional primary studies
were identified: two CCTs with a high risk of bias, two studies assessed as fair quality and three assessed
as poor quality. They used different forms of laser treatment. Outcome measures and length of follow-up
varied. There may be some improvement in VA but it is unclear if this is maintained. Drusen appear to be
reduced. Overall, the effect of laser treatment is inconclusive based on the review and primary studies.
The results in the study by Guymer et al.232 were intriguing. A similar phenomenon was reported by
Figueroa239 – most un-lasered drusen in the treated eye, distant from laser scars, regressed.
Registered research studies
NCT01799564 has the title Micropulse Laser for Geographic Atrophy and is being carried out by Mones
and colleagues in Barcelona. In 15 patients, one eye will be randomised to laser to receive subthreshold
micropulse spots in healthy RPE close to areas of GA. Estimated completion date is June 2017.
NCT02725762 is the Study of Photobiomodulation to Treat Dry AMD (LIGHTSITE 1) in Toronto. A total of
30 patients will be randomised to laser therapy or sham therapy. The laser is the LumiThera LT 300 (LumiThera,
Poulsbro, WA, USA). Patients will be treated three times a week for 3 weeks, repeated at 6 months.
NCT02800356 is the Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy
Secondary to AMD. This is a non-randomised pilot study by Querques and colleagues, using a 577 nm
yellow Pascal synthesis laser from Topcon (Tokyo, Japan). It aims to recruit 20 patients and is due to finish
at end of 2017.
NCT01790802: Laser Intervention in Early Age-Related Macular Degeneration Study (LEAD). The purpose
of this RCT is to determine whether or not 2RT nanosecond laser therapy slows the progression to
advanced age-related macular degeneration. It aims to recruit 240 patients with early AMD (no GA).
The principal investigator is Robyn Guymer. Final data collection should be in June 2018.
NCT00000167 is a trial of low-intensity laser treatment supported by the National Eye Institute in the USA.
It aimed to recruit 1052 patients, and was due to end in 2007.
NCT02569892 is a trial of subthreshold Pascal laser versus sham laser, being carried out in Stanford
University and the Bascom Palmer Eye Institute, in 56 patients with large, high-risk drusen. The aim is to see
whether or not laser treatment will reduce progression to GA or wet AMD. The trial is due to end in 2018.
Ozone
In this procedure, around 200 ml of the patient’s own blood is withdrawn, treated with ozone, and
replaced into the bloodstream (‘autohaemotherapy’ or AHT). This is done twice a week for 9–10 weeks,
and then every 10 days, for 12–24 months.
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Quantity and quality of research
All the publications come from the same group in Sienna, Italy.
Reviews
Five non-systematic reviews were identified, all from the same group, and mostly reviewing their own
studies in AMD. First authors were Bocci 2007,243 Bocci 2011,244 Borelli 2013,245 Bocci 2015246 and Zanardi
2016.247 (see Report Supplementary Material 2). However, some reviews covered other uses of ozone.
Studies
One RCT, by Borrelli et al.,248 and one CCT, by Bocci,244 were identified, with a total of 217 participants
(124 allocated to ozone therapy). Those in the RCT had 12 months of treatment and follow-up, whereas
participants in the CCT had around 7 weeks of treatment and follow-up was at 18 months. The risk of
selection bias was high in the CCT, in which patients had their blood treated with ozone or with oxygen.
In the RCT, recruits were randomised to ozone therapy or to the AREDS nutritional supplement. The
investigator and patients were aware of which treatment was used. Funding source was not reported by
either study. Mean age was 71 years248 (range 63–81 years).244 Baseline VA was reported by both studies
(Table 11).
Results
Borrelli and colleagues 2012248 included people with bilateral AMD, with > 10 large semi-soft and/or
confluent drusen within 3 mm of centre of fovea in the study eye and BCVA between 20/32 and 20/125.
After 12 months, no statistically significant difference in logMAR was reported between the treatment and
control groups, but the proportion of people gaining 1 line of vision was reported to be 25% in the ozone
group and zero in the control group (p < 0.05). It is not clear what change happened in the other 75%
but it is reported that none of the ozone group lost ≥ 2 lines, so we could presume that they had no
change or a loss of not more than 1 line. The control group had lost 0.3 ETDRS lines by 12 months
whereas the ozone group gained 0.3 lines, giving a difference of 0.6 lines.
TABLE 11 Results of ozone studies
Borrelli 2012248
RCT; low ROB O3-AHT, n= 70
AREDS Control,
n= 70 p-value
LogMAR change from baseline at 12 months, mean (SD) –0.2 (0.01) 0.3 (0.01) p> 0.05a
BCVA, change from baseline at 12 months (%)
Loss of > 2 lines 0 40
Loss of > 3 lines 0 38 p< 0.05b
Gain of > 1 line 25 0 p< 0.05b
Bocci 2011244
CCT; high ROB
Ozonated
AHT, n= 54
Oxygenated
AHT, n= 23 p-value
VA logMAR, change from baseline at 18 months 0.15c –0.2c NR
VA (%) with:
improvement (> 2 ETDRS lines) 66.6 30.4 Statistically significant
(p-value NR)
equal (≤ 2 ETDRS lines) 33.3 68.5
NR, not reported; ROB, risk of bias (selection).
a p-value is for all intergroup and intragroup (at 6 months, data not extracted; at 12 months, interventions vs control).
b p-value is for intergroup and intragroup comparison, 6 months and 12 months.
c Estimated from a figure.
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Participants in the study by Bocci 2011244 presented with dry AMD, most commonly with soft confluent
drusen followed by GA. At 18 months’ follow-up, there was a slight improvement in VA in the treatment
group and a slight deterioration in the control group, but a statistical comparison was not reported.
Two-thirds of the treatment group had an improvement of > 2 ETDRS lines compared with less than
one-third of the control group; this was described as statistically significant (p-value not reported).
Adverse events
Temporary face redness was experienced by 3%.248 No AEs were reported in the study by Bocci.244
Summary
Five non-systematic reviews, one RCT (low risk bias) and one CCT (high risk of bias) were identified. Both
studies reported that higher proportions of people with ozone therapy gained letters of VA. All the
publications came from the same group, so they reviewed their own studies.
There is a lack of convincing evidence for ozone therapy.
Intraocular telescopes or lenses
Quantity and quality of research
These studies were done in people with late advanced AMD, in contrast with most of the patients in the
previous studies who had mainly early disease.
Reviews
One non-systematic review by Hau and colleagues249 was identified (see Report Supplementary Material 2).
Hau and colleagues249 concluded that:
We believe the IMT is a viable option for people who otherwise have limited options to improve QoL
[quality of life] due to end-stage AMD.
Studies
One CCT from the implantable miniature telescope (IMT)-002 group250–253 in the USA and one case series
by Qureshi et al.254 in the UK were identified, with a total of 218 participants (total 452 eyes, 235 eyes
allocated to intervention). Follow-up was 24 months in the CCT and 4 months in the case series. The CCT
had a high risk of selection bias, and the case series was assessed as fair quality but the sample size was
small (n = 12). Both studies received commercial funding.
The Qureshi254 paper authors assessed their own device in patients with bilateral intermediate or advanced
AMD with central scotomas.
Mean age was 76–77 years and about half of the CCT and one-third of the case series participants were
men. VA at baseline was reported by the case series only, but both reported categories of visual
impairment (more details in Report Supplementary Material 2).
A number of other studies were found but were excluded because they had very small numbers, including:
l Agarwal 2008 with four patients255
l Hengerer 2015 with two patients256
l Primo 2010 (Optometry) with two patients257
l Scharioth 2015 with eight patients (using the Scharioth device).258
The article by Taberno et al. 2015259 was just a description of their device.
Older reviews were not used.
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Results
The IMT-002 group (Hudson, 2006250 Boyer, 2015251 Hudson 2008252 and Lane 2006253) included people
with bilateral, stable, central VA loss by untreatable end-stage AMD (GA, disciform scar or both); phakic
with evidence of cataract in the study eye; a distance BCVA 20/80 to 20/800 (ETDRS); and at least a 5-letter
improvement with an external telescope used for 3 days. The patients’ own lenses were removed (which
would alone would be expected to improve vision) and replaced with the IMT-002 device (VisionCare
Opthalmic Technologies, Saratoga, CA, USA). Compared with untreated fellow eyes, there was a statistically
significant improvement in both near and distance mean BCVA at 12 months, with two-thirds of treated
eyes gaining ≥ 3 lines of distance vision versus 12.5% of untreated eyes (p < 0.0001), and two-thirds of
treated eyes gaining ≥ 3 lines of near vision versus one-third of untreated eyes (p < 0.0001) (Table 12).
At 24 months, 0.6% and 7.5% of implanted and untreated eyes, respectively, had lost ≥ 3 lines of vision
(p = 0.013), and all categories of gains and losses except gain of ≥ 6 lines for BCVA were statistically
TABLE 12 Results of telescope/lens studies
Hudson et al. 2006250
CCT, high ROB
Implanted eye,
n= 192
Fellow eyes,
n= 192 p-value
BCVA (distance) mean lines improvement at 12 months, logMAR 3.47 0.76 p< 0.0001
BCVA (near) mean lines improvement at 12 months, logMAR 3.18 1.78 p< 0.0001
BCVA (distance) gain of ≥ 3 lines at 12 months (%) 66.7 12.5 p< 0.0001
BCVA (near) gain of ≥ 3 lines at 12 months (%) 67.7 33.3 p< 0.0001
BCVA (distance) loss of ≥ 2 lines at 12 months (%) 2.1 8.9 p= 0.005
BCVA gain of ≥ 3 lines at 24 months (%) N = 173
59.5
N = 174
10.35
p< 0.0001
BCVA loss of ≥ 3 lines at 24 months (%) N = 173
0.6
N = 174
7.5
p= 0.013
Mean BCVA line change from baseline at 24 monthsa N = 173
3.2
N = 174
0.4
p< 0.0001
NEIVFQ-25 (mean SD)
Baseline 43.9 (13.3), N= 206
Change at 12 months + 6.1 (14.4), N = 192
p < 0.0001
ADL, mean (SD)
Baseline 41.4 (15.7), N= 206
Change at 12 months + 14.1, N= 192
p < 0.0001
Qureshi et al. 2015254
Case series, FQ
Telescope n= 18 eyes
Mean CDVA (assume SE) 0.20 (0.13)
Mean CDVA % improvement 67
Mean BCVA (assume SE) 0.21 (0.11)
Mean BCVA % improvement 50
ADL, activities of daily living; CDVA, corrected distance visual acuity; FQ, fair quality; SE, standard error.
a Estimated from figure in Hudson et al. 2006.250
PHYSICAL TREATMENTS FOR AGE-RELATED MACULAR DEGENERATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
significant between eyes in favour of the study eye (presented in figure only). Statistically significant
improvements from baseline were found on the NEIVFQ-25 and activities of daily living scale.
Qureshi and colleagues 2015254 implanted telescopes in 18 eyes of 12 participants. Inclusion criteria were
bilateral, intermediate or advanced dry AMD with central scotomata, minimal cataract or pseudophakia,
Snellen BCVA < 0.25 and improvement with an external telescope. A 67% improvement in VA and a 50%
improvement in corrected near VA was found after 4 months, with improvement of visual impairment
classification in 11 (61%) eyes (see Table 12). One eye deteriorated from severe to profound, and six eyes
were unchanged in terms of classification.
Adverse events
Adverse events are summarised in Table 13 and Report Supplementary Material 2. Hudson and
colleagues250–253 stated that no retinal detachments, CNV or visually significant cases of posterior capsule
opacification occurred during the 2-year follow-up. However, ocular AEs and complications occurred,
including inflammatory deposits, increased IOP and corneal oedema. Qureshi and colleagues254 reported
no cases of clinical corneal decompensation, signs of cystoid macular oedema or active CNV.
A good-quality cost-effectiveness analysis by Brown et al.260 concluded that when using US costs (not
necessarily applicable to other countries), the IMT was cost-effective, improving quality of life by 12.5%.
The CentraSight telescope implant261 (VisionCare Opthalmic Technologies, Saratoga, CA, USA) is now
being used in Manchester Royal Eye Hospital and appears to be the one used in the IMT-200 trial.
TABLE 13 Adverse events in telescope studies
Hudson et al. 2006250 n= 206 eyes
Ocular AEs in ≥ 5% at 12 months (%)
Inflammatory deposits 21
Pigment deposits 10
Guttae 8
Posterior synechiae 6
Ocular complications in > 5% at 12 months (%)
Increased IOP (7 days) 28
Corneal oedema (30 days) 7
Iris prolapse 6
Corneal abrasion 5
Corneal decompensation at 12 months (%) 1
Intraoperative iris prolapse 0.5
Ocular AEs in ≥ 5% at 24 months (%)
Inflammatory deposits 25
Pigment deposits 11
Guttae 8
Posterior synechiae 7
Iris transillumination (> 21 days) 5
Iritis (> 30 days) 6
Qureshi et al. 2015254 n= 18 eyes
Replacement IOL 1
Raised IOP 1
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Summary
One large CCT and one small case series were included. The CCT found improvement in VA in implanted
eyes compared with untreated eyes, although some AEs occurred. Compared with baseline, improvements
in quality of life were found. Improvements in VA were also found by the case series but no statistical
analyses were presented. In both cases, some improvement could have been due to cataract removal.
A trial is under way in the UK [the Efficacy of the telescopic mirror implant for age-related macular
degeneration: the MIRROR Trial, Efficacy and Mechanism Evaluation (EME) project 13/160/03].262,263
A trial of the CentraSight telescope, NCT03011554, is being run in the USA in people with advanced AMD
who have had cataracts removed and replaced with an IOL. The IOL will be exchanged for the telescope lens.
Qureshi and colleagues264 have reported a case series of 244 eyes into which the Eyemax IOL had been
implanted, but the patients had a mix of dry and wet AMD, and their results are not reported separately,
making the study an exclusion for our purposes.
Night-time light
The rationale behind a trial by McKeague and colleagues265 is that, paradoxically, the retina is most
metabolically active in darkness. So the trial will test the effect of wearing a mask that produces a dim
green light, during the night. Recruits will have wet AMD in one eye and early in the other. They will wear
the mask for 12 months. The protocol has been published (ISRCTN82148651).265
Summary and conclusions
We think that there is insufficient good-quality evidence to recommend the use of acupuncture, MCS or ozone.
There is some evidence on rheopheresis (a treatment similar in some ways to renal dialysis), but the largest
trial showed no benefit. Given that most positive studies were small and mostly with uncertain risks of bias,
that most effect sizes were modest, that the largest trial was negative, and that treatment would be
inconvenient to older people, we do not see rheopheresis as a research priority. Even if stronger evidence
emerged, there might be problems implementing it into routine care in the UK, creating a capacity problem
for the NHS, although that would depend on the number of sessions required per patient per year.
We think the evidence for the use of blue-light-filtering IOLs after cataract extraction is currently
insufficient to justify their routine use, but further research is under way.
The evidence on laser treatment is mixed, but newer forms look promising enough for further research.
However, some is under way, with a large trial, the LEAD trial from a world centre of excellence in
Melbourne, so we should perhaps wait for their results.266
Telescopes or lenses also look promising, but there are different forms. Some articles are written by their
inventors, so bias may be a problem. A trial funded by the NIHR EME programme, the MIRROR RCT, is
under way.262
Research priorities
If the HTA programme were to consider research into physical treatments for dry AMD, we think that the
top priorities would be independent research into implanted lenses and a trial of newer forms of laser
treatment, both of which are under way.
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Chapter 4 Age-related macular degeneration
treatment: cell therapy
In this report, we cover only dry AMD. Techniques such as autologous transplantation of patches of RPEand macular translocation have been used mostly in wet AMD, so are not included.
Background
In AMD, the accumulation of waste products in the RPE, such as lipofuscin, is believed to lead to the
dysfunction and death of RPE cells, and the development of areas of GA. One approach to treatment is to
try to replace these cells with cells grown from stem cells.
Human embryonic stem cells have been used. Schwartz and colleagues267 reported that these cells could
be differentiated into RPE cells > 99% purity.
Research is also under way to convert skin cells from patients back into a form of stem cells, called induced
pluripotent stem cells (IPSCs), which can then be persuaded to develop into RPE cells in vitro. The IPSCs,
being from the same patient, have the advantage of not causing an immune reaction, whereas the
allogenic HESCs derived RPE cells require, at present, a short course of immunosuppressant drugs.
Cells can be implanted as suspensions of cells or as sheets of cells on a biodegradable scaffold.
Quantity and quality of research
Reviews
We found many reviews: > 30 in the last 3 years alone. None appeared to be true systematic reviews but
given the very small number of actual primary studies, it is not difficult to be comprehensive. There appear
to be rather more reviews than treated patients.
A review by Ramsden et al.268 from London, identified three teams around the world doing cell transplants:
Ocata from California, the Riken Centre in Japan in collaboration with Kobe City General Hospital (one
patient at time of article, but now at least two, with five candidates enrolled), and the London Project to
Cure Blindness (one patient at time of article, although with wet AMD, but another since then, also with
wet AMD).269
Ramsden et al.268 summarise some of the problems that are being encountered, including:
l having to deal with multiple regulatory bodies
l the need to find ways to scale up production of cells
l limitation of cell transplant to advanced disease until the balance of risks from cell therapy are known
l in this advanced group, problems of assessing benefit when there is already visual loss
l determining the optimal immunosuppression regimens.
They identify three issues when assessing success:
1. safety
2. cell survival
3. visual outcome.
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Dalkara and colleagues134 regard human IPSCs as an unlimited source of cells for transplantation, and
report that at least 15 trials were under way in late 2015, of which 10 are in dry AMD or in mixed groups
including dry AMD.
Zarbin270 gives a good account of ‘challenges to clinical translation’, which include:
l Cell production.
l Cell delivery, in suspensions or sheets on scaffolds, but with many different materials being studied as
potential scaffolds.
l Cell survival and differentiation. Survival may be impaired in areas of GA because of changes in
supporting structures such as Bruch’s membrane.
l Immune reactions. Although the subretinal space is less accessible to the immune system, this privilege
is not complete and immune reactions can occur. Not all patients (most of whom are elderly) can
tolerate immunosuppressive drugs.
l A theoretical risk of mutation to cancerous cells.
Studies
Two linked publications reporting two small before-and-after studies conducted in the USA were identified.98,123
One of the studies was in STGD, reported in Chapter 2. A total of nine patients with atrophic AMD were
included, and the eye with the worst vision was treated. After pars plana vitrectomy, a single subretinal
injection of hESC-derived RPE with 12 weeks of immune suppression was assessed. Tacrolimus and
mycophenolate were given for 6 weeks, then mycophenolate alone for another 6 weeks. Median follow-up
was 22 months. The study was assessed as fair quality and funding was from both commercial and
non-commercial sources. Mean age was 77 (range 70–88) years and one-third of participants were men.
Baseline VA ranged from 20/200 (severe vision loss) to hand motion (near blindness). These trials were
sponsored by Advanced Cell Technology, now known as Ocata Therapeutics (Santa Monica, CA, USA).
A small study by Song et al.271 from Korea had only four male patients, two of these had dry AMD
(aged 65 and 79 years) and two STGD (aged 40 and 45 years). The eye with the worst VA was treated
with a subretinal injection of hESC-derived RPE. Participants were followed up at 1 year. The study was
funded via commercial and non-commercial organisations and as a small case series study was assessed
as having fair quality.
Results
The Schwartz study (Table 14) included people with advanced atrophic AMD with > 250 µm of GA
involving the central fovea.98,123 After 12 months, VA had improved in 3 of 7 eyes and was stable in 3 of
7 eyes. Quality of life, assessed by the NEIVFQ-25 improved for general vision, peripheral vision, near
activities, distance activities and mental health. The possibility of a placebo effect on the VFQ-25 scores
cannot be excluded.
In the study by Song et al.271 improvements were seen in BCVA at 12 months in all patients in the study
eyes, ranging from 1 to 19 letters improvement. Fellow eyes deteriorated in the two dry AMD patients but
improved in the two patients with STGD. This may be chance because of the very small sample size.
Adverse events
There were no AEs from cellular therapy (e.g. acute transplant rejection or abnormalities in retinal or
choroidal circulations).98,123 AEs from the surgical procedure included one case of endophthalmitis and one
eye developing worsening cataracts requiring surgery. Adverse effects thought to be possibly related to the
systemic immunosuppression were one urinary tract infection, two people with gastrointestinal symptoms
and two cases of non-melanoma skin cancer. Without a control group, it is not possible to say whether or
not these were due to the immunosuppression.
AGE-RELATED MACULAR DEGENERATION TREATMENT: CELL THERAPY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
No patients had ocular or systemic serious AEs in the study by Song et al.271
An update of NCT01344993 was presented at the 2017 meeting of the American Academy of
Ophthalmology by Gregori and colleagues, with mean follow-up of 3 years in 10 patients, with reassuring
safety data and gains in VA > 10 letters in some patients.
At the same meeting, Banin and colleagues from Jerusalem presented data from a Phase1/2a study
(NCT02286089) of hESC-derived RPE cells (OpRegen, Cell Cure Neurosciences, Jerusalem, Israel) in patients
with GA. After up to 15 months of follow-up, there were no serious adverse effects and BCVA remained
stable.272
Summary
Three very small studies were identified. Two were assessed as fair quality. The other272 was available only
as an abstract. Improvements in VA were found in over half of treated eyes, sustained for at least 1 year.
Improvements in quality of life were also noted in one study, although AEs occurred. The evidence base is
still very sparse, but this seems a promising development. Given the very small number of studies and the
lack of RCTs this remains a treatment that should be performed under the context of research.
TABLE 14 Results from Schwartz study of cell transplantation
Schwartz et al., 2015,123 201698
Before and after, FQ RPE transplant (7 eyes)
VA (ETDRS) (12 months) improved by
≥ 15 letters 3 eyes
11–14 eyes 1 eye
≤ 10 letters (stable) 3 eyes
Worsened, 10 letters 0 eyes
NEIVFQ-25 change from baseline
General vision, median Baseline: 40.0
12–52 weeks: 20.0
Peripheral vision, median Baseline: 50.0
12–52 weeks: 25.0
Near activities, median Baseline: 20.8
12–52 weeks: 25.0
Distance activities, median Baseline: 37.5
12–52 weeks: 16.7
Mental health, median Baseline: 37.5
12–52 weeks: 18.8
FQ, fair quality.
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Case selection would be essential because if PRs have degenerated, adding just RPE will not be beneficial.
However, if the technique is rapid, low cost and safe, then potentially it could be done at an early stage,
when RPE atrophy is just started (as detected by say AF) in order to prevent progression.
Stem cells grow well in the laboratory and are thought to be capable of providing an unlimited supply of
cells for transplantation. Progress is slow, but many more trials are starting. If these are successful, the
problem may be how to increase production and implantation for the very large number of people who
may be able to benefit. The costs and cost-effectiveness also need to be considered.
NT-501
The NT-051 implant (Neurotech, Cumberland, RI, USA) contains genetically modified human cells that
secrete CNTF. The cells are contained in a semi-permeable capsule that allows CNTF to diffuse out, but
presumably protects against an immune response. The capsule can be extracted.273
Quantity and quality of research
Studies
Zhang et al.273 carried out a Phase II three-arm pilot RCT at eight sites in the USA with 51 participants
(NCT00277134). The arms were sham surgery (not explained), low-dose implants and high-dose implants.
The low dose was predicted to have little effect – almost a placebo – and for some analyses the sham and
low-dose groups were combined. The aim was to assess safety, evaluate the effects of CNTF in GA, and
to determine the dose and end points for future studies. Treatment and follow-up were of 12 months’
duration. A high dose (n = 27) and a low dose of NT-501 (n = 12) were assessed. A sham arm (n = 12) was
also included. The trial had an unclear risk of selection bias and received some commercial funding. Mean
age was 75–78 years across groups and 37–58% were men. Baseline VA was reported as mean 53.5
(SD 9.0), 49.9 (SD 10.2) and 55.3 (SD 7.3) across the three groups, respectively.
Results
In people with BCVA 20/50 to 20/200 and category 3 or 4 AMD GA, Zhang and colleagues273 (Table 15)
found a higher proportion of patients with stable VA after the implant, but this was not statistically
significant. A subgroup analysis in patients with baseline BCVA 20/63 or better did show a statistically
significant difference with none of the 10 in the high-dose group losing > 15 letters, compared with five
out of nine in a combined sham and low-dose group. There was no significant difference in area of GA,
but numbers were small and duration short. Retinal thickness increased in the high-dose group. Other
outcomes can be seen in Report Supplementary Material 3.
Adverse events
Adverse events were few and none were higher in the treatment groups.
TABLE 15 Results of NT-501 implantation
Zhang et al., 2011273
RCT; unclear ROB
High dose
NT-501,
n= 27
Low dose
NT-501,
n= 12
Sham 2,
n= 12 p-value
VA stabilisation, % losing < 3 lines (15 letters) of VA 96.3 83a 75 0.078 high vs sham
Change in area of GA, mm2, mean (SD) 2.03 (1.04) 2.19 (1.87) 2.42 (1.95) 0.788
ROB, risk of bias.
a Estimated from graph in Zhang et al., 2011.273
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Summary
This small RCT with an unclear risk of bias found no statistically significant overall differences in VA
stabilisation or area of GA between people treated with NT-501 and those not treated. However, it was
a small proof of concept trial. No further trials of NT-501 are registered with ClinicalTrials.gov (accessed
18 June 2017).
Current research
There are two main strands of cell therapy research: hESCs from donors and using the patient’s own cells
(autologous cells) using IPSCs. Research on the latter is under way in Newcastle. Producing RPE cells from
iSPCs used to take many months but this is changing.
Research in collaboration with Ocata Therapeutics (formerly Advanced Cell Technology) has been under
way at Moorfields since 2012, as part of the London Project to Cure Blindness. Ten patients will take part
in a trial of stem cell treatment and the first two patients have had the procedure.274,275
NCT01632527 was a small Phase I/II study aiming to recruit 15 people with GA, who would have injections of
human central nervous system stem cells into their eyes. The primary purpose was to establish safety. Clinical
sites were in California, New York and Texas, USA. The sponsor was StemCells Inc. (Microbot Medical,
Hingham, MA, USA). It was due to end June 2015 but no results have yet been posted. However, a long-term
safety follow-up study, NCT02137915, from the same sponsor has been terminated, with a comment that
termination was a business decision not due to any safety concern. Another stem cells trial, NCT02467634,
has been terminated.
NCT03046407 is being carried out in Henan, China, in the First Affiliated Hospital of Zhengzhou
University, sponsored by the Chinese Academy of Sciences. The plan is to recruit 10 patients with dry AMD
and inject hESCs into the subretinal space. The main aim is to establish safety and tolerance. The study is
due to end in December 2020.
The Chinese Academy of Sciences is also sponsoring NCT02755428, subretinal transplantation of RPE,
in 10 patients in Beijing, which is due to end 2020.
NCT02749734 is called Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived
Retinal Pigment Epithelium in Treatment of Macular Degeneration Diseases. It is being carried out in
Southwest Hospital, Chongqing, China. It aims to recruit 15 patients with either dry AMD or STGD.
NCT02755248 is called Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related
Macular Degeneration Diseases. It is being carried out in Beijing Tongren Hospital, sponsored by the Chinese
Academy of Sciences. Recruitment target is 10. The primary aim is safety and tolerance over 1 year, and
completion date is December 2020.
NCT02590692 is called A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human
Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects
with Advanced, Dry Age-related Macular Degeneration. It aims to recruit 20 people in California, in two
cohorts of 10. The first will have advanced GA with BCVA 20/200 or worse. If safety is shown, a second
cohort with BCVA 20/80 to 20/400 will be added. The study is sponsored by Regenerative Patch
Technologies LLC (Glendale, CA, USA), and completion date is 2022.
NCT02286089 is called Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form
Age-Related Macular Degeneration. It is a Phase I/IIa study of dose escalation, safety and efficacy, being run in
Israel in stages, first recruiting nine legally blind people then, if safety is shown, recruiting another six people
with BCVA 20/100 or less. This is due to end in 2018. The manufacturer is BioTime, Alameda, CA, USA.
DOI: 10.3310/hta22270 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 27
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
Janssen Pharmaceutical have a product derived from adult umbilical tissue cells called palucorcel
(formerly CNTO 2476), which is injected subretinally. It was assessed from safety and for dose decision
in NCT01226628, with gains of ≥ 10 letters in 35% and of ≥ 15 in 24% reported by Ho et al.276 However,
complications of surgery including retinal perforations (6 out of 35) and detachments (13 out of 35) were
of concern and Ho et al.276 suggest that a different surgical approach will be needed in further studies. A
large multicentre trial in the USA (13 centres) and Canada (two centres) – NCT02659086 – will aim to
recruit 285 people, followed up for 5 years. There will be a sham arm. The trial is called PRELUDE; it is not
clear how this abbreviation was derived.
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Chapter 5 Drug treatment in dry age-related
macular degeneration
Statins
As noted earlier, AMD and cardiovascular diseases, such as stroke and heart disease, share some risk
factors. Given the success of statins in reducing heart disease, and the presence of lipids in drusen, there
was therefore interest in whether they could prevent, reverse or delay progression of dry AMD.
The case for statins in AMD could be based on several types of evidence:
l pathophysiological – hypotheses based on changes in the retina in AMD, such as lipid-containing drusen
l trials of statins in AMD
l epidemiological studies of the risk of AMD in people using statins for cardiovascular disease
l basic science studies, such as studies of the effect of statins on retinal cells in the laboratory.
The second group would be the most useful, but as reported below, there are few data, so we have
examined a wider range of evidence.
The epidemiological studies compare people taking statins with those not taking them, but as allocation is
not random, there are likely to be problems with other factors being different.
Guymer and colleagues277 reviewed the evidence for the effect of statins in 2005. They noted that there
could be several possible mechanisms, including lipid-lowering, anti-inflammatory and anti-angiogenic
effects. One problem with the literature was that some of the large epidemiological studies of AMD had
started before statin use became common. Guymer and colleagues278 also reviewed the evidence on
dietary factors and noted that high cholesterol and high dietary fat were associated with an increased risk
of AMD, whereas intakes of omega 3 fatty acids and fish were associated with a lower risk.
Gehlbach and colleagues278 suggested four mechanisms by which statins could affect AMD:
1. serum-lipid lowering, which might reduce deposition of lipids in Bruch’s membrane
2. preserving vascular supply
3. an anti-inflammatory effect
4. an antioxidant effect.
Quantity and quality of research
Reviews of effectiveness of statins
Two systematic reviews by Gehlbach et al.278 and Ma et al.,279 one non-systematic ‘mini-review’ (authors’
term) by Peponis et al.280 and one narrative review based on systematic searches (Tsao and Fong281) of the
effectiveness of statins were identified. One of the systematic reviews278 was rated as of good quality and
the other of fair quality.279
The Cochrane review278 was last updated in March 2016. It included only two trials. One, Martini and
colleagues,282 used a very low dose of simvastatin (20 mg) for only 3 months in 15 people and was graded
as having unclear risk of bias. The other trial was a good-quality trial from Guymer and colleagues283 in
Melbourne, which is described in detail below.
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Gelbach et al.278 concluded that evidence from currently available RCTs is insufficient to conclude that
statins have a role in preventing or delaying the onset or progression of AMD.
The systematic review by Ma and colleagues279 was of observational studies, seven cohort, five case–control
and two cross-sectional. The seven cohort studies mostly reported that statins were protective in early AMD,
but none had statistically significant effects. However, once pooled, the RR was 0.83 (95% CI 0.66 to 0.99;
I2 13.5%). Statin use was associated with a reduced risk of soft indistinct drusen (RR 0.55, 95% CI 0.20 to
0.81) and a slightly reduced risk of large drusen (RR 0.84, 95% CI 0.68 to 0.99). In all AMD there was no
significant effect overall but with such high heterogeneity (I2 91.7%) that a meta-analysis might be thought
inappropriate. The RRs in the studies ranged from 0.30 (95% CI 0.21 to 0.44) in McGwin 2003284 to 1.30
(95% CI 1.17 to 1.44) in Etiman 2008.285 Wet AMD was slightly reduced (RR 0.90, 95% CI 0.80 to 0.99)
but there was no effect on GA (RR 1.16, 95% CI 0.77 to 1.56). No analysis by individual statin or dose
was provided.
Ma and colleagues279 noted an age difference, with statins not protective in people > 65 years, but with a
RR of 0.75 (95% CI 0.53 to 0.98) in the those < 65 years. However, there were only four studies reporting
results in those < 65 years.
Ma and colleagues279 concluded that statin use was protective for early and exudative AMD, but that
additional large studies are required to determine the potential effect of statins on AMD prevention. They
suggest that the effects of statins may vary by stage, with lipid-lowering in early AMD, perhaps reducing
the development of drusen, and an anti-inflammatory effect in late AMD.
Peponis and colleagues280 carried out systematic searches for a narrative review and found 23 studies. They
stated that no conclusion could safely be reached on whether statins protected against AMD. They did not
analyse by which statin or dose.
Tsao and Fong281 also carried out systematic searches for a narrative review of observational studies of the
role of statins in reducing the risk of AMD. They note some evidence of benefit from cross-sectional and
case–control studies, for example in reducing the risk of developing drusen, but because of weaknesses in
study design, their overall conclusion is that there was insufficient evidence that statins could prevent AMD.
Primary studies
Two intervention studies were included. One was a RCT by Guymer and colleagues283 and the other was a
before-and-after study by Vavvas and colleagues.286 We excluded the Martini study282 because of dose and
duration, as noted above.
The remaining studies below were observational in nature, identifying people taking statins and compared
results with those who were not, including some narrative reviews of observational studies.
Results
Intervention studies
The RCT [Age-Related Maculopathy Statin Study (ARMSS)] by Guymer and colleagues283 included 114 people
with intermediate AMD at high risk of progression, VA at least 20/60 in one eye and either high-risk drusen
in both eyes, or late AMD (CNV, central GA) in one eye and any drusen or pigment change in the study eye.
Randomisation was to 40 mg of simvastatin or placebo for 3 years. It was assessed as being at low risk of
bias. However, it did have problems with 24% of recruits failing to attend the 3-year follow-up visit (recorded
by Gehlbach et al.278 based on communication with the authors), and 40 mg of simvastatin would not be
regarded as a potent dose, compared with, for example, atorvastatin 80 mg daily.
Late AMD was seen in 42% at baseline. Recruits had to have normal plasma lipid levels (defined as not
meeting National Heart Foundation of Australia criteria for treatment). Baseline levels were total cholesterol
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5.71 and 5.63 mmol/l in placebo and statin groups, respectively. LDL-C levels were 3.34 and 3.27 mmol/l
and HDL-C levels were 1.86 and 1.78 mmol/l. The main outcome measure was progression of AMD,
assessed by four masked observers, independently, using a six-level severity scale. VA was not reported at
the end of study but was reported to show no statistically significant differences in the 12-month preliminary
results. At 3 years’ follow-up (after 3-years of treatment with 40 mg simvastatin daily or placebo) 70% of
participants in the placebo group had had progression compared with 54% of the simvastatin group. The
OR was not statistically significant in univariate analysis (OR 0.51, 95% CI 0.23 to 1.09; p = 0.08) but was
in multivariate analyses adjusting for baseline age, sex, smoking, and unilateral advanced AMD status
(OR 0.43, 95% CI 0.18, 0.99; p = 0.047). The effect of simvastatin was greater in the intermediate group
with non-advanced AMD, in which 49% of the placebo group and 32% of the statin group progressed: OR
0.23 (95% CI 0.07 to 0.75), with no benefit in the advanced groups, in which 21% progressed in each arm.
The effect varied by genotype, with a much greater protective effect in people with the CFH genotype CC
(Y402H). Guymer and colleagues283 describe the study as a ‘proof of concept’ one.
Simvastatin 40 mg daily is not a very potent dose. In a small before-and-after study, Vavvas and colleagues286
in Boston, USA, and Heraklion, Crete, treated 24 patients with intermediate AMD (many large drusen and
DPEDs but no CNV or GA in either eye) with high-dose (80 mg daily) atorvastatin. Baseline BCVA was 77.6
and the authors found that 10 (43.5%) participants had significant regression of drusen after an average of
1.5 years’ follow-up. Near complete resolution of drusen was reported in 34.8%. The responders gained
3.3 letters in VA whereas the non-responders lost 2.3 letters (not quite statistically significant).
In a small pilot study, reported only as an abstract, Tzotzas and colleagues287 treated seven women with
simvastatin 20–40 mg for 12 months, and reported a reduction in drusen score (based on number, size
and area covered).
Observational studies
Observational studies are always susceptible to confounding variables. If AMD is associated with
cardiovascular disease, then it is likely to appear associated with statin use, because people with
cardiovascular disease are likely to be on statins.
In one of the earlier studies from the UK (Sheffield), in people 66–75 years, Hall and colleagues288 reported
an OR of AMD in statin users of 0.14 compared with non-users, but the confidence interval was wide
(95% CI 0.02 to 0.83). They provide a useful example of possible confounding, in that AMD was strongly
associated with coronary revascularisation, which was in turn associated with statin use. However, after
logistic regression adjusting for various factors including revascularisation, use of statins remained protective.
A case–control study, from the Atherosclerosis Risk in Communities study284 also found an association
between statins and a reduced risk of AMD, but the OR was only modestly reduced (0.79, 95% CI 0.63 to
0.99) and statistical significance was only reached after adjusting for age, gender and race. No data are
provided on which statin or dose.
Conversely, the Beaver Dam study289 found no association between statin use and the incidence or
progression of AMD. Again, no data on statin or dose are provided.
Tan and colleagues from the Blue Mountain study290 reported that statin use was associated with a
reduced risk of indistinct soft drusen – HR 0.33, 95% CI 0.13 to 0.84. Interestingly, they also show that
statin use was ineffective in reducing total cholesterol, because the mean in those prescribed statins was
5.69 mmol/l. This was statistically significantly lower than in people not on statins (mean 6.00 mmol/l) but
not clinically significantly so.
In a prospective cohort study, Al-Holou and colleagues291 assessed the risk of progression to late AMD in
those taking part in a RCT of nutritional supplements (AREDS2) who reported taking any statin. A total of
44% of AREDS 2 patients were statin users. Details of which and dose were not provided. Participants had
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bilateral large drusen or unilateral late AMD in one eye and large drusen in the fellow eye. Al-Holou and
colleagues291 used propensity scoring to create two subgroups of the AREDS 2 patients who differed, as
far as was known, only in statin use.
After a median follow-up of 5 years, 43.5% of participants progressed to late AMD (any). This was not
reduced among statin users with HRs of 1.08 (95% CI 0.83 to 1.41; p = 0.56) before adjusting for
competing risk of death and 0.94 (95% CI 0.72 to 1.22) after adjustment (Table 16). Similarly, there were
no statistically significant associations between statins and progression to GA, nAMD or central GA.
Unfortunately, the AREDS group did not have data on which statins were used or the doses.
Al-Holou and colleagues291 also reviewed 14 previous studies. Nine reported that statins were protective,
but only four of these had an upper CI that did not overlap with no difference. Two reported ORs of 1.0.
Three studies showed an increase in progression of AMD associated with statin use but all overlapped with
no difference. None showed a statistically significant increase in AMD progression on statins.
Maguire and colleagues293 examined the effect of statins in a cohort study nested in the CAPT laser trial.
CAPT included people with at least 10 drusen, no evidence of CNV and a VA at least 20/40. Statins were
used by 40% of participants, but most started statins after entry to CAPT. After 5–6 years’ follow-up,
statin use had no significant overall effect on progression to advanced AMD (see Table 16). There was an
increase in the risk of CNV (RR 1.35, 95% CI 0.99 to 1.83) and a decrease in the risk of GA (0.80, 95% CI
0.46 to 1.39), but neither was statistically significant. No data provided on which statin or dose. Maguire
and colleagues293 did find a strong association with hypertension.
It may be worth noting that statins belong to two subgroups – hydrophilic (e.g. pravastatin) and lipophilic
(e.g. simvastatin).
Barbosa and colleagues294 used data from the cross-sectional National Health and Nutrition Examination
Survey (NHANES) 2005–8 survey, from people with complete ophthalmological examinations with retinal
photographs. Only 22% of the population used a statin, but of those diagnosed with AMD, 28.6% were
taking a statin. They found a statistically significantly lower rate of AMD diagnosis in those aged ≥ 68
years who were long-term users of statins than in those not using statins – unadjusted OR 0.64, 95% CI
0.49 to 0.84 (see Table 16). However, in the age range 40–67 years, there was no reduction, but an
increase for early AMD (OR 1.61, 95% CI 0.85 to 3.03). For any AMD, the unadjusted OR was 2.15
(95% CI 1.26 to 3.66). They provide no details of which statins were used.
TABLE 16 Results of trials of statins
Guymer et al., 2008292 2013283
RCT; low ROB Simvastin, N= 57 Placebo, N= 57
Total progression of AMD from baseline, by person, n (%) at 3 years 31/57 (54) 40/57 (70)
Progressed to advanced AMD, n (%) 12 (21.1) 12 (21.1)
Progressed, but not to advanced AMD, n (%) 18 (31.6) 28 (49.1)
Vavvas et al., 2016286
B+A study; PQ Atorvastatin, N= 23
Significant regression of drusen, n (%) 10 (43.5)
Near complete regression of drusen, n (%) 8 (34.8)
VA, mean (SDa) 77.7 (8.4)
B+ A, before and after; ROB, risk of bias.
a Estimated from graph.
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The overall association between statin use and risk of any AMD diagnosis was only statistically significant in
analyses unadjusted for age, gender, demographic characteristics, health-related behaviours, comorbidities,
and general health condition. However, the risk reduction in those aged ≥ 68 years remained statistically
significant, although a confounding variable not included in the adjusted analysis was duration of statin
use, which was longer (61 vs. 44 months) in those > 68 years.
In a case–control study, McGwin and colleagues295 included men aged > 50 years who had at least one
visit to a Veterans Affairs Medical Center in Alabama during the study period, and were newly diagnosed
with AMD. Ten matched controls without a diagnosis of AMD were selected for each case. The study
reported prescriptions for any statin use, but no details on which or doses. Men with AMD were statistically
significantly less likely to have filled a statin prescription prior to the study start (see Table 16): OR 0.30
(95% CI 0.21 to 0.45). Similar associations were seen for current or past statin used, and according to
various data cuts of duration of use. ORs for other outcomes were reported without the proportions by
cases and controls, see Report Supplementary Material 4 for details.
VanderBeek and colleagues296 included 486,124 people aged ≥ 60 years who had been enrolled for at
least two years with a national insurance claims database, and who had had at least one visit to an eye care
provider. Statins were used by 46% but details of which and doses were not provided. The development
of dry AMD [identified by the recording of ICD (International Classification of Diseases)-9 code 362–50,
362.51 or 362–57] was observed in 4.3% of eligible participants, 52.9% of whom used statins. There was
no association between using statins and the development of dry AMD. Wet AMD developed in 7% of
participants, of which 57.5% used statins. Those on statins for longer than 12 months had a higher risk of
progressing to wet AMD than those on statins for shorter periods (see Table 16). Progression from dry AMD
to wet AMD (defined by recording of ICD-9 code 362.52) was seen in 3.8% of people with dry AMD at
baseline, of which 55% used statins. The risk was highest in people who used statins for longer. Use of
statins for 19–24 months was associated with 1.6 times the risk than use of under 6 months. All analyses
were controlled for various characteristics, including age, sex, race, region of the country (see Report
Supplementary Material 4 for more details). However, there were associations between risks, statin use and
lipid levels. Looking only at those on statins for > 1 year, the risks of progression from dry to wet AMD were
0.54 (95% CI 0.40 to 0.73) in those with normalised LDL, but 2.1 (95% CI 1.29 to 3.36) in those with high
LDL. Therefore, statins appeared protective only if LDL was reduced to normal. Curiously, a normal HDL was
associated with a higher risk of progression (HR 1.96, 95% CI 1.58 to 2.42) than lower HDLs. Normal HDL is
usually regarded as good to have.
Kaiserman and colleagues297 studied people aged > 50 years who were members of a health maintenance
organisation and who had received photodynamic therapy for nAMD, and used statins for 2 years. The
proportion who had AMD was higher in those who had used statins (0.27%) than had not used statins
(0.16%). The RR (unadjusted) was 1.66 (95% CI 1.29 to 2.19) but this was not statistically significant
(p = 0.07) after adjustment for age, gender, socioeconomic status, place of residence, hypertension,
hyperlipidemia, place of birth, ischaemic heart disease (IHD), diabetes and congestive heart failure. They
also carried out a case–control study (reported in the same publication) with five matched controls for each
AMD case. The proportions using statins were similar in those with (37.7%) and those without (37.6%)
AMD (see Table 16). The OR was 1 (95% CI 0.8 to 1.3). Neither study showed any association between
statin use and the risk of nAMD. Kaiserman and her colleagues therefore concluded that statins did not
reduce the risk of wet AMD.
Fong and colleagues298 included all people from the Kaiser Permanente health plan in Southern California
who had had an eye examination in the preceding year (86,635 people). They compared 719 people with
a new diagnosis of exudative AMD with 78,650 people who did not have a diagnosis of AMD. As seen in
Table 16, the study found no association with wet AMD and statin use (all statins combined), with an OR
of 0.89 (95% CI 0.77 to 1.03). This was also the case in analyses of a subset of participants with longer
term use of statins (OR 0.89, 95% CI 0.77 to 1.04; p = 0.14) and in those just using statins in the year of
study (OR 0.83, 95% CI 0.59, 1.14; p = 0.64).
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In a case–control study, Etminan and colleagues285 included people aged > 65 years in Quebec who had
received a coronary revascularisation procedure, either angioplasty or bypass. Cases were those (2867)
with a diagnosis of wet AMD (based on a recording of ICD-9 codes 362.5 and 362.52) and for each case
four controls were chosen randomly from the cohort and matched by age. They reported a small increased
risk of AMD in current users of statins compared with controls (RR 1.30, 95% CI 1.17 to 1.44; p-value not
reported; see Table 16). Use of statins in the past year was similarly associated. The analyses were adjusted
for gender, age, comorbidity, prior history of diabetic medications, myocardial infarction, stroke, IHD and
congestive heart disease.
Lipoproteins and age-related macular degeneration
High-density lipoprotein cholesterol is usually regarded as ‘good cholesterol’ because of an association with
reduced cardiovascular risk. The picture in AMD is mixed. Dashti and colleagues299 identified 20 studies of
AMD risk and HDL cholesterol: seven reported higher risk with higher HDL, four showed reduced risk, eight
showed no effect and one showed a mixed pattern.
In a more recent review, Wang and colleagues300 included 19 studies. They carried out meta-analysis and
concluded that higher HDL cholesterol was associated with an increased risk of early AMD, but not of wet
AMD or GA. High LDL-C was associated with a lower risk, but only just (RR 0.93, 95% CI 0.88 to 0.99).
In a case–control study with 82 patients with AMD (early or late, with late including both wet AMD or GA),
Colak and colleagues,301 from Belgrade, found no association between HDL cholesterol and AMD, but
did find higher total and LDL cholesterols in the AMD group (total 6.25 mmol/l vs. 5.57 mmol/l, p < 0.001;
LDL 3.99 mmol/l vs. 3.60 mmol/l, p = 0.018). However, when they examined the subfractions of HDL
cholesterol, they found differences in the HLD3 subfraction in men but not in women. The HLD3 sub fraction
is not regarded as ‘good HDL’.
Therefore, looking just at HDL and LDL may be too broad in AMD, and we may need to explore gender
differences in risks. To complicate things further, it has been suggested that the lipid deposition in Bruch’s
membrane and drusen may not all be derived from plasma sources such as LDL cholesterol – some may be
produced in the RPE itself.302
Problems with statin studies
An almost universal problem with the observational studies is that they record use of any statin, but do
not analyse by individual statin or dose, thereby lumping low-potency and high-potency statins together.
The older studies probably reflect the use of older, less potent statins, rather than the more recent
high-potency ones, such as atorvastatin 80 mg or rosuvastatin. There are other problems. One is that ‘use’
may mean prescription, not consumption. Another is that statin use may only have an effect if lipid levels
are reduced and we do not know how great a reduction is required to affect AMD, if there is an effect.
One study by Shalev et al.303 did subdivide statins into:
l low efficacy – fluvastatin 40 mg or less, pravastatin 40 mg or less, simvastatin 10 mg or less, cerivastatin
0.2 mg, lovastatin 40 mg or less
l moderate efficacy – fluvastatin 80mg, rosuvastatin < 10mg, simvastatin 20 or 40 mg, atorvastatin 10mg
l high efficacy – atorvastatin 20 mg or more, simvastatin 80 mg, lovostatin 80 mg, rosuvastatin > 10 mg,
pravastatin 80 mg.
These bands were based on LDL lowering. Note that high-dose statins are now regarded as doses such as
atorvastatin 80 mg daily.
Shalev et al.303 noted that only about one-fifth of patients took statins on ≥ 90% of days. Only 19% were
prescribed a high-efficacy dose.
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One problem with some older negative studies is that they may not have enough patients on statins.
Smeeth and colleagues304 used UK data from General Practice Research Database from the years 1987 to
2002, but only 2.1% of people on the database had ever been prescribed a statin. In a later study305 using
The Health Improvement Network (THIN) data, 1996–2006, they found much larger numbers on statins and
were able to match 129,288 statins users with > 600,000 controls who had not been prescribed statins.
They also provide data on which statins were used, but not dosages. Simvastatin was used by 39% of
people on the database, atorvastatin by 21% patients and more than one statin by 33% patients. They
reported that statin use was associated, after adjustment, with HR of 1.17 (95% CI 1.00 to 1.38) for any
AMD (as recorded on the THIN database).302 Another problem is that people treated with statins are at high
risk of cardiovascular disease and may have other confounding factors that cannot be entirely adjusted for.
Adverse events
Adverse events were recorded in the two intervention studies (Table 17). Simvastatin was well tolerated
in the RCT by Guymer and colleagues283 with major illnesses reported in seven participants in the statin
group and 15 in the control group. Muscle aches were reported by two recruits on placebo and five on
simvastatin (see Report Supplementary Material 4 for full details.) In the before-and-after study by Vavvas
and colleagues,286 three participants withdrew from study due to AEs.
TABLE 17 Results from selected recent observational studies of statins and dry AMD
Al-Holou et al., 2015291
Prospective cohort; FQ All, N= 3791 HR (95% CI); p-value
Progression to late AMD (any) 1650 (43.5%) a1.08 (0.83 to 1.41); p= 0.56
b0.94 (0.72 to 1.22)
Progression to GA (any) 869 (22.9%) a1.21 (0.85 to 1.73)
b1.06 (0.74 to 1.51)
Progression to nAMD 998 (26.3%) a1.24 (0.89 to 1.73)
b1.07 (0.80 to 1.50)
Progression to central GA 479 (12.6%) a1.08 (0.67 to 1.74)
b0.92 (0.57 to 1.48)
Maguire et al., 2009293
Cross-sectional; FQ All patients, N= 744
Adjusted risk ratios (95% CI) associated
with statin usec
End-point GA, n/N (%) 80/743d (10.8) 0.75 (0.43 to 1.30)
States that analyses are adjusted for age, per cent of retinal area covered by drusen, level of focal hyperpigmentation,
and RPE depigmentation. Also reports unadjusted risk ratios (not data extracted)
CNV, n/N (%) 176/744 (23.7) 1.32 (0.95 to 1.84)
Analyses adjusted for age, cigarette smoking status, hypertension, and level of focal hyperpigmentation. Also reports
unadjusted risk ratios (not data extracted)
Advanced AMD, n/N (%) 242/744 (32.5) 1.19 (0.89 to 1.60)
Analyses adjusted for risk factors for either CNV or GA. Also reports unadjusted risk ratios (not data extracted)
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TABLE 17 Results from selected recent observational studies of statins and dry AMD (continued )
Barbosa et al., 2014294
Cross-sectional; FQ Statin use, N= 1231
No statin use,
N= 4374 p-value
AMD diagnosis 9.9 5.8 p = 0.0003
Statin users with AMD, n = 126,
OR (95% CI) p-value
Risk of Any AMD diagnosis 1.77 (1.32 to 2.38) Unadjusted p < 0.0001
Risk of early AMD 0.95 (0.67 to 1.33) Adjustede p = 0.745
Risk of late AMD 0.78 (0.34 to 1.80) p = 0.556
McGwin et al., 2015295
Case–control study; FQ Cases of ARM, N= 550 Controls, N= 5500 OR (95% CI)f
Proportion of patients with a statin
prescription filled before the index date (%)
6.7 13.6 0.30 (0.21 to 0.45)
Current statin use (%) 4.4 8.0 0.34 (0.21 to 0.53)
Past statin use (%) 2.4 5.6 0.26 (0.14 to 0.47)
Duration of use (%)
< 12 months 2.0 4.3 0.32 (0.20 to 0.52)
12–23 months 2.0 2.9 0.29 (0.12 to 0.67)
> 23 months 2.7 6.3 0.29 (0.15 to 0.56)
VanderBeek et al., 2013296
Case–control; FQ
Statin use
0–6 months 1.0 (reference)
7–12 months 0.99 (95% CI 0.69 to 1.41); p= 0.952
13–18 months 1.57 (95% CI 1.16 to 2.13); p= 0.003
19–24 months 1.48 (95% CI 1.17 to 1.88); p= 0.001
Progression From non-exudative to exudative AMD, HR (95% CI)
Statin use
0–6 months 1.0 (reference)
7–12 months 1.04 (95% CI 0.62 to 1.75); p= 0.870
13–18 months 1.27 (95% CI 0.78 to 2.06); p= 0.337
19–24 months 1.63 (95% CI 1.16 to 2.29); p= 0.005
Kaiserman et al., 2009297
Case control (two studies); FQ
Study 1 Statins, n = 107 No statins, n = 176 p-value
Proportion with AMD (had PDT) 0.27%
(95% CI 0.20 to 0.34)
0.16%
(95% CI 0.14 to 0.18)
p = 0.002
Study 2 AMD, n = 334
Matched controls,
n = 1670 p-value
Proportions using statins, any 126 (37.7%) 628 (37.6%) 0.97
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Summary
The evidence from observational studies is rather mixed and probably best regarded as inconclusive overall.
Some studies have attempted to adjust for confounding variables, for example by propensity scoring. Most
studies gave no details of which statins were used or dosages. Patients on statins are more likely to have
had cardiovascular disease, which is associated with an increased risk of AMD.
The trial by Guymer and colleagues,283 using 40 mg of simvastatin, did show benefit in terms of reduced
progression in patients with non-advanced AMD. The results in the study of high-dose atorvastatin by
Vavvas and colleagues286 were more impressive and visual benefits were reported, but there were no controls.
Conclusion
We recommend a trial of high efficacy statins in early and intermediate AMD.
A trial may be getting under way in Spain, called Statins4 drusen.306
TABLE 17 Results from selected recent observational studies of statins and dry AMD (continued )
Fong et al., 2010298
Case–control; FQ Statin use, N= 43,026
No statin use,
N= 36,343
Wet AMD (%) 51.5 48.5
No wet AMD (%) 54.2 45.8
OR 0.89 (95% CI 0.77 to 1.03); p= 0.14
Recent longer-term use of statins
(3 years to 2007) Statin use, n = 32,743
No statin use,
n = 46,626
Wet AMD (%) 38.5 61.5
No wet AMD (%) 41.3 58.7
OR 0.89 (95% CI 0.77 to 1.04); p= 0.14
Lipid-lowering agent use in 2006 Statin use, n = 5016
No statin use,
n = 74,353
Wet AMD (%) 5.3 94.7
No wet AMD (%) 6.3 93.7
OR 0.83 (95% CI 0.59 to 1.14); p= 0.64
Etminan et al., 2008285
Nested case–control; FQ Cases, N= 2867 Controls, N= 11,468 Adjusted RR (95% CI)
Current users: statins, n 642 2042 1.30 (1.17 to 1.44)
Use in past year: statins, n 1268 4268 1.31 (1.20 to 1.43)
ARM, age-related maculopathy; FQ, fair quality.
a Adjusted for propensity scores, baseline AMD status, age and not accounting for competing risk of death.
b Adjusted for age and accounting for competing risk of death.
c Patient-specific analyses were the time to an event in the first affected eye, baseline ocular characteristics of the worse
eye were used. Eye-specific analyses used a robust variance estimator to accommodate the correlation between two eyes
of the same patient.
d Numbers are stated in text as 1477 and 744.
e Adjusted for demographic characteristics, health-related behaviours, comorbidities and self-reported general health condition.
f Adjusted for diabetes, lipid metabolism disorders, hypertension, IHD, cerebrovascular disease, and arterial disease.
DOI: 10.3310/hta22270 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 27
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
Visual cycle inhibitors
Mechanism of action
Detection of light in the PRs (rods and cones) begins with the transformation of 11-cis-retinal
(a photosensitive molecule derived from vitamin A, attached to an opsin protein) into all-trans-retinal.
This molecule is not light sensitive so in order to replenish the 11-cis-retinal stocks, a recycling process is
required. This process is called the visual cycle and is illustrated in Figure 1.
In AMD, this cycle malfunctions, and some all-trans-retinal goes down a different pathway into the A2E
dimer, which is a major component of the toxic lipofuscin deposition. A2E is formed of two molecules of
all-trans vitamin A (bisretinoid) and one molecule of ethanoloamine.307 The aim of visual cycle inhibitors
(also called modulators) is to reduce the accumulation of A2E.
Emixustat
Emixustat is an oral drug that inhibits RPE65, which is found only in the eye. So adverse effects elsewhere
are unlikely.
One RCT was found. Dugel and colleagues308 included adults with a clinical diagnosis of GA, and BCVA
20/400 or better in the study eye, in a dose-ranging, Phase II RCT (NCT01002950) in 15 centres in the
USA. The trial had an unclear risk of selection bias, although random generation was adequate. A total of
72 participants were randomised to one of five doses of oral emixustat or placebo for 90 days. The 7-mg
and 10-mg groups were discontinued by the sponsor at an early stage owing to the frequency of adverse
effects. Change in GA area is summarised in Table 18, but no statistical comparisons were presented. Two
participants in the emixustat cohorts (one in the 7 mg dose arm, one in the 5 mg dose one) had a decrease
in VA ≥ 15 letters, compared with none of the placebo group.
Another trial has been registered, testing three doses of emixustat (2.5 mg, 5 mg and 10 mg) and placebo,
but no results have yet been posted (NCT01802866). The primary outcome was area of GA. This is also
registered as EUCTR2012-004952-12-DE.
Adverse events
Overall, there were 29 discontinuations due to ocular AEs (emixustat, n = 23; placebo, n = 6) in the study
by Dugel and colleagues.308 Serious AEs were reported by three participants in the emixustat groups (one
exacerbation of chronic obstructive pulmonary disease and two with chromatopsia, a disturbance of colour
vision, sufficient to interfere with driving) and none of the placebo group. At least one ocular event was
experienced by 93% of the combined emixustat groups and 28% of the placebo group. The adverse
11-cis-retinal
11-cis-retinol All-trans-retinal
All-trans-retinol
(vitamin A)
FIGURE 1 Visual cycle.
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ocular events included chromatopsia (57% emixustat vs. 17% placebo), delayed dark adaptation (48% vs.
6%), visual impairment (26% vs. 6%), reduced VA (11% vs. 0%) and blurred vision (15% vs. 6%).
Dugel and colleagues308 considered that the adverse effects were not sufficient to prevent the drug being
trialled in a longer RCT with progression of GA and VA as the outcomes.
Another study of emixustat has been reported in a EURORETINA 2016 conference abstract to have shown
no difference in GA growth rates between drug and placebo.309
Fenretinide
Fenretinide inhibits bisretinoid accumulation by binding with retinol binding protein 4 (RBP4).
Quantity and quality of research
Reviews
Fenretinide was mentioned in three non-systematic reviews of multiple interventions.9,310,311 However, all
three reviews include only one trial, by Mata et al.,144 described below.
Studies
Mata et al.144 from the USA carried out a RCT (NCT00429936) in 246 participants. The aim was to see if
reductions in RBP retinol would slow GA growth rates. The RCT was a three-arm comparison of oral
fenretinide 100 mg (n = 80), oral fenretinide 300mg (n = 84) and placebo (n = 82), taken daily for 24 months
(details from trial registration). The study had an unclear risk of selection bias (see Report Supplementary
Material 4). The median age of participants was around 79–80 years, and between 35% and 46% were
male. Baseline mean BCVA was between 67 and 69. Mata is based in ReVision Therapeutics (La Jolla, VA,
USA), which supported the trial jointly with Sirion Therapeutics (San Diego, CA, USA). The authors included
people from both companies. The trial was carried out in 30 sites in the USA but no details of the locations or
investigators are given. One author was from Retina Associates of Cleveland, OH, USA.
The aim was to slow growth of GA, which is logical as the aim is to slow down deterioration.
Mata et al.144 included people with GA secondary to dry AMD and a BCVA between 20/20 and 20/100.
GA was measured by FAF and recruits had total atrophic areas of one to eight disk areas. There were
no significant differences in GA growth rates overall, but a trend towards a slower growth rate was
seen in patients whose RBP fell < 2 mg/dl (Table 19). There were too few of these to show any statistical
TABLE 18 Results of Dugel emixustat trial
Dugel and colleagues
2015308
RCT, unclear ROB
2mg qAM
(N= 12)
5 mg qAM
(N= 12)
5mg qPM
(N= 12)
7mg qAMa
(N= 12)
10mg qAM
(N= 6)
Placebo
(N= 18)
GA lesion size change from baseline at Day 90, Total area, mm2 by
Colour photography,
mean (SD) (n)
0.2 (0.5) 11 0.3 (0.5) 10 0.1 (0.5) 8 0.4 (0.7) 9
FAF photography mean
(SD) (n)
–0.1 (1.4) 11 0.0 (0.2) 4 0.0 (1.0) 8 0.2 (0.4) 8
Fluorescein angiography,
mean (SD) (n)
0.2 (0.6) 12 0.5 (0.5) 10 0.2 (0.6) 9 0.4 (0.5) 12
VA (decrease of
≥ 15 letters)
0 0 1 1 0 0
qAM, every morning; qPM, every evening; ROB, risk of bias.
a Lesion data were not analysed for the emixustat 7 mg qAM and 10mg qAM cohorts.
DOI: 10.3310/hta22270 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 27
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
significance. At 25 months, VA had reduced by 10–11 letters in all groups (see Table 19). The time to first
CNV event showed a reduced incidence of CNV in both fenretinide groups, with incidence 18.3% on
placebo, 8.8% on fenretinide 100 mg and 9.6% on 300 mg (OR for placebo group 2.2; p = 0.06).
Adverse events
The study reported higher rates of AEs leading to withdrawal in the two fenretinide groups than the
placebo group (17.5% fenretinide 100; 20.2% fenretinide 300; 6.1% placebo). The most commonly
reported AEs leading to withdrawal were eye disorders such as visual disturbance and night blindness in
the fenretinide 300 mg group (for specific events see Report Supplementary Material 4). Other commonly
reported AEs that did not lead to withdrawal were also reported.
Fenretinide has been very widely used in cancer trials, both of treatment and prevention, with thousands
treated. De Palo and colleagues312 report three trials with 1422 women with breast cancer on fenretinide
200 mg daily and 363 with basal cell cancer. Veronesi and colleagues313 randomised 2972 women to
fenretinide 200 mg daily or no treatment for 5 years in a trial of prevention of second breast cancer. We
cite these studies to show that fenretinide can be well tolerated in younger patients; however, it causes
fetal abnormalities so could not be used in women likely to become pregnant.
In a trial by Camerini et al.314 of 5 years of fenretinide in 2867 women to prevent a second breast cancer,
the commonest adverse effects were diminished dark adaptation in 19% and skin problems in 19%
(placebo rates 3% for both).
It has been trialled for prevention of oral cancers in Italy. Chiesa and colleagues from Milan315 reported
that only seven of 137 patients had to stop because of adverse effects.
In a breast cancer prevention trial, Costa et al.316 tried three doses (100 mg, 200mg and 300mg for 6 months
and then 200 mg for another 6 months). Impaired night vision was seen only with the 300mg doses.
There was a lag between reduction in RBP retinol levels (maximum reached by 3 months) and reduced GA
growth rates (not seen until after 12 months). Mata and colleagues144 argue that VA is unlikely to be
correlated with reduced GA growth rates because the GA is outside the fovea, and that slowing of GA
growth rate over 24 months would not be expected to affect VA. We agree.
The aim of slowing of GA growth rates is primarily to preserve vision, which was not shown in this trial.
However, restriction of the size of GA may be also helpful as if one has a small area of GA it would be
TABLE 19 Results of Mata fenretinide trial
Mata et al., 2013144
RCT; unclear ROB
Fenretinide 100,
n= 80
Fenretinide 300,
n= 84
Placebo,
n= 82 p-value
VA change from baseline (mean letters lost) at
25 monthsa
–11.0 –10.0 –8.0 NR
Mean % change in delayed dark adaptation grade 28 38 16 NR
Incidence of CNV onset in study or fellow eye (%)
No CNV event 91.3 90.4 81.7 Reporting
unclear
≥ 1 CNV event 8.8 9.6 18.3
Growth rate 2.14 1.95 2.03 –
Growth rate in patients with RBP ≤ 2m/dl 2.53 1.70 – –
ROB, risk of bias.
a Estimated from figure in Mata et al., 2013.144
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more likely that extrafoveally fixating patients may be able to still read with visual aids whereas if the area
of GA is very large, extrafoveal fixation is very difficult or impossible so people may not do so well even
with visual aids. The drop-out rate was quite high in the fenretinide groups (17.5% and 20.2%) compared
with 6% in the placebo groups. Despite this, Mata et al.144 say that the drug was well tolerated.
Summary
The RCT by Mata et al.144 had an unclear risk of bias. It reported slowing of growth of areas of GA, but
reported no difference in VA. The study found that fewer people in the treated groups progressed to wet
AMD over 2 years of follow-up, which was a reduction of about half. AEs were more common in the
fenretinide groups and, in particular, the higher-dose group, but no serious AEs due to the drug were reported.
The authors conclude that the results justify further trials.
Complement inhibitors
Mechanism of action
The complement system is part of the body’s immune system. There are three main complement
pathways: classic, alternative and mannose-binding pathway. Complement components have been found
in drusen and in AMD, and it is thought that the complement system is inappropriately activated. The aim
of complement inhibitors is to reduce the activity.
One drug, lampalizumab, has been shown to have some effect. For completeness, a brief account is given
here, but as trials are already under way, it is not anticipated that the HTA programme would commission
any further trials.
Lampalizumab is an antigen-binding fragment targeting complement factor D, which is a key component of
the alternative complement pathway. The MAHALO Phase II trial317 recruited 129 patients randomised to sham
injections, or to two lampalizumab regimens, 10 mg once a month or twice a month, by intravitreal injection.
The primary outcome measure was spread of GA, measured by AF, and follow-up was for 18 months. Almost
one-quarter of patients dropped out. There was a 20% reduction in GA area on lampalizumab compared with
sham. In a subgroup with the biomarker complement factor 1, the reduction was 44%.
Two very large trials are under way, CHROMA and SPECTRI.
SPECTRI is NCT02247531 and will compare lampalizumab 10 mg given every 4 weeks and every 6 weeks
with sham injections. It aims to recruit 936 people in 160 sites worldwide (so only about six per site, which
suggests a marketing element), although most are in the USA. There are 14 UK sites. Data collection is
due to end in November 2017.
CHROMA (NCT02247479) aims to recruit 936 patients in 144 sites, again mainly USA but four in the UK.
The design is the same as SPECTRI. Data collection is due to end in September 2018.
OMASPECT (NCT024745119) will recruit patients coming out of these two RCTs.
There is also another smaller trial, NCT02288559, that will compare two doses, 10 mg every 2 weeks
versus 10 mg every 4 weeks, with sham injections, in 96 patients with GA in 37 sites in the USA. Final data
collection is due in 2017.
All these trials are sponsored by Genentech-Roche (South San Francisco, CA, USA).
A trial without a NCT number is registered on the WHO trials portal. It looks very similar to NCT0268658
but has a slightly different start date and a recruitment target of 900.318
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NCT02515942 is a trial of the combination of CLG561, an antiproperdin drug, with tesidolumab (formerly
LFG316), a C5 blocker, in GA. CLG561 was not effective on its own (NCT01527500). The trial is due to
end in November 2017.
NCT02503333 is the FILLY trial of the complement inhibitor, APL-2 from Apellis Pharmaceuticals
(Crestwood, KY, USA). Early results have been posted on the Apellis website (www.apellis.com; accessed
26 December 2017). In this Phase 2 study, APL-2 slowed the growth of GA by 29% compared with sham
injections, but with a greater reduction becoming apparent in later months. However, in a subgroup with
wet AMD in one eye, there was a higher incidence of wet AMD.
Quantity and quality of research
Reviews
One Cochrane review by Williams et al.319 in 2014 and two non-systematic reviews320,321 were identified
(see Report Supplementary Material 4). The Cochrane reviews found no trials – it preceded the MAHALO
study. So no evidence based recommendations could then be made on the potential safety and efficacy of
complement inhibitors for prevention or treatment of AMD. Complement inhibitors were also considered
in four non-systematic reviews of multiple interventions.9,310,311,322
Studies
Eculizumab
Eculizumab (Soliris®, Alexion Pharmaceuticals, New Haven, CT, USA) is a C5 inhibitor. One RCT of
eculizumab has been reported, the COMPLETE (Complement Inhibition with Eculizumab for the Treatment
of Nonexudative Macular Degeneration) study (NCT00935883).
This study was conducted in the USA, had an unclear risk of selection bias (although random sequence
generation was adequate), and received commercial and non-commercial funding. Mean age was 79 years.
Baseline VA was reported (Table 20).
Results
In the Phase II COMPLETE Study, Yehoshua and colleagues323 included people with total GA area of
1.25–18 mm2 and VA 20/63 or better. A total of 30 participants were randomised to treatment with i.v.
eculizimab, (high or low dose) or placebo for 24 weeks, with one eye selected as the study eye. There was
no difference in change from baseline for GA or VA between eculizumab and placebo at 12 months’
TABLE 20 Results of eculizumab trial
Yehoshua et al., 2014323
RCT, unclear ROB Eculizumab, n= 20 eyes Placebo, n= 10 eyes p-value
Mean change in GA at 52 weeks, mm (SD) 0.37 (0.21) 0.37 (0.22) p= 0.93
Change in ETDRS VA at 52 weeks 0.7 (7.2) 2.9 (7.0) p= 0.43
Change in ETDRS letters (%)
≤ –15 5 10
–6 to –14 10 0
Within ± 5 70 90
5 to 14 10 0
≥ 15 5 0
ROB, risk of bias.
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follow-up (see Table 20). Yehoshua and colleagues323 suggest several possible reasons for the lack of effect.
First, it may just be that the drug has no effect. Second, it may have been that the effect was smaller than
detectable given the power of the trial, which could detect a reduction in GA growth rate down to 55%. It
was powered to detect a 75% reduction. Third, the drug might have had more effect if given intravitreally.
Adverse events
Yehoshua et al.323 reported no AEs.
Summary
The Cochrane review319 (last updated January 2014) found no published trials on the use of complement
inhibitors in AMD.
One small RCT323 with an unclear risk of bias found no significant improvement with eculizumab. It seems
unlikely that further research on eculizumab would be a priority.
Lampalizumab looks more promising but a considerable amount of research is under way.
L-dopa
Mechanism of action
Brilliant and colleagues324 report their discovery of a protein receptor, GPR143, that is activated by levodopa
(L-dopa). This receptor is found in the RPE and their hypothesis is that GPR143 signalling might protect
people from AMD, possibly by altering the balance between pigment epithelium derived factor and VEGF.
Quantity and quality of research
One study was identified. Brilliant and colleagues324 carried out a large retrospective cohort study of three
registries with a total of 15,252,958 people in the USA. Data on exposure were according to L-dopa
prescriptions, but the duration of follow-up was not reported. The study was funded by non-commercial
grants, including two from NIH. Mean age was reported only according to L-dopa treatment and AMD
diagnosis with and without L-dopa treatment, for each of the registries separately (Table 21). No baseline
characteristics of the participants were reported.
TABLE 21 AMD and L-dopa use
Brilliant et al., 2016324
Retrospective cohort, PQ
Marshfield Clinic,
n= 20,000
Marshfield Epidemiology
study, n= 17,500
TruvenMarket Scan
(Truven Health
Analytics, Ann Arbor,
MI, USA),
n= 15,215,458
Age, years mean (SD) L-dopa treatment 67.1
AMD diagnosis without
L-dopa 71.2
AMD with L-dopa 79.3
L-dopa treatment 67.2
AMD diagnosis without
L-dopa 71.3
L-dopa treatment 68
AMD diagnosis without
L-dopa 71.4
AMD with L-dopa 79.3
Clinic Personalised Medicine Research Project, n = 20,000:
AMD present 1142/20,000 (5.7%)
AMD present and prescribed
L-dopa
39/20,000 (0.2%)
Marshfield Epidemiologic study area, n = 17,500
AMD present and prescribed
L-dopa
20/17,500 (0.1%)
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Brilliant and colleagues324 found that age of AMD onset was significantly later in patients who used L-dopa
than in non-users (79.3 years vs. 71.2–71.3 years; p < 0.01). L-dopa users were significantly less likely to
have a diagnosis of AMD (OR 0.78, 95% CI 0.76 to 0.80; p < 0.001) after controlling for age and gender.
Adverse events were not reported.
The authors consider that the results justify clinical trials.
Summary
This huge study found that people who used L-dopa were less likely to have an AMD diagnosis and that
the age of AMD onset was delayed, suggesting that L-dopa protects against AMD.
The study does not tell us whether L- DOPA would be useful in treating dry AMD. It is a very cheap drug
with few adverse effects.
Alprostadil
Alprostadil is prostaglandin E1 and one proposed mechanism of action is to improve blood flow by
vasodilation to improve choroidal blood flow, which is reduced in people with dry AMD compared with
age-matched patients without it. However, prostaglandin E has other effects, including an anti-inflammatory
one. It has been used in peripheral vascular disease, and a chance finding in a study for that, was an
improvement in VA.325 This led to a pilot study by Ladewig et al.,326 which was followed by a trial by
Augustin et al.325 The studies were conducted in Germany and Austria, respectively.
Studies
The pilot study by Ladewig et al.326 recruited a series of 11 patients and compared them with 10 untreated
patients, all with dry AMD (≥ 10 soft and/or hard drusen, early GA and pigment epithelial detachment
without indications of CNV and BCVA ≥ 0.2 and ≤ 0.8). The distributions of stages of AMD are reported
to be similar but details are not given. The study was graded as poor quality (see Report Supplementary
Material 4). Participants were treated with daily i.v. infusion of 60 µg alprostadil for 3 weeks. The duration
of follow-up was 6 months. Funding was from an independent source.
Visual acuity at 6 months improved in the alprostadil-treated group and deteriorated in the non-treated
group; however, no analysis of the difference between groups was reported (Table 22). Other outcomes
were reported only for the treated group.
The RCT by Augustin et al.325 was carried out at six sites in Germany and Austria. The trial (NCT00619229)
was sponsored by UCB Pharma SA (Brussels, Belgium) and two authors were from the company. Augustin
et al.325 recruited 36 people with dry AMD with hard drusen and possible early GA limited to the perifoveal
area in one eye and VA between 0.2 and 0.7 logMAR. They received daily i.v. infusion of 60 µg of
alprostadil for 3 weeks. The controls received a placebo infusion. Follow-up was for 6 months. There was
an unclear risk of selection bias. Mean age was 74 years and half of the recruits were male.
The study was stopped prematurely after the first interim analysis, which led to a need to recalculate the
sample size, which showed a need for greater numbers if power was to be achieved. In addition,
recruitment was slow. So results were based on interim data because the study was stopped early.
Augustin et al.325 state that only exploratory results can be presented.
The BCVA (using ETDRS charts) improved in the alprostadil-treated group, with benefit seen at end of
treatment and at 3 and 6 months, but with greatest improvement at 6 months (see Table 22). BCVA
deteriorated in the placebo group, but no analysis of the difference between groups was reported
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(see Table 22). Progression of dry AMD, stabilisation of dry AMD, contrast sensitivity and colour vision
appeared to be similar in each group. No participants in either group developed nAMD.
Adverse events
There were no drug-related AEs in the pilot study.327 In the RCT325 there were fewer AEs in the alprostadil
group (11.1%) than the placebo group (33.3%). No serious AEs were experienced.
Summary
The trial did suggest some benefit in BCVA but this was not statistically significant with the limited
numbers recruited (no p-value reported but the CIs overlap), and there was no improvement in
progression, although the duration may have been too short. Whether daily infusion for 3 weeks would be
acceptable in wider populations is not known, and nor do we know how long benefit would last. The
value of prostaglandin infusion is therefore unproven.
TABLE 22 Results of alprostadil studies
Augustin et al. 2013325
RCT: uncertain ROB Alprostadil, n= 16 Placebo, n= 17 p-value
Change in BCVA ETDRS lines, 6 months mean (SD) [95% CI] 1.47 (0.569)
[0.30 to 2.64]
–0.04 (0.613)
[–1.30 to 1.22]
NR
Progression of dry AMD, recorded at least once 11/16 (68.8%) 12/17 (70.6%) NR
Stabilisation or amelioration of dry AMD 5/16 (31.3%) 5/17 (29.4%) NR
Contrast sensitivity study eye (Pelli Robson), mean (SD)
[95% CI] at 6 months
1.81 (0.299)
[1.02 to 1.34]
1.094 (0.224)
[0.98 to 1.21]
NR
Colour vision, change from baseline at 6 months, n
Normal – pathological 1 0
Unchanged 12 15
Pathological – normal 3 2 0.47
Ladewig et al., 2005326
Prospective cohort study: PQ
Prostaglandin E1
(Alprostadil) n= 11
No treatment,
n= 10 p-value
Change in VA at 6 months,% of patients
Improvement of 3 lines 9 NR
Improvement of 1 line 27 NR
No change 45 NR
Decline by 1 line 18 NR
Mean change from baseline in VA, ETDRS lines 0.4a –0.8
Change in contrast vision at 6 months, % of patients
Improvement of 1 line 18 NR
Impairment of 1 line 18 NR
BCVA, best corrected visual acuity; PQ, poor quality; ROB, risk of bias.
a Estimate from figure, scale not linear.
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Dorzolomide
Mechanism of action
Dorzolomide (Trusopt, Chibret, Munich, Germany) is a carbonic acid or carboanhydrase inhibitor. Such
agents have been used in glaucoma and the rationale of testing in AMD is that in addition to lowering
IOP, they also improve choroidal perfusion.
Quantity and quality of research
Only one study was identified. A placebo-controlled RCT by Remky and colleagues328 from Germany included
20 participants in the dorzolamide group and 20 in the placebo group. Treatment with a three-times-daily
eye drop (dorzolamide 0.2% eye drop, placebo an artificial tear drop) lasted for 12 weeks with follow-up
immediately afterwards. The study had an unclear risk of selection bias (see Report Supplementary Material 4).
Participants were aged 70 years and 60–70% were male. Baseline BCVA was 0.12 to 0.13 logMAR. The
funding source for the study was not reported.
Results
Remky and colleagues328 included people with AMD with VA > 0.4 (20/50). The eye with better VA was
selected. At 12 weeks, VA was the same in each groups (Table 23). Pericentral visual field analysis showed
an increased retinal sensitivity (1.55 dB, comparison from baseline p = 0.04) in the dorzolomide group but
no significant change in the placebo group (+0.58 dB; p = 0.1). Other outcomes were also similar between
groups (see Report Supplementary Material 4). The study was small and short, so power was limited.
Adverse events
There were no severe AEs in the study. Minor AEs were reported (see Report Supplementary Material 4).
Summary
This pilot RCT with an unclear risk of bias showed no significant differences in VA or other outcomes
between those treated with dorzolamide and those treated with placebo, but the duration of treatment
was very short and the power of the study was low. Few AEs were reported. This group of drugs have
been used for many years with no serious adverse effects.
TABLE 23 Results of dorzolamide study
Remky et al., 2005328
RCT; unclear ROB Dorzolamide, n= 20 Placebo, n= 20 p-value
VA, mean LogMAR (SD) 0.14 (0.12) 0.14 (0.12) NR
ROB, risk of bias.
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Glatiramer acetate (copaxone)
The proposed mechanism of action extrapolates from a study in a mouse model of Alzheimer’s disease in
which glatiramer reduced plaque size.
Quantity and quality of research
Two publications from Landa et al.329,330 The first study was a pilot CCT that included 14 participants
treated with glatiramer acetate (seven participants) or placebo (seven participants). The second study was a
pilot RCT that included six participants (four participants treated with glatiramer acetate and two participants
treated with a placebo). The studies were conducted in the USA. Participants were treated for 12 weeks in
both studies and follow-up was immediate. The intervention was by subcutaneous injection (for dosing
details see Report Supplementary Material 4). The studies had an unclear risk of selection bias. Ages, male
sex and baseline BCVA were not reported. The funding source was not reported.
Results
Landa and colleagues330 included people with dry AMD (no further inclusion criteria reported). At 12 weeks
the CCT reported a statistically significant difference in the proportion of convex drusen disappeared or
shrank (Table 24), but no difference in the proportion of total drusen or concave drusen that disappeared
or shrank. In the pilot RCT the change in drusen area was reported. This appeared to be lower in the
glatiramer acetate treated people than the placebo controls but no statistical analysis was undertaken.
Adverse events
The study did not report AEs.330
Summary
Two linked studies with unclear risk of bias were included. The studies were small and of short duration,
and the outcome measure used was drusen area, which was reported to have reduced. The main interest
of the authors seems to have been to test an outcome measure, using high-resolution spectral domain
OCT, that could predict response. The evidence is too sparse to come to any conclusions on efficacy
of glatarimer.
TABLE 24 Results of glatiramer study
Landa et al., 2011330
CCT; unclear ROB Glatiramer acetate, n= 7 Placebo, n= 7 p-value
% drusen disappeared or shrank at 12 weeks 19.2 6.5 0.13
% convex drusen disappeared or shrank at 12 weeks 27.8 6.8 0.008
% concave drusen disappeared or shrank at 12 weeks 4.7 5.6 0.89
Pilot study
RCT; unclear ROB Glatiramer acetate, n= 4 Placebo, n= 2
Change in drusen area, arbitrary units Baseline: 48,130
12 weeks: 16,205
Baseline: 32,294
12 weeks: 32,781
ROB, risk of bias.
A trial of weekly glatiramer, NCT00541333, started in New York but the last report in May 2013 was that it had been
suspended while data were reviewed.
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OT 551
OT 551 (Othera Pharmaceuticals, Exton, PA, USA) is a drug with antioxidant properties, that forms a
compound called Tempol-H, which has been reported to protect RPE cells in the laboratory from oxidative
damage. It is given as eye drops, three times daily.
Quantity and quality of research
One pilot RCT92 conducted in the USA with 10 participants with bilateral GA was included. Treatment and
follow-up were 2 years duration and one eye of each participant was randomised to treatment or
observation. The trial had unclear risk of selection bias. The funding source was non-commercial. The
mean age of participants was 77 years and 40% were men. Mean baseline BCVA was 46.1–55.7 letters.
Results
Wong and colleagues92 included participants with bilateral GA. A statistically significant difference between
treated eyes and untreated eyes was found for change in BCVA at 2 years (p = 0.026), but no significant
difference was found for contrast sensitivity, GA area or drusen area (Table 25). No eyes progressed
to nAMD.
Adverse events
No serious AEs occurred. There were 32 grade 1 and four grade 2 events (see Report Supplementary
Material 4).
Summary
One small RCT with an unclear risk of bias found a statistically significant improvement in BCVA in eyes
treated with OT-551 for 2 years compared with untreated eyes. There was no significant difference in
other outcomes. The authors conclude that OT 551 has limited or no benefit in GA. A larger trial was
carried out with 137 subjects, using the eye drops on one eye four times a day for up to 2 years, but we
found no publications other than a conference abstract331 reporting no benefit.
TABLE 25 Results for OT-551
Wong et al. 201092
RCT; unclear ROB OT-551, n= 10 (eyes) No treatment, n= 10 (eyes) p-value
BCVA letters change at 104 weeks, mean (SD) 0.2 (13.3) –11.3 (7.6) 0.0259
Loss of BCVA, 104 weeks (%)
≥ 5 letters 30 90
≥ 10 lettersa 30 60
≥ 15 lettersa 10 30
CS, change at 104 weeks, mean (SD) –0.075 (0.33) –0.15 (0.27) 0.6059
Increase in GA area at 104 weeks (mm2) fundus
photos mean (SD)
2.46 (1.25) 2.47 (0.73) 0.9502
Total drusen area at 104 weeks, by fundus photosa 0.32 0.39 0.5391
ROB, risk of bias.
a Estimated from a figure.
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Sirolimus
Sirolimus is an immunosuppressant drug.
Quantity and quality of research
Two small RCTs, Wong 2013332 and Petrou 201594 conducted by the same group in the USA were
included, with a total of 17 participants (total 34 eyes, 17 eyes treated). Randomisation was by eye, with
the other eye acting as control. The first study used subconjunctival sirolimus, the second intravitreal.
The studies had 12 months’ and 24 months’ follow-up, respectively. Both studies had an unclear risk of
selection bias, although in one332 the random sequence was generated by a computer algorithm. Both
studies received non-commercial funding, although the drug was donated by a commercial entity. Mean
age was 74–78 years and the majority of participants were men. Visual baseline acuity was reported by
both studies (Table 26) (NCT00766649 and NCT01445548).
Results
Both studies had similar eligibility criteria: bilateral GA with area of a half or more of a disc area, one or
more large drusen (≥ 125 µm) in each eye, and BCVA 20/20 to 20/400 in each eye. Eyes from each
participant were randomised to receive sirolimus injection or no treatment. Wong and colleagues333
administered sirolimus by subconjunctival injection every 3 months for 2 years. Petrou and colleagues94
administered sirolimus every 2 months for 1 year.
Both studies found that treated eyes had a statistically significantly greater decrease in BCVA compared
with untreated eyes (p = 0.03,333 p = 0.01394) and that a higher proportion of treated eyes lost ≥ 10 lines
of vision (50% vs. 12.5%,332 80% vs. 20%;94 p-value not reported). A non-significant greater increase in
GA area in treated eyes was also found in both studies. No eyes developed CNV during either study.
TABLE 26 Results for sirolimus
Wong et al., 2013332
RCT; unclear ROB
Sirolimus,
n= 8 (eyes)
No treatment,
n= 8 (eyes) p-value
Change in GA area (mm2) mean (SD), by
fundus photography at 24 monthsa
2.46 (1.18) 2.08 (0.83) 0.17
Change in drusen area (mm2) mean (SD),
by fundus photography at 24 monthsa
0.04 (0.58) 0.08 (0.36) 0.81
Change in BCVA letters at 24 months,
mean (SD)
–21.0 (21.5) –3.0 (8.1) p= 0.03 difference 18 letters
(95% CI 0.9 to 25 letters)
Proportion of eyes with ≥ 10 letters vision
loss at 24 monthsb
50 12.5
Petrou et al., 201594
RCT; unclear ROB
Sirolimus,
n= 5 (eyes)
No treatment,
n= 5 (eyes) p-value
Change in GA area (mm2) mean (SD), by
fundus photography at 12 monthsc
2.26 (0.94)d 1.53 (0.75)d 0.15
Change in BCVA at 12 months, mean (SD) –15.6 (7.23)d 0 (13.47)d 0.013
Proportion of eyes with ≥ 10 letters vision
loss at 12 months
80c 20c NR
ROB, risk of bias.
a Values from trial record, p-values from the publication.
b Estimated from figure in Wong et al., 2013.332
c Estimated from figure in Petrou et al., 2015.94
d From trial record.
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Adverse events
Wong and colleagues332 reported mild to moderate ocular AEs, including small haemorrhages, raised IOP,
and one death unrelated to the study medication. Petrou and colleagues94 reported accelerated retinal
thinning in two treated eyes and treatment was suspended.
A third trial, NCT01675947, was terminated in 2014.
Summary
Two small RCTs with an unclear risk of bias found no benefits, but rather a worsening of vision in eyes
treated with sirolimus injection. Serious AEs occurred in some participants. There seems to be no place for
sirolimus in AMD.
Prednisolone
Quantity and quality of research
One prospective cohort study conducted on 475 participants (prednisolone, n = 400; control, n = 75) was
identified.334 Participants from Croatia were given either peribulbar injections of prednisolone 5 mg for 5 days,
or received multivitamins. Allocation was temporal – the first 400 patients received the steroid. Follow-up was
at 6 months. The study was of poor quality (see Report Supplementary Material 4). Participants were aged
between 39–80 years, no further baseline characteristics were provided. The funding source was not
reported. The study was published in the journal of the Croatian Anthropological Society.
Results
Vojnikovic´ and colleagues334 included people with dry AMD but no other inclusion criteria were reported.
At 6 months, peripheral visual field had improved by 10% to 25% in participants in the prednisolone group
but there was no improvement in the control participants (Table 27). Central visual field improved by 5% to
20% in the prednisolone group (only a subgroup of controls were reported, assume no improvement was
seen in the remaining participants). No statistical analyses were reported. AEs were not reported.
Summary
One study of poor quality provided sparse evidence on the effects of prednisolone on dry AMD.
TABLE 27 Results for prednisolone
Vojnikovic´ et al., 2008334
Prospective cohort; PQ Prednisolone, n= 400 Control, n= 75 p-value
Peripheral visual field Improvement of 10 to 25% No significant improvement NR
Central visual field Improvement of 5–20% Improvement of 0.5–1% in 43 patients NR
PQ, poor quality.
DRUG TREATMENT IN DRY AGE-RELATED MACULAR DEGENERATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
Tandospirone
Tandospirone is a 5-HT1A agonist, referred to also as AL-8309B. 5-hydroxytriptamine (5-HT) is also known
as serotonin. The 5-HT1A agonists are used in depression but have also been thought to be ‘neuroprotective’
and in a rat model exposed to severe photo-oxidative stress, they protected the PR and RPE cells.
Quantity and quality of research
One three-arm RCT was identified, the Geographic Atrophy Treatment Evaluation (GATE) trial.190 The study
was undertaken in 48 sites in a number of countries including the USA, Germany, Canada and the UK (see
Report Supplementary Material 4). Participants were allocated to eye drops of 1% tandospirone (n = 252),
1.75% tandospirone (n = 259) or placebo (n = 261). Treatment was given twice daily for 24 months.
Participant follow-up was at 30 months. The RCT had an unclear risk of selection bias. The mean age of
participants was around 78 years and between 37% and 48% of participants were male. Baseline BCVA was
not reported. The study was sponsored by Alcon Research (NCT00890097 and EUCTR2008-007705–37-DE).
Results
Jaffe and colleagues190 (Table 28) included people with GA secondary to dry AMD and no evidence of
CNV. BCVA was required to be at least 35 letters. At 30 months VA was reduced in all groups, but the
difference between groups was not statistically significant (see Table 28). The primary outcome for the
study was the annualised lesion growth rate, this was not statistically significantly different between
the active groups and the placebo.
Adverse events
The study reported similar rates of any ocular AEs across the three treatment groups. There were slightly
higher rates of serious ocular AEs in the placebo group (Table 29 and see Report Supplementary
Material 4).
Summary
This RCT found no benefit on BCVA or GA growth from tandospirone eye drops in in people with GA.
AEs were similar in the tandospirone groups and the placebo group.
TABLE 29 Adverse events with tandospirone
Jaffe and colleagues 2015190
Tandospirone 1.0%
n= 250
Tandospirone 1.75%
n= 258 Placebo n= 260
Any ocular AEs in study eye (%) 66 67 60
Serious ocular AEs in study eye (%) 0 1 2
TABLE 28 Results for tandospirone
Jaffe and colleagues 2015190
RCT; unclear ROB
Tandospirone 1.0%
n= 250
Tandospirone 1.75%
n= 258 Placebo n= 260
Annualised lesion growth rate,
mean (95% CI)a
1.725 (1.595 to 1.855) 1.758 (1.626 to 1.890) 1.707 (1.585 to 1.830)
BCVA change (ETDRS) estimated
from figure
–0.8 –0.6 –0.7
ROB, risk of bias.
a Tandospirone 1.0% vs. vehicle solution mean difference 0.017 (95% CI –0.161 to 0.196); tandospirone 1.75 vs. vehicle
solution mean difference 0.051 (95% CI –0.129 to 0.231).
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Trimetazidine
Trimetazidine is a drug used in France as a prophylactic for angina, and also for vertigo and tinnitus, and
for visual field loss presumed to be due to vascular causes.
Quantity and quality of research
One placebo-controlled RCT by Cohen et al.335 from France (324 centres), Belgium (6 centres) and Spain
(11 centres) compared 594 participants given trimetazidine 35 mg with 598 given a matched placebo.
Treatment was one tablet twice daily for a mean of 37.6 months. Follow-up was a minimum of 3 years.
The study had a low risk of selection bias (see Report Supplementary Material 4). Drop-out rates were
23% in the trimetazidine group and 27% in the placebo arm. Participants had a mean age of 73.5 years
and 38% were male. Baseline distance VA was at least 0.5 (20/40) in 91.5% of the trimetazidine treated
participants and 93% in the placebo group. The study was sponsored by Servier Laboratories, Suresnes,
France.
Results
Cohen and colleagues335 included people with AMD and unilateral CNV, and the unaffected eye was the
study eye. At follow-up, CNV incidence was similar between groups (p = 0.78) (Table 30). Five-year
incidence of CNV, atrophy of greater than one-third disc diameters and atrophy of greater than one-third
disc diameters were similar between groups. In atrophy greater than one-third disc diameters, the
trimetazidine group did slightly better – incidences per 100 patient-years 5.11 on drug versus 6.45 on
placebo; HR 0.76, 95% CI 0.56 to 1.02. In some subgroups (prespecified) the drug group did better, such
as the under 75s where HR for atrophy was 0.57 (95% CI 0.38 to 0.88) based on 11% and 17%
developing atrophy greater than one-third disc diameters. VA was not reported.
Adverse events
Adverse events including eye disorders were similar between groups with any AEs experienced in 75% of
the trimetazidine group and 79% of the placebo group.
Summary
This RCT was essentially negative overall, with no differences in the incidence of CNV and atrophy
between those treated with trimetazidine and those treated with placebo.
Further research does not seem to be indicated.
TABLE 30 Results for trimetazidine
Cohen et al., 2012335
RCT; low ROB Trimetazidine, n= 546 Placebo, n= 540 p-value
CNV Incidence per 100 patient-years 10.86 11.13 HR= 0.97 (95% CI 0.79 to 1.19);
p= 0.78
CNV 5-year cumulative incidence,
mean (SD) (%)
45.35 (3.27) 48.50 (3.59) NR
ROB, risk of bias.
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Visaline
Visaline is a drug and nutrient mixture registered in Switzerland for AMD. The drug is buphenine, a
beta-agonist to increase perfusion. The other components are beta-carotene, vitamin C and tocopherol.
Quantity and quality of research
One study was identified. Kaiser and colleagues from Switzerland336 carried out a placebo-controlled pilot
RCT with nine participants in the visaline group and 11 in the placebo group. Treatment was with two
tablets twice daily, 5 days per week (buphenine HCI 1.5 mg, beta-carotine 10 mg, tocopherol acetate
10 mg and ascorbic acid 50 mg or placebo) for 6 months with follow-up immediately afterwards. The
study had an unclear risk of selection bias (see Report Supplementary Material 4). Participants were aged
73 years and 55% of treated participants and 9% (1 of 9) of placebo participants were male. Baseline near
VA was 0.45 – 0.57. The funding source for the study was not reported.
Results
Kaiser and colleagues 1995336 included people with early AMD with BCVA between 20/100 and 20/25.
The eye with better VA was selected if both eyes were affected. At 6 months, near and far VA were similar
in each group as shown in Table 31. The proportions with improved visual function (not defined) was
greater in the visaline group than the placebo group (44% vs. 27%); however, there appears to be some
missing data (see Report Supplementary Material 4 for unchanged and worsened categories). Other
outcomes were similar between groups.
Adverse events
There were no AEs.
Summary
This RCT showed no difference in VA or other outcomes between those treated with visaline and those
treated with placebo.
TABLE 31 Results for visaline
Kaiser et al., 1995336
RCT; unclear ROB Visaline, n= 9 Placebo, n= 11 p-value
Far VA at 6 months, mean (SD) 0.67 (0.2) 0.6 (0.22) NS
Near VA at 6 months, mean (SD) 0.62 (0.14) 0.55 (0.23) NS
NS, not significant; ROB, risk of bias.
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Antihypertensive drugs and risk of developing wet age-related
macular degeneration
Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers are very
commonly used for controlling high blood pressure. It has been reported that they can induce regression
of CNV in rodent models of AMD and so the question was raised whether or not they could reduce the
risk of wet AMD. However, Thomas and colleagues337 found no such protection. They compared 250
patients with dry AMD and 250 with wet AMD and found no difference in the frequency with which these
drugs were used. However, they did note that 65% of people with AMD had hypertension, with no
difference between wet and dry AMD.
The case–control study by Etminan and colleagues285 from Vancouver in people who had had coronary
angioplasty or bypass found that those with AMD (based on recording of ICD-9 codes) had a slightly
higher rate of using ACE inhibitors (RR 1.19, 95% CI 1.07 to 1.33).
Ranibizumab
Ranibizumab is an anti-VEGF drug used in wet AMD and other eye conditions.
Quantity and quality of research
One small before-and-after study of ranibizumab by Gallego-Pinazo and colleagues338 was identified. The
study was described as a pilot. It was conducted in Spain. Six participants received intravitreal ranibizumab
0.5 mg/0.05 ml at least once. Retreatment was permitted if there was persistence or recurrence of elevation
of the RPE contour on OCT, or if retinal fluid was seen on OCT, or if ≥ 5 letters were lost. The mean number
of injections was two and the range was one to five. Participants were then followed up at 12 months. The
study was of fair quality apart from the very small size. The mean age of participants was 69 years and 33%
were male. Baseline VA was 0.40 (decimal ETDRS equivalent). The study funder was not reported.
Results
Gallego-Pinazo and colleagues338 included people with BCVA < 20/30 and DPED from AMD. At 12 months
the mean BCVA had improved (p = 0.046, Table 32) and the study found that 33.3% of patients gained
between 19 and 21 letters, with no participants experiencing loss of BCVA. There was a decrease in
central macular thickness but this was not statistically significant.
Adverse events
The study did not report AEs.
Summary
In a very small before-and-after study of fair quality, a significant improvement on BCVA was seen at
12 months in people with DPEDs. AEs were not reported. The authors recommend a long-term randomised
trial. If there is any prospect of benefit in dry AMD, the manufacturers will no doubt pursue it vigorously.
TABLE 32 Results for ranibizumab
Gallego-Pinazo et al., 2013338
Prospective B+A; FQ Ranibizumab, n= 6 p-value
BCVA, mean (decimal ETDRS equivalent)
Baseline 0.40 (0.15) 0.046
End of study 0.58 (0.3)
BCVA, best corrected visual acuity; FQ, fair quality.
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Brimonidine
Brominidine is an alpha-adrenergic agonist used in glaucoma, but there is some evidence from animal and
in vitro cell studies that it may protect RPE. In glaucoma it is used as eye drops, but when given thus, little
of the drug reaches the retina. It is made by Allergan (Dublin, Ireland), who also produce the dexamethasone
implant (Ozurdex®, Allergan, Dublin, Ireland). Allergan have used the same technology to produce implants
of brimonidine.
A Phase IIA trial (NCT00658619) comparing implants with two doses of brimonidine in a slow-release
matrix versus sham injections was reported at ARVO 2017.339 Recruits had AMD with bilateral GA. A total
of 113 patients were randomised to brimonidine 132 or 264 µg or sham, given at baseline and 6 months.
The primary end point was change from baseline in GA area. At 12 months, growth of GA was lower in the
brimonidine groups (p = 0.032) by 19% for the lower dose and 28% for the higher. After 24 months, the
difference was less, and GA growth was reported to be reduced only in the higher dose group (p = 0.059).
This might imply that treatment would need to be given every 6 months (or even every 4 months, based
on the timescale of release of dexamethasone from the Ozurdex implant). A Phase IIB trial, the Beacon Trial
(NCT02087085), is now under way with brimonidine 400 µg given every 3 months. The matrix carrier slowly
dissolves, leaving no foreign bodies floating in the eye.
Integrin inhibitors: luminate
Luminate is a new drug currently being trialled in wet AMD and DMO, but results from a case series of five
patients with intermediate dry AMD (‘intact PR and RPE layers with no subretinal fluid’) were reported at
ARVO 2017.340 Four out of five patients were reported to show improved VA after 3 months.
Tetracyclines
NCT01782989 is using the Oracea brand of doxycycline (Galderma Laboratories, Fort Worth, TX, USA) in a
trial to see if it slows progression of GA. The trial is called TOGA (Treatment with ORACEA for Geographic
Atrophy). It is due to complete data collection by end of 2018.
A trial of oral minocycline, NCT02564978, is under way in GA, sponsored by the National Eye Institute, and
involving centres in Maryland, USA, and Bristol and Moorfields. It aims to recruit 40 people and to end in 2021.
Other drugs
A drug called MC-1101 (MacuCLEAR®, MacuCLEAR Inc., Richardson, TX, USA) was being trialled in dry
AMD. It could be given topically by spray on to the ocular surface and was said to improve choroidal blood
flow. No data have been added to the registration for NCT02127463, a Phase II/III trial aiming to recruit
60 patients since 2014. Data collection was expected to be complete by 2016. NCT01601483 has been
terminated, and NCT01922128 was completed in 2013.
NCT02684578 is a trial of metformin, an old, very cheap drug used in type 2 diabetes, versus placebo, in
California. The drug will be given to people without diabetes for 18 months. The trial will end in 2019.
NCT00332657 and NCT00307398 were trials of anecortave in people with wet AMD in one eye and dry in
the other, with the aim of preventing the development of wet AMD in the dry eye. It recruited 2500
people but was terminated because of lack of effectiveness.
NCT01603043 was also terminated was a trial of Alcon’s AL-788898A, a compstatin analogue, in GA.
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NCT01342926 was a trial of GSK933776 (GlaxoSmithKline, Middlesex, UK), an antibody targeting amyloid
beta, but it had no effect on growth of GA or on VA.
Another antibody against amyloid beta was (or is) RN6G from Pfizer (New York, NY, USA). Three trials
were registered as NCT00877032 with 57 patients, NCT01577381 with 10, and NCT01003691 with 24.
The second was terminated early after only the 10 recruits. No results are yet published.
Summary
We have reviewed the evidence on 23 drugs or groups of drugs. In 10 cases, there was some evidence
showing no or very little benefit, or even harm, so when it comes to reporting back to the NIHR
programmes, mainly HTA, we are minded to exclude these from further consideration. They are alprostadil,
eculizumab, dorzolomide, OT 551 eye drops, prednisolone, sirolimus, tandospirone, trimetazidine, visaline
and emixustat. In the case of prednisolone, we note that a trial of an implantable steroid is under way.
The current evidence on lampalizumab suggests benefit, but very large trials are under way, sponsored by
the manufacturer, so no new research is indicated meantime.
There is a little evidence of benefit from glatarimer, but only shrinkage of drusen. This is too sparse to
prompt NIHR research and we think future trials can be left to the manufacturer in the meantime. It is
used in multiple sclerosis and the manufacturer, Teva Pharmaceutical Industries (headquartered in Petah
Tikva, Israel), is one of the fifteenth largest Pharma companies in the world [according to their website
(www.tevapharm.com; accessed 19 June 2107)]. So if glatarimer (also known as copaxone) works, there
is a major incentive to do further research. However, no new research has been published since 2008,
from which we conclude that Teva do not think the drug is worth pursuing (they may have further
unpublished data).
There is some evidence of benefit from ranibizumab in pigment epithelial detachment (PED) in apparently
dry AMD, but we think that more sensitive assessment of patients with PED may disclose evidence of wet
AMD, so we are excluding this.
L-dopa is a drug very widely used in Parkinson’s disease. An impressively large study324 from the USA found
that people taking L-dopa were less likely to develop AMD and that if they did develop it, they did so
about 7 years later than people not taking L-dopa. Epidemiological studies such as this can be difficult to
interpret due to confounding variables (i.e. the people taking L-dopa may be different in other ways from
people not taking it, so the L-dopa may be a correlate not a cause). There have been past occasions where
a large observational study suggests benefit but a subsequent trial has not shown any. Nevertheless, we
think L-dopa merits further study, perhaps using the very large UK general practice databases such as
Clinical Practice Research Datalink (CPRD) or THIN. This epidemiological research does not fit with NIHR
remits. It might appear to fit with the MRC Population Systems and Medicine theme, but that appears to
exclude vision and other central nervous system conditions. The MRC Neurosciences and Mental Health
Board seems focused on basic science research. So it is not clear who would fund a UK study into whether
or not L-dopa protects against AMD.
That leaves two topics that seem to justify NIHR research. The first is high-potency statins, such as
atorvastatin 80 mg daily. The evidence from observational studies (mainly comparing the frequency of
AMD in people taking statins and those not taking statins) is mixed and contradictory. The evidence from
intervention studies comes mainly from a RCT by Guymer et al.,283 using simvastatin 40 mg, which showed
some benefit. But simvastatin 40 mg is not a potent dose. Vavvas et al.286 found more impressive benefits
from atorvastatin 80 mg but in a case series not a RCT. Atorvastatin is now out of patent and cheap, so no
drug company would fund a trial. We recommend that the HTA programme do so. Any such study should
use genetic subtyping, because Guymer and colleagues283 found that simvastatin worked much better in
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some people than others. There is also an issue about stage of AMD, with statins appearing more effective
if used early. So selection of people for a statin trial would be important.
The second is fenretinide, which is a visual cycle inhibitor which may reduce the deposition of abnormal
and toxic lipofuscin. There is one trial, run and written up by the manufacturer’s staff, which had mixed
results. Progression of GA was little different overall, but there were better results in the subgroup that
achieved the most plasma RBP lowering. However, progression to wet AMD was halved by fenretinide. We
think, based on the understanding of the physiopathology of AMD and the visual cycle, and on the results
from Mata et al.,144 that an independent trial in a selected subgroup may be justified.
DOI: 10.3310/hta22270 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 27
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85

Chapter 6 Nutritional interventions in dry
age-related macular degeneration
Introduction
There are many studies of nutrition and nutritional interventions in AMD but a number of issues need to
be considered in their interpretation, including:
l Are the interventions for primary prevention of AMD or to slow progression, or reverse changes?
l Studies can be epidemiological, looking at associations between diet and AMD, or interventional.
In epidemiological studies, it is important to think about correlation, causation and confounding.
For example, people who eat a lot of fish may differ in other ways from people who do not eat fish.
They may not eat much red meat. So any difference could be either due to eating fish or to not
eating red meat. In the best studies, the authors try to adjust for known confounding variables, but
there may be unknown ones. In intervention studies, exposures are much more under the control of
the investigators, but trials may be much smaller and shorter than large epidemiological studies.
l Are studies of dietary intake or of supplements? If the latter, what doses are used?
l If supplements, what form is used? For example, zinc comes up a lot in AMD studies, but can be used
as zinc oxide, zinc sulphate, zinc gluconate and perhaps others, and bioavailability varies.
l If supplements are given in combinations, do some ingredients affect others? For example, if beta-
carotene and lutein are given together, is absorption of lutein reduced?
l How long are supplements given for? For example, after supplementation with lutein and zeaxanthin,
serum levels rise quickly, but macular pigment concentration increases over several months, and visual
function may take a year or two to reach statistically significant changes.341
l Responses to supplements may vary according to baseline levels. Those with the lowest baseline level
may have more to gain. Conversely, if a trial (such as AREDS, see below) recruits people who are better
nourished than the average member of the population, the recruits may have less to gain, and the
results may under-estimate the benefits to the wider population.
l Effects may vary across different manifestations of AMD, for example having more effect on the
development of wet AMD than on GA. So an outcome of ‘advanced AMD’ may need to be refined.
The Age-Related Eye Disease Study trials
The first Age-Related Eye Disease Study (AREDS) trial started in 1992. The background was that some,
but not all, epidemiological studies had found an association between the intake of antioxidants and zinc
intake, and one small placebo-controlled trial of zinc342 had reported a reduction in VA loss in the zinc arm.
Marketing of supplements to preserve vision had become common but had outstripped the evidence base.
This led the National Eye Institute (part of the US NIH) to support a trial, by the AREDS research group.
The first AREDS study recruited 4757 participants.32 They were divided by extent of AMD, as shown in
Table 33.
The generalisability of predictive capacity of the AREDS trial categorisation was tested by Liew and
colleagues343 from the Blue Mountains Eye Study (BMES) Group, which found very similar rates of
progression when the simplified AREDS severity scale categories 1 and 2 were applied the Blue Mountains
population. A 10-year progression to late AMD from category 2 was 7.3% in BMES and 8.4% in AREDS.
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The outcome measures chosen were progression to advanced AMD (wet or GA), based on colour
photography, and VA loss of ≥ 15 letters, equivalent of progress from, for example, 20/20 to 20/40
or worse.
These broad inclusion criteria lead to some problems. In category 1, only 5 out of 1117 recruits developed
advanced AMD over the mean follow-up of 6.3 years. Participants in category 2 had only a 1.3%
probability of progression to advanced AMD by year 5, whereas progression was expected in 18% of
category 3 patients and in 43% of category 4.
So the analysis used mainly participants in categories 3 and 4. Randomisation was to one of four arms:
1. placebo
2. zinc (80 mg zinc oxide)
3. antioxidants (vitamin C 500 g, vitamin E 400 IU, beta-carotene 15 mg, daily)
4. zinc + antioxidants.
Compared with placebo for progression to advanced AMD from categories 3 and 4, risk reductions were
(note the use of 99% CIs):
l antioxidants OR 0.83 (99% CI 0.66 to 1.06)
l zinc OR 0.79 (99% CI 0.62 to 0.99)
l antioxidants + zinc OR 0.66 (99% CI 0.47 to 0.93) (p = 0.001).
For VA loss, the OR was 0.73 (99% CI 0.54 to 0.99) with the combination, but the reductions with zinc
alone or antioxidants alone were not statistically significant.
Compared with placebo, antioxidant and zinc combination significantly reduced progression to wet AMD
(OR 0.62, 99% CI 0.43 to 0.90). Progression to wet AMD was significantly reduced by zinc (OR 0.76,
99% CI 0.58 to 0.98) but not by antioxidants (OR 0.79, 99% CVI 0.56 to 1.13). None of the reductions in
OR for development of central GA were statistically significant, possibly because the number of GA events
was much lower than the number of wet AMD events (257 vs. 592), so that the AREDS study had only
40% power to show a significant 25% reduction in risk.
The AREDS 1 trial showed benefit which persisted for 7 years, with a modest but useful slowing of progression,
which could mean that 30% of people expected to progress to advanced AMD over a 5-year period, would
not.344 The trial did not have enough power to confirm, or not, effects in categories 1 and 2.
TABLE 33 AMD categories used in AREDS
AMD
category Drusen size Drusen area
Pigment
abnormalities Fellow eye
1 None or small 5–15 small drusen None Same as first
2 Small or intermediate, or none
if pigment abnormalities present
About 1/150 disk area, at
least one drusen
Absent or present
but no GA
Same as first or
category 1
3a Intermediate or large or
non-central GA
About 1/16 disc area if soft
indistinct drusen; about 1/5
if no soft drusen
Absent or present
but no central GA
Same as or better
than first eye
3b As for 3a VA < 20/32
4 As above Advanced AMD or VA
< 20/32 due to AMD
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An extension of the AREDS 1 trial207 showed that at 10 years, despite all arms taking the AREDS 1 formula
(when available – there was a 2-year gap), fewer of the category 3 and 4 recruits who had been
randomised to antioxidants + zinc progressed to advanced AMD (34% vs. 44% randomised to placebo).
An analysis of dietary data obtained at recruitment345 found that participants reporting the highest intake
of the macular pigments, lutein and zeaxanthin, were less likely to have advanced GA. Lutein and
zeaxanthin protect the retina against photochemical damage and oxidative stress by filtering harmful short
wavelength light.
No serious AEs were reported. A protocol amendment was made in 1996 to allow participants who were
current smokers to discontinue masked medication following evidence of the potential harmful effects of
beta-carotene in smokers. This led to 72 participants stopping medication and 84 being reassigned, but
analyses remained by intention to treat.
The quality of the AREDs trial32,346 was good as shown in Table 34.
Concerns about the generalisability of the AREDS 1 results has been raised, including in the NICE guideline
on AMD.347 The AREDS recruits are described as well-nourished and better educated than the general
population. However, the key point is that if AREDS 1 recruited people who were more health conscious
and were eating a healthier diet than the average person, the AREDS 1 results would underestimate the
benefits in the general population. The AREDS 2 investigators noted that their recruits tended to have
higher intakes of lutein and zeaxanthin than the general population (about 20% higher than the NHANES
population), which reduced the power of the study to show benefit from supplementation. Some of those
in the highest decile of dietary lutein and zeaxanthin intake were already taking more than was in the
supplement. A daily intake of 10 mg of lutein may be rather more than is required.
TABLE 34 Quality of the AREDS trial: Cochrane Risk of bias for RCTs
Quality criterion
Risk of bias
(high, unclear, low) Support for statement
Random sequence generation (selection bias) Low Computer randomisation
Allocation concealment (selection bias) Low Performed by co-ordinating centre
Blinding participants and personnel
(performance bias), objective outcomes
Low Described as double masked (including
participants and investigators). Tablets
identical in appearance and taste
Blinding participants and personnel
(performance bias), subjective outcomes
N/A N/A
Blinding outcome assessors (detection bias),
objective outcomes
Low Double masked (participants, investigators
and Reading Centre personnel)
Blinding outcome assessors (detection bias),
subjective outcomes
N/A N/A
Incomplete outcome data (attrition bias),
objective outcomes
Low 2.4% lost to follow-up, states balanced
across groups, only stated reason was missed
at least 2 appointments. Some participants
did not have photographic or VA assessment,
also balanced across groups
Incomplete outcome data (attrition bias),
subjective outcomes
N/A N/A
Selective reporting (reporting bias) Low No evidence of selective reporting
Other biases Low No other bias
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Mortality among the AREDS recruits was about half that in the general population, confirming the
healthier habits.
At the time when AREDS 1 was being carried out (1992–8), neither lutein nor zeaxanthin were available
as supplements for research purposes. Observational studies suggested that higher intake of these
carotenoids protected against AMD. One such study345 came from the AREDS 1 study, where participants
aged ≥ 60 years (4519 people) completed a food frequency questionnaire at recruitment. Recruits
reporting the highest intake of lutein and zeaxanthin were less likely to have advanced AMD, with ORs
versus the lowest quintile of intake of 0.65 (95% CI 0.45 to 0.93) for wet AMD, 0.45 (95% CI 0.24 to
0.86) for GA, and 0.73 (95% CI 0.56 to 0.96) for large or extensive drusen.
AREDS 2
The AREDS 2 trial30 assessed the value of adding lutein and zeaxanthin supplements to the original AREDS
formula. It recruited 4203 people aged 50 to 85 years, at high risk of progression to advanced AMD, with
either bilateral large drusen or non-foveal GA, or large drusen or non-foveal GA in one eye and advanced
AMD in the other eye, in 82 clinical centres. The primary outcome was the development of advanced
AMD. Secondary outcomes included three or more lines of VA loss or treatment for wet AMD.
The primary randomisation included arms in which supplements of the long-chain omega-3
polyunsaturated fatty acids, DHA and EPA were given. This results in four arms:
1. placebo
2. lutein 10 mg and zeaxanthin 2 mg
3. DHA 350 mg and EPA 650 mg
4. lutein, zeaxanthin, DHA and EPA.
In the second randomisation, recruits (27% declined) were allocated to the above with:
l the original AREDS 1 supplement (vitamins C and E, beta-carotene and zinc)
l AREDS 1 without beta-carotene
l AREDS 1 with reduced zinc (25 mg instead of 80 mg)
l AREDS 1 with no beta-carotene and reduced zinc.
The quality of the AREDS 2 trial30,348 was good (Table 35).
The median follow-up was 4.9 years. The mean age at recruitment was 73 years and 9% died during
follow-up. Other loss to follow-up was good at only 3%. The recruits were a somewhat select group of
highly educated and well-nourished people. Over 65% were educated beyond high-school level, and only
6.7% were smokers.30
The main results were that:
l There were no differences among the primary trial arms in progression to advanced AMD. For lutein
and zeaxanthin compared with placebo, HR was 0.90 (99% CI 0.76 to 1.07).
l Neither lowering the zinc dose nor omitting beta-carotene affected progression to advanced AMD.
l Lutein and zeaxanthin supplements were more effective than beta-carotene – HR 0.82 (95% CI 0.69 to
0.96) for progression to advanced AMD, HR 0.78 (95% CI 0.64 to 0.94) for development of wet AMD
and 0.94 (95% CI 0.70 to 1.26) for central GA.
l Analysis by quintiles of baseline lutein and zeaxanthin, versus no lutein and zeaxanthin, showed a
significant reduction in progression to advanced AMD only in the lowest quintile; HR 0.74 (95% CI
0.59 to 0.94).
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l A post hoc analysis across all arms that compared taking supplements with lutein and zeaxanthin
versus those without, showed HR of 0.90 (95% CI 0.82 to 0.99; p = 0.04). The effect was seen more
on wet AMD (HR 0.89, 95% CI 0.79 to 1.00) than GA (HR 0.92, 95% CI 0.78 to 1.07).
l Adding DHA and EPA to the AREDS 1 formula conferred no benefit.
l The reduction in zinc dose made no difference.
l The VA outcome of ≥ 15 letters lost did not differ among arms.
One finding was that serum levels of lutein and zeaxanthin were lower when recruits also took
beta-carotene, probably because beta-carotene competes with lutein and zeaxanthin for absorption.
One weakness of the study was that recruits had a much higher baseline intake of lutein and zeaxanthin
than the general population (at least as reflected by NHANES participants).
The conclusion of AREDS 2 was that lutein and zeaxanthin should replace beta-carotene in the AREDS
formula, and that the zinc could be reduced to 25 mg.
One problem with taking supplements is that they are bought over the counter, not prescribed. After the
AREDS 1 study, Arora and colleagues349 from Wolverhampton identified 22 eye nutrient products but only
two matched the dosages used in the trial.
There was some controversy over the role of genetic testing, with a theory put forward by Awh and
colleagues350 that only some genetic subgroups benefited from antioxidants and zinc, and that some were
actually harmed. This theory was refuted by Chew et al.122 However, there may be different progression
rates according to genetic factors. Seddon et al.351 reported higher rates of progression in genotypes CFH
Y402H (CC) and ARMS2 (TT).
TABLE 35 Quality of the AREDS 2 trial: Cochrane Risk of bias for RCTs
Quality criterion
Risk of bias
(high, unclear, low) Support for statement
Random sequence generation (selection bias) Low Random design using AREDS2 Advantage
Electronic Data Capture system
Allocation concealment (selection bias) Low Undertaken by co-ordinating centre
Blinding participants and personnel (performance
bias), objective outcomes
Low Participants, investigators, study coordinators,
and all other study personnel masked to
treatment assignment
Blinding participants and personnel (performance
bias), subjective outcomes
N/A N/A
Blinding outcome assessors (detection bias),
objective outcomes
Low States all study personnel masked to
treatment assignment, also masked graders
at a central reading centre
Blinding outcome assessors (detection bias),
subjective outcomes
N/A N/A
Incomplete outcome data (attrition bias),
objective outcomes
Low Attrition reasonably balanced between
groups
Incomplete outcome data (attrition bias),
subjective outcomes
N/A N/A
Selective reporting (reporting bias) Low No evidence of selective reporting
Other biases Low No other bias
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Summary
The first AREDS trial showed that the supplement reduced the risk of progression by about 25%. At
10 years’ follow-up progression to advanced AMD was reduced from 44% to 34%. The AREDS 2 trial
showed that beta-carotene should be replaced by lutein and zeaxanthin.
Other studies of lutein and zeaxanthin supplements
Quantity and quality of research
Reviews
Four systematic reviews of lutein alone or with zeaxanthin were identified. One by Ma and colleagues352
was about dietary intake rather than supplements. It was a high-quality review. Ma and colleagues352
concluded that dietary lutein and zeaxanthin did not reduce the incidence of early AMD, with a
meta-analysis of six studies giving a RR between highest and lowest quintile of intake of 0.96. However,
there was an association with a reduced progress to late AMD (wet AMD and GA) with a meta-analysis of
four studies giving a RR of 0.74 (95% CI 0.57 to 0.97, I2 for heterogeneity 0%).
A systematic review of RCTs of lutein and zeaxanthin supplementation by Liu et al.353 found that it improved
both VA and contrast sensitivity. Although there is an error in the Liu review in that it uses a figure of
433 patients for the Beatty 2013 RCT at 36 months, whereas only 58 people were followed for that long.354
Another high-quality review by Ma and colleagues in 2016355 examined the evidence for the effect of
lutein, zeaxanthin and meso-zeaxanthin on macular pigment density. Ma and colleagues355 summarised
some key points in the background to this review, including:
l macular pigment is composed mainly of lutein, zeaxanthin and meso-zeaxanthin
l the concentration of these carotenoids in the macular region is around 1000 times more than in the blood
l it is thought that they protect the retina and the RPE from oxidative stress triggered by light
l their previous trial of supplements had shown a trend towards improvement in BCVA after 4 weeks,
in people with early AMD.
The Ma 2016 review355 included 20 RCTs of supplementation, in both people with AMD and healthy
individuals. There were significant benefits of lutein, zeaxanthin and meso-zeaxanthin supplementation
on MPOD augmentation both in AMD patients and healthy subjects with a dose–response relationship.
In both cases, heterogeneity was high, but in effect size rather than direction.
Another systematic review and meta-analysis from China, by Wang and colleagues356 looked only at trials
with only lutein supplementation. All these trials were included in the Ma 2016 review.355 Wang and
colleagues356 concluded that lutein supplements improved MPOD significantly but that the improvement in
VA seen in five trials was modest and not statistically significant. Trial duration ranged from 4 to 12 months.
They did conclude that there was nothing to be gained by using doses of > 10 mg daily.
In addition, one systematic review of vitamins and minerals by Evans et al.357 was identified that included
lutein and zeaxanthin among other supplements including minerals. This review concluded that there
was no evidence that any of the supplements reduced the onset of AMD but that there was evidence
supporting a reduction in progression. This analysis was dominated by the first AREDS trial (see Report
Supplementary Material 5).
Eleven non-systematic reviews were also identified (see Report Supplementary Material 6). Some of these
pre-dated AREDS 2, but most of the later ones supported use of the AREDS 2 supplement (Andreatta and
El-Sherbiny 2014,358 Broadhead 2015,359 Gregori and Goldhardt 2015,360 Querques and Souied 2014361
and Scripsema 2015341).
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Studies
Twenty-two studies were identified that compared the use of lutein and/or zeaxanthin either separately or
in combinations with placebo or other active comparators. First authors and years were: Berrow 2013;362
Murray 2013;363 Weigert 2011;364 Wolf-Schnurrbusch 2015;365 Ma 2012;366 Richer 2011;367 Akuffo 2015;368
Huang 2015;192 Peng 2016;369 Wu 2015;370 Arnold 2013;371 Kelly 2014;372 Trieschmann 2007;373 Robman
2007;374 Olk 2015;375 Vishwanathan 2009;376 Bartlett 2007;377 Kelly 2017;378 Richer 2004;379 Dawczynski
2013;380 García-Layana 2013;381 Piermarocchi 2012.382
There were 15 RCTs (1403 participants), two CCTs (186 participants), three prospective cohort studies
(102,724 participants) and two before-and-after studies (112 participants). The studies were undertaken in
the USA (5 studies), UK (3 studies, one of which was also undertaken in the Netherlands), China (2 studies),
Germany (3 studies), the Netherlands (2 studies), Austria (1 study), Australia (1 study), Ireland (2 studies),
Switzerland (1 study), Spain (1 study), Italy (1 study) and Taiwan (1 study). Duration of treatment ranged
from 90 days to 2 years for RCTs, 8 to 24 weeks for the CCTs and 10 weeks to 2 years for the cohort studies
and before-and-after studies. The duration of follow-up differed between the studies, ranging from 90 days
to 3 years for RCTs, 8 weeks to 9 months for the CCTs and 18 weeks to 24 to 26 years for the cohort
and before-and-after studies. The majority of studies assessed the effect of the nutrients on intermediate
outcomes, such as MPOD, in people with early or intermediate AMD (15 studies: Berrow 2013;362 Murray
2013;363 Wolf-Schnurrbusch 2015;365 Weigert 2011;364 Bartlett 2007;377 Ma 2012;366 Richer 2011;367 Akuffo
2015;368 Huang 2015;192 Peng 2016;369 Arnold 2013;371 Piermarocchi 2012;382 Richer 2004;379 Dawczynski
2013;380 García-Layana 2013381), in a general population (3 studies: Vishwanathan 2009,376 Kelly 2014372 and
Kelly 2017378) and in a mixed AMD/healthy population (Trieschmann 2007373).
The cohort study by Robman et al.374 assessed the effects on progression of early AMD and another cohort
study by Olk et al.375 investigated whether the intervention reduced the risk of CNV in the fellow eye.
In the remaining prospective cohort study by Wu et al.370 the association between the nutrients and the
occurrence of AMD was assessed in a general population.
Lutein was compared with:
l placebo or no supplement (control) (7 RCTs: Berrow 2013,362 Murray 2013,363 Weigert 2011,364
Ma 2012,366 Huang 2015,192 Kelly 2014,372 Richer 2004379)
l with other doses of lutein (2 RCTs: Ma 2012366 and Huang 2015192)
l with lutein plus omega fatty acid (1 RCT: Wolf-Schnurrbusch 2015365)
l with lutein plus vitamins and minerals (Richer 2004379)
l and with lutein plus zeaxanthin or zeaxanthin (4 RCTs: Ma 2012,366 Huang 2015,192 Richer 2011367 and
Kelly 2014372).
Lutein in combination with zeaxanthin or meso-zeaxanthin was compared with no supplements or placebo
in two CCTs by Trieschmann373 and Kelly 2017,378 and with meso-zeaxanthin plus lutein plus zeaxanthin
by Akuffo et al. 2015.368 Lutein plus vitamins/minerals was compared with placebo in one RCT by Bartlett
et al.377 and lutein plus zeaxanthin plus ω–3 long-chain polyunsaturated fatty acids (LCPUFAs) were
compared at different doses and with placebo in the RCT by Arnold et al.371 The effects of the combination
of lutein plus zeaxanthin were assessed in the before-and-after studies by Peng et al.369 and Vishwanathan
et al.,376 and with fats in the cohort study by Robman et al.374 Three RCTs compared lutein, zeaxanthin
and other supplements with placebo or no supplement – Piermarocchi 2012,382 Dawczynski 2013380 and
García-Layana 2013.381 Wu et al.370 looked at a combination of lutein and other carotenoids in the diet
and the Olk et al. RCT375 compared zeaxanthin plus triple therapy (including intravitreal bevacizumab,
intravitreal dexamethasone, photodynamic therapy with verteporfin) with triple therapy alone. Doses of
lutein varied from 6 mg to 20 mg and zeaxanthin 0.6 mg to 17 mg whether provided separately or in
combination treatments.
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Selection bias was found to be low in two RCTs371,382 and high in one RCT381 and two CCTs.373,378 In 12
RCTs the risk of selection bias was unclear.192,362–368,372,377,379,380 The Peng et al.369 before-and-after study was
judged as being of good quality, but the Vishwanathan376 study to be of poor quality. Of the three cohort
studies, Wu 2015370 was judged to be of good quality and the others fair quality374 or poor quality.375
Sample sizes varied. Most studies had < 40 participants per arm but Wu,370 Trieschmann,373 Olk370 and
Piermarocchi382 had arms with > 100 participants. The majority of studies had mean ages of 60–70 years.
The proportion of male participants varied between 30% and 50% in most studies, although 96% of
participants were male in two studies.367,379 BCVA was reported at baseline in most studies. Most studies
received some funding from commercial organisations, but often by provision of the supplement only.
Results
Lutein versus placebo or no active comparison
Seven studies included a lutein-only group and a placebo group or no active comparison. Huang and
colleagues192 and Ma and colleagues366 used two different doses of lutein (Table 36) and also had a
lutein + zeaxanthin arm. Richer and colleagues379 had a third arm with lutein plus vitamins and minerals.
Six studies assessed changes in VA. Murray 2013363 included people with AMD grade 0–4 in one eye and
BCVA at least 0.5 logMAR; Weigert 2011364 included those with AMD, grade 2–4, no CNV and VA above
0.4; and Richer 2004379 included people with atrophic AMD and at least one vision-degrading abnormality.
These studies reported a benefit in VA for those receiving lutein compared with placebo at 6 months
(Weigert364) and 12 months (Murray363 and Richer379) with statistically significant benefit shown by the
Murray and Richer studies. In contrast, Berrow 2013362 [in those with age-related maculopathy (ARM) and
BCVA at least 0.2 logMAR], Huang 2015192 and Ma 201366 (both in those defined as having early AMD)
found no or limited difference in VA for participants receiving either lutein or placebo at 40 weeks, 2 years
and 48 weeks, respectively (statistical significance not reported for any of these studies, no data presented
in the Berrow and colleagues362 study).
Changes in contrast sensitivity were examined by four RCTs. Compared with placebo, both Huang 2015192
and Ma 2012366 found significantly greater improvement for participants receiving lutein 20 mg (but not
10 mg) at 3 cycles/degree and 6 cycles/degree (see Table 36). Richer 2004379 reported significant within-
group improvements from baseline at 3, 6 and 12 cycles/degree in the right eyes and at 6 and 12 cycles/
degree in the left eyes of both lutein groups (data presented in a figure only, see Report Supplementary
Material 5). Berrow 2013362 found no significant difference between lutein and placebo at 40 weeks
(no data or p-value reported, therefore, not tabulated below).362
Six RCTs192,363,364,366,372,379 assessed the effects of lutein supplementation on MPOD outcomes. Four reported
an increase in MPOD. Ma366 reported no change and Kelly 2014372 found a slight decrease after 90 days of
lutein supplementation in healthy volunteers (this study also had a zeaxanthin arm, reported below).
Adverse events
Four studies reported AEs.192,364,366,379 Of these studies, only two (Weigert364 and Richer379) reported any
actual events, reporting similar rates in the groups receiving lutein or placebo.
Overall, the picture is mixed. Supplementation with lutein alone has beneficial but modest effects on BCVA
and contrast sensitivity in some of the studies, but the significance is doubtful. Lutein does increase MPOD.
A small trial of supplementation with lutein 20 mg daily is starting in Japan but with only 40 patients it is
unlikely to make a major contribution.385
Lutein plus zeaxanthin
Eleven studies are discussed in this section.
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Four studies assessed the effect of combined lutein and zeaxanthin supplementation on VA in people with
early to moderate AMD, including three RCTs (Huang et al. 2015,192 Ma et al. 2012366 and Richer et al.367)
and the before-and-after study by Peng et al.369 (which confusingly, has ‘randomised controlled trial’ in the
title). Huang and colleagues192 and Ma and colleagues366 found small improvements on BVCA logMAR for
lutein (10 mg) plus zeaxanthin (10 mg) and for placebo at 2 years and 48 weeks follow-up, respectively,
but little difference between groups (Table 37).
TABLE 36 Results of lutein supplementation studies
Murray et al., 2013363
RCT; unclear ROB Lutein 10mg, n= 36 Placebo, n= 36 p-value
Change in VA (ETDRS, logMAR),
mean (12 months)
0.01 0.04 < 0.05
Weigert et al., 2011364
RCT; unclear ROB Lutein (20mg to 10mg), n= 84 Placebo, n= 42 p-value
Change in VA, ETDRS letters,
at 6 months mean (SD)
2.1 (0.4) 1a 0.07
Huang et al., 2015192,383
RCT; unclear ROB Lutein 10mg, n= 26
Lutein 20mg,
n= 27 Placebo, n= 28 p-value
BCVA, logMAR, at 2 years,
mean (SD)
0.26 (0.15) 0.28 (0.16) 0.30 (0.25) NR
Contrast sensitivity at 2 years, log, mean (SD)
3 cycles/degree 1.47 (0.34) 1.32 (0.25)b 1.25 (0.32) See
below
6 cycles/degree 1.50 (0.33) 1.54 (0.36)b 1.25 (0.30)
12 cycles/degree 1.10 (0.35) 1.05 (0.36) 0.87 (0.33)
18 cycles/degree 0.59 (0.45) 0.65 (0.39) 0.40 (0.34)
Ma et al., 2012366,384
RCT; unclear ROB Lutein 10mg, n= 27
Lutein 20mg,
n= 27 Placebo, n= 27 p-value
Change in BCVA, logMAR, mean
(95% CI), 48 weeks
–0.04 (–0.11 to 0.03) –0.02 (–0.11 to 0.06) –0.00 (–0.06 to 0.05) NR
Change in CS, log, mean (95% CI), 48 weeks
3 cycles/degree 0.13 (0.03 to 0.29) 0.18 (0.07 to 0.28)b –0.03 (–0.19 to 0.13)
6 cycles/degree 0.18 (0.03 to 0.34) 0.21 (0.10 to 0.32)b –0.01 (–0.17 to 0.16)
12 cycles/degree 0.14 (0.02 to 0.27) 0.15 (0.02 to 0.28) 0.02 (–0.15 to 0.19)
18 cycles/degree –0.01 (–0.18 to 0.15) 0.10 (–0.06 to 0.26) –0.02 (–0.18 to 0.13)
Richer et al. 2004379
RCT; unclear ROB Lutein, n= 29
Lutein+ other,
n= 30 Placebo, n= 30 p-value
Near VA change, letters (95% CI) 5.4 (2.5 to 8.2) 3.5 (1.2 to 5.8) –0.2 (–3.0 to 2.7) 0.013
Distance VA change, logMAR,
right eye/left eye (95% CI)
–0.10 (–0.19 to –0.01)/
–0.03 (–0.09 to 0.03)
–0.03 (–0.12 to 0.07)/
–0.06 (–0.14 to 0.03)
–0.14 (–0.30 to 0.03)/
0.05 (–0.14 to 0.23)
0.01/NS
ROB, risk of bias.
a Estimated from a figure in Weigert et al., 2011.364
b Versus placebo p < 0.05.
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TABLE 37 Result of combined lutein and zeaxanthin supplementation: visual outcomes
Huang et al., 2015192,383
RCT; unclear ROB
Lutein+ zeaxanthin,
n= 27 Placebo, n= 28 p-value
BCVA, logMAR, at 2 years,
mean (SD)
0.27 (0.24) 0.30 (0.25) NR
Contrast sensitivity at 2 years, log, mean (SD)
3 cycles/degree 1.39 (0.39) 1.25 (0.32) See below
6 cycles/degree 1.50 (0.36) 1.25 (0.30)
12 cycles/degree 1.09 (0.35) 0.87 (0.33)
18 cycles/degree 0.74 (0.33)a 0.40 (0.34)
Ma et al., 2012366,384
RCT; unclear ROB
Lutein
20mg+ zeaxanthin
10mg, n= 27 Placebo, n= 27 p-value
Change in BCVA, logMAR, mean
(95% CI), 48 weeks
–0.04 (–0.10 to 0.01) –0.00 (–0.06 to 0.05) NS
Change in CS, log, mean (95% CI), 48 weeks
3 cycles/degree 0.18 (0.05 to 0.32) –0.03 (–0.19 to 0.13) NS
6 cycles/degree 0.15 (0.04 to 0.31) –0.01 (–0.17 to 0.16)
12 cycles/degree 0.12 (–0.04 to 0.28) 0.02 (–0.15 to 0.19)
18 cycles/degree 0.09 (–0.11 to 0.29) –0.02 (–0.18 to 0.13)
Richer et al., 2011367
RCT; unclear ROB
Zeaxanthin
8mg+ lutein 9mg
n= 25
Lutein, 9mg
(faux placebo)
n= 10 p-value
ETDSR Colenbrander average eye
near high-contrast VA (SE) at
12 months
92.8 (5.9) 98.9 (5.7) NR
Colenbrander average eye
low-contrast near VA, 12 months
81.5 88.2 NR
Contrast sensitivity function, area
under the curve at 5 special
frequencies (SE), 12 months
247.1 (35) 310.5 (33.8) NR
Kelly et al., 2017378
CCT; High risk of bias
Carotenoid-enriched
eggs, n= 25
Placebo eggs,
n= 25 p-value
BCVA mean (SD) final visit 107.7 (4.45) 105.4 (4.78) p= 0.035
Peng et al., 2016369
B+A; GQ
Lutein complex
(lutein 12 g+ zeaxanthin 2mg) n= 56 p-value
BCVA (LogMAR), mean (SD)
5.5 months
12.38 (3.41) NR
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Richer and colleagues,367 in their study of people with early and moderate AMD, identified limited
differences on the ETDRS Colenbrander high-contrast VA score at 12 months’ follow-up, comparing
zeaxanthin (8 mg) plus lutein (9 mg) and lutein alone (9 mg). On low-contrast VA, significance testing was
not reported. The study also had a zeaxanthin only arm, see Supplementation with zeaxanthin alone
below. The before-and-after study by Peng and colleagues369 reported that lutein (12 mg) plus zeaxanthin
(2 mg) in people with early stage AMD and soft drusen, led to a statistically significant improvement in
BCVA logMAR at 5.5 months’ follow-up (p < 0.05).
Kelly and colleagues378 compared eggs enriched with lutein and meso-zeaxanthin with standard eggs in
healthy volunteers. After 8 weeks, a significant difference in BCVA was found in favour of the enriched
eggs (NCT00527553).
Four RCTs (Huang 2015,192 Ma 2012,366 Richer 2011367 and Akuffo 2015368) assessed the effects of lutein
and zeaxanthin on measures of contrast sensitivity in people with early mild to moderate AMD (mostly
defined as soft drusen and/or pigmentary abnormalities with no GA or CNV). In people with early AMD,
Akuffo and colleagues,368 with three active treatments and no controls, reported changes from baseline to
36 months in contrast sensitivity that did not differ among the treatments (i.e. lutein 20 mg plus zeaxanthin
2 mg, meso-zeaxanthin 10 mg plus lutein 10 mg plus zeaxanthin 2 mg, meso-zeaxanthin 17 mg plus lutein
3 mg plus zeaxanthin 2 mg). In Huang 2015192 and Ma 2012366 comparisons between lutein (10 mg) plus
zeaxanthin (10 mg) and placebo did not differ significantly except in 18 cycles/degree in Huang192 (see
Table 37). Richer and colleagues367 found that contrast sensitivity, assessed using area under the curve on
five spatial frequencies, for people receiving zeaxanthin (8 mg) plus lutein (9 mg) and lutein alone (9 mg),
appeared to show those receiving lutein appearing to benefit most (but statistical significance was not
reported). In healthy volunteers, Kelly and colleagues378 found an improvement in the enriched egg group
at 15.15 cycles/degree (p = 0.046); other data were not reported.
The Akuffo 2015368 RCT assessed progression in participants all receiving active interventions: lutein
20 mg plus zeaxanthin 2 mg, meso-zeaxanthin 10 mg plus lutein 10 mg plus zeaxanthin 2 mg, and
meso-zeaxanthin 17 mg plus lutein 3 mg plus zeaxanthin 2 mg on the 11-step AREDS scale.368 They found
no statistically significant differences when assessing people making a two-step increase on the AREDS
scale (p = 0.29) or for those likely to have either a low or high risk of progression to advanced AMD.
Two prospective cohort studies (Table 38) examined factors that may influence the development and
progression of AMD, including the intake of lutein and zeaxanthin. Robman and colleagues374 found that
an intake of lutein and zeaxanthin was associated with an increased OR of AMD progressing in people
TABLE 37 Result of combined lutein and zeaxanthin supplementation: visual outcomes (continued )
Akuffo et al., 2015368
RCT; unclear ROB
Lutein
20mg+ zeaxanthin
2mg n= 13
Meso-zeaxanthin
10mg+ Lutein
10mg+ zeaxanthin
2mg n= 16
Meso-zeaxanthin
17mg+ Lutein
3mg+ zeaxanthin
2mg n= 12 p-value
Letter contrast sensitivity at 36 months, mean (SD),% change from baseline
1.2 cpd 1.89 (0.16), 1 1.86 (0.18), 9 1.82 (0.20), 4 NR
2.4 cpd 1.87 (0.17), 6 1.81 (0.21), 8 1.78 (0.21), 9 NR
6.0 cpd 1.60 (0.15), 13 1.52 (0.25), 11 1.52 (0.27), 24 NR
9.6 cpd 1.35 (0.16), 18 1.27 (0.34), 20 1.30 (0.22), 38 NR
15.15 cpd 1.02 (0.23), 36 0.91 (0.38), 30 0.97 (0.25), 59 NR
B+ A, before and after; cpd, cycles per degree; FQ, fair quality; GQ, good quality; PQ, poor quality; ROB, risk of bias;
SE, standard error.
a p< 0.05 versus placebo.
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with early AMD, whether considering the worse eye, either eye, an increase ≥ 2 steps in the grades of size,
total number, area occupied by a lesion and spread, or a qualitative assessment (i.e. better, worse, same)
from macular photographs. The association found with lutein and zeaxanthin and progression of the
worse eye was statistically significant (p = 0.02), but this depended on the definition of the progression
used.
In contrast, Wu and colleagues370 reported that lutein and zeaxanthin was associated with a statistically
significantly reduced risk of developing advanced AMD among people from a general population (i.e.
without a diagnosis of AMD at baseline) (p < 0.001) (see Table 37). Although the RR of intermediate AMD
was decreased with lutein and zeaxanthin, its effects were not statistically significant (p = 0.42).
The Huang 2015,192 Ma 2012,366 Akuffo 2015368 and Vishwanathan 2009376 RCTs, the Arnold 2013371 and
Trieschman373 CCTs and the Kelly 2017378 before-and-after study assessed changes to MPOD (Table 39).
Akuffo 2015368 found no statistically significant difference in MPOD at follow-up for the different active
treatments, whereas some benefit was shown when active treatments were compared with the placebo or
no supplement control in the Arnold 2013371 RCT and the Trieschmann CCT.373 Arnold and colleagues371
found that participants with non-exudative AMD receiving a supplement of lutein, zeaxanthin and LCPUFAs
at either single or double dose experienced a statistically significant increase in MPOD when compared with
those receiving placebo (p-value not reported). Comparison between the two doses of the active supplement
showed no significant difference in MPOD (p-value not reported). Akuffo and colleagues368 reported that
change from baseline to follow-up at 36 months did not differ between the three active interventions of
lutein 20 mg plus zeaxanthin 2 mg, meso-zeaxanthin 10 mg plus lutein 10 mg plus zeaxanthin 2 mg, and
meso-zeaxanthin 17 mg plus lutein 3 mg plus zeaxanthin 2 mg (p-value not reported). In a CCT of people
with no or minimal lens opacity, Trieschmann and colleagues373 identified a statistically significant difference
in MPOD at 9 months’ follow-up for participants receiving lutein (12 mg) plus zeaxanthin (1 mg) when
compared with the control who received no supplements (p < 0.0008). In a before-and-after study assessing
the effects of egg yolk consumption on MPOD in people without AMD, Vishwanathan and colleagues376
found no statistically significant difference between baseline and follow-up at 5 or 14 weeks (p-value
not reported).
TABLE 38 Combined lutein and zeaxanthin supplementation: AMD outcomes
Robman et al., 2007374
Cohort study: FQ
Dietary intake of lutein, zeaxanthin and fats, n= 252
All 7 years’ follow-up p-value
Progression of AMD – Definition 1 2.65 (95% CI 1.13 to 6.22) 0.02
Progression of AMD – Definition 2 1.72 (95% CI 0.78 to 3.78) 0.18
Progression of AMD – Definition 3 1.84 (95% CI 0.84 to 2.96) 0.13
Definition 1: increase in AMD severity 1 or more levels in worse affected eye
Definition 2: increase in AMD severity 1 or more levels in either eye; or an increase in ≥ 2 steps in grades of size, total
number, area occupied by a lesion and spread
Definition 3: qualitative (better, worse, same) from macular photographs
Wu et al., 2015370
Cohort study: GQ Dietary intake of lutein and zeaxanthin, n= 102,046 p-value
Advanced AMD – RR 0.59 (95% CI 0.48 to 0.73) < 0.001
Intermediate AMD – RR 0.93 (95% CI 0.78 to 1.12) 0.42
Comparison of quintile 1 with 5 of predicted plasma carotenoid scores
FQ, fair quality; GQ, good quality.
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Adverse events
Four studies reported AEs,192,366,367,378 although only Richer and colleagues367 identified any: two deaths
unrelated to any intervention and a case of pneumonia.
Summary
The lutein + zeaxanthin studies show a mixed picture, partly because some studies had no placebo arm,
and showed little or no difference among active arms. Most studies had quite small numbers of recruits.
The cohort studies by Robman374 and Wu370 gave contrasting results on progression of AMD.
Supplementation with zeaxanthin alone
Two studies by Richer 2011367,372 and Olk 2015375 investigated zeaxanthin alone (Table 40).
The prospective cohort study by Olk and colleagues375 assessed the effects of zeaxanthin plus triple therapy
versus triple therapy alone [bevacizumab (Avastin® Roche, Basel, Switzerland), dexamethasone, photo-dynamic
therapy with verteporfin (Visudyne®, Roche, Basel, Switzerland)] on the development of CNV in the fellow
eyes of people with unilateral CNV. A significantly lower proportion of people who received zeaxanthin and
triple therapy developed CNV in the fellow eye than those receiving triple therapy (p = 0.03). The Olk study375
TABLE 39 Combined lutein and zeaxanthin supplementation: MPOD (studies without VA)
Trieschmann et al., 2007373
CCT; high ROB
Lutein 12mg and
zeaxanthin 1mg
supplement n= 108 No supplement (control) n= 28 p-value
MPOD at 0.5° eccentricity mean (SEM) difference at
Baseline 0.504 (0.197) 0.525 (0.189) 0.6
9 months’ follow-up 0.1 (0.009) 0.03 (0.02) < 0.0008
Arnold et al., 2013371
RCT; low ROB
Supplement of lutein
10mg, zeaxanthin
1mg and LCPUFAs
n= 50
Supplement of
lutein 20mg,
zeaxanthin 2mg
and LCPUFAs,
n= 54 Placebo n= 40 p-value
MPOD units (degrees) 0.22 0.25 –0.01 NR
Vishwanathan et al., 2009376 Egg yolk consumption (lutein and zeaxanthin) n= 37 p-value
B+ A; PQ
MPOD, mean (SE) at week 5 (end of 2-egg period)
0.25° 0.55 (0.04) NR
0.5° 0.52 (0.04) NR
1° 0.37 (0.03) NR
Akuffo et al., 2015368
RCT; unclear ROB
Lutein
20mg+ zeaxanthin
2mg, n= 13
Meso-zeaxanthin
10mg+ Lutein
10mg+ zeaxanthin
2mg, n= 16
Meso-zeaxanthin
17mg+ Lutein
3mg+ zeaxanthin
2mg, n= 12 p-value
MPOD at 36 months, mean (SD),% change from baseline
0.25° eccentricity 0.72 (0.24), 41 0.76 (0.23), 52 0.85 (0.25), 67, 0.000 NR
0.5° eccentricity 0.62 (0.26), 51 0.64 (0.20), 42 0.68 (0.20), 74, 0.000 NR
1.0° eccentricity 0.45 (0.19), 50 0.46 (0.15), 59 0.52 (0.16), 100, 0.000 NR
1.75° eccentricity 0.23 (0.19), 35 0.28 (0.11), 87 0.34 (0.14), 183, 0.000 NR
B+ A, before and after; ROB, risk of bias; SE, standard error.
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had its weaknesses. It compared two consecutive cohorts of people with unilateral wet AMD, with
zeaxanthin 20 mg daily being added after a specific date, and added a control group from a study of six
RCTs of anti-VEGF treatment. The people were already taking an AREDS 1 supplement that may, because
of the beta-carotene content, have reduced the bioavailability of zeaxanthin. Olk et al.375 suggested that a
RCT of zeaxanthin supplementation should be done, but that seems unnecessary after the AREDS trials.
The reduction in progression to wet AMD in the zeaxanthin cohort was statistically significant (p = 0.03).
In the RCT by Richer and colleagues367 zeaxanthin 8 mg compared with lutein 9 mg did not appear to lead
to any differences in high-contrast VA or low-contrast near VA.
Kelly and colleagues372 found no difference between groups in MPOD after 90 days of zeaxanthin
supplementation from enriched eggs in healthy volunteers (this study also had lutein arms, see above) but
had only about 20 recruits per arm. Their trial was more about the feasibility of increasing lutein and
zeaxanthin intake by eggs rich in those carotenoids, by feeding hence diets with enriched amounts,
sourced from maize and marigold sources.
In summary, there is little evidence on supplementation with zeaxanthin alone, the most significant being
the reduction in progress to wet AMD reported by Olk et al.375
Lutein plus zeaxanthin plus other nutrients versus control
Four studies compared lutein plus zeaxanthin plus vitamins and minerals (Piermarocchi382 and the Dawczynski380)
or lutein plus zeaxanthin plus DHA (García-Layana381) with a placebo or no supplement (see Report
Supplementary Material 5 for dose details). In the CARMA (Carotenoids in Age-related Maculopathy) trial,
Beatty and colleagues354,386 randomised people to supplementation with lutein, zeaxanthin, vitamins E and
C, zinc 20 mg and copper 0.4 mg daily, using the Ocuvite preparation (Bausch and Lomb, Berlin, Germany).
Piermarocchi and colleagues382 included people with dry AMD in at least one eye, having extensive
intermediate drusen and at least one large drusen or GA not involving the macula centre, and BCVA in
trial eye of ≥ 20/32. They found significantly better VA in the supplement group (lutein, zeaxanthin,
astaxanthin, zinc and copper and antioxidant vitamins) after 24 months’ follow-up compared with no
supplementation (Table 41).
Dawczynski and colleagues380 carried out a three-arm trial comparing two different doses of lutein plus
zeaxanthin plus vitamins and minerals in people with non-exudative AMD in at least in one eye. They
found a statistically significant change in BCVA reading letters at 12 months with both doses of lutein
TABLE 40 Effect of supplementation with zeaxanthin alone
Olk et al., 2015375 cohort study: PQ
Triple therapy,
n= 160
Triple therapy+
zeaxanthin, n= 80 p-value
Fellow eyes that developed CNV (%) 12–24 months 12.5 6.25 0.03
Richer et al., 2011367
RCT; unclear ROB
Zeaxanthin 8mg,
n= 25
Lutein 9mg
(faux placebo), n= 10 p-value
ETDSR Colenbrander Mixed Constrast Reading Card
(Precision Vision, IL, USA) average eye near
high-contrast VA (SE) at 12 months
96.8 (8.35) 98.9 (5.7) NR
Colenbrander average eye low-contrast near VA, 12 months 81.5 88.2 NR
Contrast sensitivity function, area under the curve at
5 special frequencies (SE), 12 months
254.7 (35.2) 310.5 (33.8) NR
PQ, poor quality; ROB, risk of bias; SE, standard error.
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compared with placebo. However, differences in BCVA by logMAR at 12 months did not reach statistical
significance. García-Layana and colleagues381 included people with early AMD and found no significant
difference in VA between lutein plus zeaxanthin plus DHA and placebo at 12 months’ follow-up.
A significantly different change in contrast sensitivity at 24 months was found by Piermarocchi and
colleagues,382 but no difference was found by García-Layana and colleagues.381 Dawczynski and
colleagues380 did not report contrast sensitivity.
Piermarocchi and colleagues382 found no difference in the development of CNV between groups. However,
an improvement in NEIVFQ-25 score at 24 months was found in the supplement group, compared with a
deterioration in the control group.
TABLE 41 Results of combination of lutein + zeaxanthin+ other supplements
Piermarocchi et al. 2012382
RCT; low ROB
Lutein+ zeaxanthin+
vitamins/minerals,
n= 84 Control, n= 26 p-value
Mean (SD) BCVA at 24 months,
ETDRS letter score
81.4 (7.2) 76.8 (8.9) p= 0.003
Mean (95% CI) change in BCVA at
24 months, ETDRS letter score
–0.02 (–1.42 to 1.36) –4.18 (–7.34 to –1.01) p= 0.008
Mean (95% CI) change in contrast
sensitivity at 24 months
2 (0.80 to 3.19) –1.15 (–2.86 to 0.54) p= 0.01
Development of CNV (%) (n = 103)
12.7
(n = 43)
9.3
p= 0.760
NEIVFQ-25 composite score, mean
(SD) 24 months
82.1a (15.9) 74.2b NR
NEIVFQ-25 composite score, mean
(95% CI) change, 24 months
3.6 (0.50 to 6.81) –8.7 (–16.54 to –0.97) NR
Dawczynski et al. 2013380
RCT; unclear ROB
Lutein+ zeaxanthin+
vitamins/minerals
dose 1, n= 50
Lutein+ zeaxanthin+
vitamins/minerals
dose 2, n= 55
Placebo,
n= 40 p-value
BCVA, logMAR at 12 months 0.104 (0.18) 0.064 (0.16) 0.127 (0.16) See belowc
BCVA change in reading letters at
12 months, mean (SD)
1.46 (2.8) 2.02 (3.1) 0.08 (2.8) See belowd
García-Layana et al. 2013381
RCT; high ROB Lutein/zeaxanthin/DHA, n= 23
Placebo,
n= 21 p-value
ETDRS letters, mean (SEM) at 1 year 74.3 (9.2) 75.9 (5.8) NS
Contrast sensitivity letters, mean
(SEM) at 1 year
26 (5) 26 (6) NS
Beatty et al., 2013354
RCT; low ROB
Lutein+ zeaxanthin+ vitamins/minerals,
n= 216
Placebo,
n= 217
BCVA at 12 months mean (SD) 79.7 (8.9) 80.4 (6.5)
ROB, risk of bias.
a Reported in text, 85.2 calculated by reviewer, likely difference in numbers participants at baseline and follow-up.
b Calculated by reviewer.
c Placebo vs. dosage 1 p= 0.526; placebo vs. dosage 2 p= 0.063; dosage 1 vs. dosage 2 p= 0.232.
d Placebo vs. dosage 1 p= 0.038; placebo vs. dosage 2 p= 0.006; dosage 1 vs. dosage 2 p= 0.354.
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Beatty and colleagues reported the 36 month secondary outcomes in a full paper354 but the primary
outcome of BCVA at 12 months only in a letter386 which followed the paper. There was no difference in
VA at 12 months, after which numbers dropped off markedly because 12 months was the minimum
follow-up.
Two studies reported MPOD outcomes. Dawczynski and colleagues380 reported a ‘considerable increase’
in MPOD. García-Layana and colleagues381 reported that after 12 months, MPOD increased by 0.059 units
on placebo and 0.162 units on lutein + DHA (p < 0.05).
Adverse events
Adverse events were reported by Peirmarochi et al.,382 which found no significant systemic or ocular
AEs related to the nutritional supplementation or adverse reactions leading to study withdrawal or
discontinuation.
Summary
The main problem with such studies is that the relative contributions of the components cannot be
assessed – we cannot say whether all the effects are due to lutein and zeaxanthin or whether the additional
supplements have any marginal value. The other problem is that durations of 12 months are too short for
changes in VA.
Lutein plus vitamins and minerals versus placebo
Lutein plus vitamins and minerals (retinol, vitamins C and E, zinc and copper) was compared with placebo
in people with no ocular pathology, other than ARM, in at least one eye by Bartlett and colleagues.377
VA outcomes were not reported in this small study. Although mean contrast sensitivity score at 9 months
improved for people in the lutein plus vitamins and minerals at 9 months and worsened for participants
receiving placebo, the difference between the groups was not statistically significant (p = 0.366).
Richer et al.379 had a three-arm RCT comparing results in groups receiving lutein 10 mg alone, lutein 10 mg
plus a mixture of 36 other ingredients including minerals, vitamins and other compounds, including black
pepper (OcuPower, from Nutraceutical Sciences Institute, Boynton Beach, FL, USA), and maltodextrin as
placebo. They found no difference between the lutein and OcuPower arms.
Adverse events
Bartlett and colleagues377 reported that no AEs were experienced as a result of either intervention.
Summary
The one study that assessed the effect of adding a package of minerals and other compounds found no
advantage over lutein alone.379
Lutein versus lutein plus omega-3 fatty acid
Wolf-Schnurrbusch and colleagues365 compared the efficacy of lutein and lutein plus omega-3 fatty acid
(DHA + EPA 160 mg daily) in people with early to intermediate AMD in a RCT with unclear risk of selection
bias. There were no changes in BCVA letter score at 6- or 12-month follow-up for either group (p-value
not reported). Despite improvements in contrast sensitivity for the lutein group at 6 months’ follow-up, the
statistically significant benefit compared with lutein plus omega had disappeared by 12 months’ follow-up
(6-month post-treatment cessation). The study reported that MPOD and contrast sensitivity improved on
lutein alone but not when DHA and EPA were added. The authors suggest that a possible explanation is
that adding the omega-3 acids might reduce the bioavailability of lutein.
Adverse events
None reported with either lutein nor lutein plus omega groups.
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Summary
There appeared to be no added value, and possible disbenefit, from adding omega-3 fats.
Summary: other studies of lutein and zeaxanthin supplements
Twenty-two studies (15 RCTs, two CCTs, two before-and-after studies and three cohort studies) compared
lutein and/or zeaxanthin either separately or in combinations of intervention with themselves or inactive
controls (i.e. placebo).
Three out of five lutein-only studies showed some improvement in VA, contrast sensitivity and MPOD.
The trials of lutein + zeaxanthin showed few differences but several compared different active arms, such
as lutein + zeaxanthin versus lutein alone, with no placebo groups. Several studies reported reduced
progression.
The three studies of zeaxanthin alone gave mixed results. One compared zeaxanthin alone versus lutein
alone and found no differences. One found that zeaxanthin halved progression to wet AMD.
Several studies of combinations of lutein plus zeaxanthin plus other supplements reported benefit in BCVA
and MPOD, but this could have been due to the lutein plus zeaxanthin, with other components of
unproven benefit.
Fatty acids and antioxidants
One of the papers from AREDS 1387 followed up 1929 participants at moderate to high risk of progression
(AREDS category 3a), and reported incidence of advanced AMD by baseline quintiles of ‘long-chain
omega-3 polyunsaturated fatty acids’ – in effect DHA and EPA. Those in the highest quintile of baseline
DHA and EPA had the lowest risk of progression: OR 0.65 (95% CI 0.45 to 0.92) for GA and 0.68
(95% CI 0.49 to 0.94) for wet AMD.
Reviews
One Cochrane review of fatty acids (Lawrenson and Evans 2015388) and one non-systematic review of fatty
acids (Souied 2016389) were identified. Fatty acids were also mentioned in five reviews of multiple
interventions but these were generally inconclusive except for the AREDS trials.9,358,390–392
The Cochrane review388 concluded that there is no evidence from RCTs to support increasing omega 3
intake for preventing or slowing the progression of AMD. The systematic review included two studies, the
AREDS 2 trial, already described, and the Nutritional AMD Treatment 2 (NAT-2) study by Souied et al.,393
described below.
The review by Souied389 noted that there was quite strong epidemiological evidence that diets rich in
omega 3 fatty acid were protective against AMD, but that there was lack of evidence from intervention
studies, including AREDS. However, they make the point that perhaps the well-nourished AREDS recruits
had little to gain, but that people with low omega-3 fatty acid intake might gain more.
A systematic review by Huang et al.394 examined the relationship between serum homocysteine, folic acid
and vitamin B12 levels, and the risk of AMD. The authors concluded that AMD is associated with elevated
homocysteine levels and decreased vitamin B12 levels, and that plasma homocysteine may act as a
modulator of the risk for AMD.
One systematic review by Evans 2008357 and six non-systematic reviews (Bartlett 2003,395 Broadhead
2015,359 Evans and Lawrenson 2014,390 Gregori and Goldhardt 2015,360 Johnson 2010,391 Schmidl 2015396
and Scripsema 2015341) of antioxidants and nutritional supplements were identified. The Bartlett 2003395
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review has been superseded by more recent ones. The Evans and Lawrenson 2014390 review summarises
and updates their two Cochrane reviews. Gregori and Goldhardt360 described mainly the AREDS trials.
The Johnson review391 preceded AREDS 2.
The Broadhead review, while not a systematic review, provides a very good summary of key issues, including:
l consumption of leafy green vegetables and fish is recommended as a way of reducing the risk of AMD
l a lot of studies have shown an inverse relationship between fish consumption and AMD
l this may be related to the presence of omega-3 fatty acids in fish and carotenoids in green vegetables
l the beneficial effects of eating a diet rich in fish are not replicated in intervention trials of DHA and
EPA supplements
l the role of omega-3 fatty acids in the diet may be linked with reduced intake of omega-6 fatty acids
(such as linoleic) from red meats and cheese
l it may be the overall diet that matters [increased fish consumption (2–4 helpings a week) may mean
reduced red meat consumption]
l carbohydrates with a low glycaemic index (meaning a slow rise in blood glucose after consumption)
instead of those with a high glycaemic index, may reduce the risk of AMD
l if supplements are to be used, the AREDS 2 formula should be used
l all patients with AMD should be advised to eat fish at least twice a week, eat more green leafy
vegetables, and restrict high glycaemic index foods.
The Evans review357 concluded that people with AMD, or early signs of the disease, may experience some
benefit from taking supplements as used in the AREDS trial, but that current evidence does not support
the use of vitamin E or beta-carotene supplements to prevent AMD. However, it did support the use of the
AREDS supplement.
The present systematic review includes three studies from the Evans systematic review357 (Teikara 1998,397
Christen 2007398 and Taylor 2002399) because these studies add to the totality of the evidence base for the
research question of relevance here.
Five reviews of multiple interventions (Buschini 2015,310 Girmens 2013,67 Hanus 2012,9 Querques 2014361
and Sin 2013392) covered nutritional supplements and some epidemiological relationships. They came to no
firm conclusions other than those by Hanus9 and Sin392 recommending the AREDs supplement.
Studies
The AREDS 2 trial, reported above, found no advantage in adding DAH and EPA to the original AREDS formula.
Five studies evaluated fatty acids including three RCTs by Feher et al. 2005,400 Souied et al. 2013393 and
Tao et al. 2016401 and two cohort studies by Reynolds et al. 2013402 and Cougnard-Gregoire et al. 2016.403
A total of 251 participants were randomised to a fatty acid intervention and 255 to placebo, while the
cohort studies assessed dietary intake in a total of 3494 healthy participants. The studies were conducted
in France (n = 2), the USA (n = 1), Hungary (n = 1) and China (n = 1). Follow-up ranged from 3 months to
3 years in the RCTs, and 7–12 years in the cohort studies. The RCTs had an unclear risk of selection bias,
and the cohort studies were assessed as fair quality403 and poor quality.402 Where reported, mean age was
63–74 years and 31–56% were men.
A recent study by Wu and colleagues404 combined cohorts from the Nurses’ Health Study (75,889 women)
and the Health Professionals Follow-up Study (38,961 men), in which 1589 people developed intermediate
AMD (defined as at least one of intermediate drusen, pigmentary abnormalities, large drusen or non-central
GA) and 1356 developed advanced (curiously 96% wet) AMD. Comparison of extreme quintiles of DHA
showed a lower incidence with higher intake in intermediate AMD (HR 0.78, 95% CI 0.66 to 0.92) but not
in advanced AMD (HR 1.01). The HR for intermediate AMD in those consuming five or more helpings of fatty
fish was 0.61 (95% CI 0.46 to 0.81) compared with those who rarely are fatty fish.404
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Results
Fatty acids
Feher and colleagues 2005400 randomised people with early bilateral AMD and BCVA between 0.8 and 0.4
(Snellen chart) in the most affected eye to Phototrop (Sigma-Tau Industrie, Pomezia, Italy), which contains
acetyl-L-carnitine (an amino acid) 100 mg, EPA 230 mg, DHA 160 mg and co-enzyme Q10 10 mg, or to a
soy oil placebo. After 12 months no difference in change in VA was found between groups (Table 42), but
a significantly greater proportion had VA categorised as improved or unchanged in the phototrop group
compared with placebo (OR 2.48; p = 0.027). In addition, the drusen area decreased by 15% in the
phototrop group while it increased by 11% in the placebo group (p = 0.045). Other outcomes, including
other measures of VA and secondary analyses on the fellow eye can be seen in Report Supplementary
Material 5.
The Souied 2013393 RCT compared DHA with placebo in people with early ARM (defined as any drusen or
RPD with or without pigmentary changes) and VA of ≥ +0.4 logMAR units in the study eye, and nAMD in
the fellow eye. After 3 years of treatment, no significant differences were found between groups in the
mean time to occurrence of CNV, the proportion developing CNV, change in BCVA, the proportion with a
decrease of > 15 letters on ETDRS (see Table 42) or drusen area (see Report Supplementary Material 5).
GA was not reported.
Tao and colleagues 2016401 randomised people with dry AMD to 3 months’ treatment with α-lipoic acid
(a fatty acid) or a vitamin C placebo. No significant differences were found between groups immediately
following the intervention in BCVA or contrast sensitivity at 6, 12 or 18 cycles/degrees (see Table 42).
However, significantly higher contrast sensitivity at 3 cycles/degree and Chinese-Version Low Vision Quality
of Life score was found in the α-lipoic acid group in favour of the intervention.
Reynolds and colleagues 2013402 assessed intake of dietary omega-3 fatty acids and other fats in 2531
previous participants of the AREDs RCT, with 525 eyes that progressed and 4165 that did not. People
were assigned a grade of no AMD, early AMD, intermediate AMD, or two forms of advanced or late
stage AMD (GA and neovascular). There were 16.9% of participants progressing to GA over 10 years. In
multivariate analysis controlling for covariates and genetic variants (see Report Supplementary Material 5
for details), there was a significant trend for a reduction in risk of progression to GA with increasing intake
of DHA [p-trend = 0.008, HR 0.68 for quintile 1 vs. quintile 5 (95% CI 0.48 to 0.94)] and intake of DHA
and EPA (p = 0.02). Further multivariate analysis found differing effects in people with different risk
genotypes.
The prevalence of early and late AMD was compared between regular users and non-users (or occasional
users) of olive oil among community-dwelling people, aged at least 65 years, in Bordeaux in the Alienor
study by Cougnard-Grégoire and colleagues 2016.403 Regular consumption of olive oil was found to be
significantly associated with a lower risk of late AMD (OR 0.44, 95% CI 0.21 to 0.91; p = 0.03) but not
early AMD (OR 0.84, 95% CI 0.59 to 1.24; p = 0.36) in multivariate analyses (see Table 42). No significant
associations were found between AMD and consumption of other dietary fats, and no interaction with
genetic factors was found.
Chong et al.17 looked at the effect of trans-fatty acids and found an increased risk of AMD with higher
intake, with an OR of 1.76 (95% CI 0.92 to 3.37; p = 0.02) when comparing the highest quartile of
trans-fat intake with the lowest.
Adverse events
Three studies did not report AEs.401–403
Adverse events were reported by Feher and colleagues 2005400 but these were unrelated to treatment
(see Report Supplementary Material 5). Souied and colleagues393 found no statistically significant
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TABLE 42 Results of fatty acid studies
Feher et al. 2005400
RCT; unclear ROB Phototrop, N= 48 Placebo, N= 53 p-value
Mean (SD) change in VA at 12 months, logMAR
(study eye)
–0.009 (0.23) 0.14 (0.23) p= ns
Change in VA, logMAR, at 12 months (study eye)
Improved or unchanged (%) 75 55 OR 2.48, 0.027
Deteriorated 25 45
Drusen-covered area [ratio of drusen area at
12 months to screening (SD)]
n= 46
0.85 (0.39)
n = 52
1.11 (0.65)
0.045
Souied et al. 2013393
RCT; unclear ROB DHA, N= 134 Placebo, N= 129 p-value
Mean (SD) BCVA change, logMAR at 3 years –0.155 (0.297) –0.116 (0.258) 0.311
Proportion with a decrease of > 15 letters on
ETDRS at 3 years
17.8 14.3 0.469
Mean time to occurrence of CNV (months) 19.5 (10.9) 18.7 (10.6) 0.613a
Proportion in whom CNV developed over 3 years 28.4 25.6
Tao et al. 2016401
RCT; unclear ROB α -lipoic acid, N= 50 Placebo, N= 50 p-value
BCVA (LogMAR), mean (SD) at 3 months 0.66 (0.41) 0.63 (0.42) NS
Contrast sensitivity, mean (SD)
3 cycles/degree, log 1.02 (0.28) 0.87 (0.29) < 0.05
6 cycles/degree, log 1.26 (0.39) 1.15 (0.36) NS
12 cycles/degree, log 0.92 (0.30) 0.88 (0.35) NS
18 cycles/degree, log 0.51 (0.34) 0.44 (0.31) NS
CLVQOL, mean (SD) 82.6 (19.36) 72.81 (18.05) < 0.05
Cougnard-Grégoire et al. 2016403
Cohort study; FQ Olive oil, N= 936 eyes
No olive oil,
N= 333 eyes
No AMD (n= 945 eyes), n eyes (%) 712 (75.3) 233 (24.7)
Early AMD (n= 268 eyes), n eyes (%) 191 (71.3)
OR 0.84 (95% CI 0.59, 1.24),
p= 0.36b
77 (28.7)
Late AMD (n= 56 eyes), n eyes (%) 33 (58.9)
OR 0.44 (95% CI 0.21, 0.91),
p= 0.03b
23 (41.1)
CLVQOL, Chinese-Version Low Vision Quality of Life; FQ, fair quality; NS, not significant; PQ, poor quality; ROB, risk of bias.
a HR 0.89, standard error 0.272, (95% CI 0.55 to 1.42), analysis adjusted for age at randomisation, smoking status, and
stage of maculopathy.
b Adjusted for age, gender, educational level, marital status, smoking, BMI, regular consumption of raw fruits, regular
consumption of cooked fruits and vegetables, plasma HDL cholesterol, plasma total n-3 PUFAs, plasma total n-6 PUFAs
and total energy intake. Eyes without AMD were the reference.
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differences between groups in treatment related AEs, ocular AEs or serious non-ocular events (Table 43).
However, worsening of cataract occurred more frequently in the placebo group (p = 0.032). Deaths were
reported in both groups but were considered unlikely to be related to the study treatment.
Summary
Results are mixed, with little difference in mean BCVA, but some evidence of reduced progression with
increasing DHA and EPA intake, and a reduction in prevalence of AMD associated with olive oil intake.
The Cochrane review388 of two RCTs393,405 concluded there is no evidence from RCTs to support increasing
omega-3 intake for preventing, or slowing the progression of, AMD.
Five primary studies evaluating fatty acids were identified: three RCTs with an unclear risk of bias,393,400,401
one fair-quality cohort study403 and one poor-quality cohort study.402 Interventions, length of follow-up and
outcomes measures varied, and results were inconsistent between studies. Overall, the effects of fatty acids
are inconclusive.
NCT01782352 is an AMD substudy of the Vitamin D and Omega-3 Trial (VITAL) being run in Boston,
Massachusetts by Christen and colleagues. The main VITAL trial is concerned with cardiovascular disease
cancer and stroke (www.vitalstudy.org/). It is due to end in 2017, after recruiting almost 26,000 people.
NCT02613572 is a trial of alpha lipoic acid in GA, being carried out in Pennsylvania by Kim and colleagues.
There are doubts about tolerability in older people.
NCT02379169 is a 6-month trial in Finland of sea buckthorn oil (which has beta-carotene and zeaxanthin)
combined with lutein.
Homocysteine, folic acid and vitamins
The Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS) by Christen and colleagues406
randomised 5205 women, who did not have a diagnosis of AMD at baseline, to a daily supplement
containing folic acid, vitamin B6 and vitamin B12 or to placebo. After 7.3 years of follow-up there were
fewer cases of AMD in those randomised to a combination of folic acid 2.5 mg/day, vitamin B6 50 mg/day,
and vitamin B12 1 mg/day than among those given daily placebo (Table 44). The RR was significant 0.66
(95% CI 0.47 to 0.93). The study also reported that visually significant AMD was significantly less frequent
in those taking the folic acid/B6/B12 supplements (RR 0.59, 95% CI 0.36 to 0.95).
Three studies focused on homocysteine levels in healthy populations.
TABLE 43 Adverse events in fatty acid studies
Souied et al., 2013393
RCT; unclear ROB DHA, n= 134 Placebo, n= 129
Ocular AE 58.7 50 NS
Worsening of cataract 50 62.5 0.032
Serious non ocular eventa 23.1 23.6 NS
Deaths 2.2 4.7
ROB, risk of bias.
a Considered to be unlikely to be related to the study treatment, except for two undetermined serious AEs (pulmonary
embolism in the DHA group and cerebral haemorrhage in the placebo group).
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Cohort studies by Merle 2016407 and Gopinath 2013408 assessed dietary intake of folate and vitamin B in a
total of 3915 participants, and Gopinath 2013408 also assessed serum homocysteine, folate, and vitamin
B12 levels. The studies were conducted in the USA (n = 2) and Australia (n = 1). Follow-up was 7.3 years in
the RCT and 5–13 years in the cohort studies. The cohort studies were assessed as good quality. The three
studies received non-commercial funding, although the supplements were provided by the manufacturer in
the RCT. Where reported, mean age was 63–72 years and 0% to about 45% were men. Baseline VA was
not reported by the studies.
Gopinath and colleagues 2013408 from the BMES in Australia, included people invited to attend an eye
examination following a door-to-door census in the study area. Cross-sectional data from BMES had
shown that increased serum homocysteine and low vitamin B12 were associated with an increased risk of
AMD. In this cohort study, after 10 years’ (the BMES 4 visit) follow-up, those with AMD at 10 years had
had higher baseline (at the BMES 2 visit) serum levels of homocysteine and lower levels of serum vitamin
B12 than those without AMD (see Table 44). Serum levels of folate were not different between those with
and those without AMD. They also examined the association with fish consumption (none), consumption
of folate (no association) or vitamin B12 (lower in those with AMD, p = 0.03) supplements and total intake
of folate (no association) and vitamin B12 (lower in those with AMD, p = 0.004).
Merle and colleagues 2016407 included participants from the AREDs trial with at least one eye with a VA
no worse than 20/32 and at least one eye free from any disease that could complicate the assessments of
AMD. The progression to GA was reported to be 16% after a mean of 8.7 years follow-up. The study
reported that, after adjustment for age, sex and total energy intake, those who progressed to GA had lower
intakes of thiamine (p = 0.01), riboflavin (p = 0.03) and folate (p = 0.001) than those who did not progress.
In multivariate analysis, the trend for lower risk of progression was statistically significant for folate only
(p = 0.007), see Report Supplementary Material 5 for more details. Subgroups by 10 single-nucleotide
polymorphisms were reported for those who progressed and those who did not, and the difference in risk
between quintiles of dietary folate intake was seen in some groups (subjects with C3 R102G CC, HR in
highest quintiles about 0.4) but not others. So there was an interaction between genes and diet.
Summary
Folate supplementation may reduce the risk of AMD.
Vitamins
The potential antioxidant effects of vitamins were examined in five RTCs in healthy populations by Christen
et al. 2007,398 Christen et al. 2010,409 Christen et al. 2014410 Taylor et al. 2002399 and Teikari et al. 1998411
and one cohort study in people with dry AMD in at least one eye by Cangemi et al. 2007.411 A total of
TABLE 44 Effect of folic acid on AMD
Christen et al., 2009406
RCT; unclear ROB Folic acid/B6/B12 (n= 2607) Placebo (n= 2598) RR (95% CI); p-value
Total AMD, n cases 55 82 0.66 (0.47 to 0.93); 0.02
Visually significant AMD, n cases 26 44 0.59 (0.36 to 0.95); 0.03
Gopinath et al., 2013408
Cohort study; GQ With AMD, n= 219 Without AMD, n= 1171 p-value
Serum homocysteine (µmol/l) 13.0 (4.6) 12.0 (4.2) p = 0.002
Serum folate (nmol/l) 18.0 (9.6) 18.0 (8.5) p = 0.96
Serum vitamin B12 (pmol/l) 263.4 (116.6) 284.3 (138.0) p = 0.02
GQ, good quality; ROB, risk of bias.
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20,529 participants were randomised to vitamin E/alpha-tocopherol, 10,819 to beta-carotene, 7111 to
a multivitamin, 257 to alpha-tocopherol plus beta-carotene and 38,214 to placebo. The cohort study
included 34 people receiving an ‘oral antioxidant and omega-3 supplement’ (see below for details).
Four of the studies were conducted in the USA, one in Australia and one in Finland. Follow-up was from
≤ 4 years to 12 years in the RCTs and was 6 months in the cohort study. The RCTs all had an unclear risk
of selection bias and the cohort study was assessed as fair quality. One study received commercial funding,
one received both commercial and non-commercial funding, and four had non-commercial funding but
the supplements were provided by the manufacturer in two of these. Mean age ranged from 52–76 years
and 42–100% were men, where reported. Baseline VA was reported by three of the studies.
Christen and colleagues 2007398 assessed the incidence of ARM in healthy male physicians receiving
beta-carotene (50 mg on alternate days) or placebo for 12 years in a large RCT. There was no difference
between groups in the risk of visually significant ARM (RR 0.96, 95% CI 0.78 to 1.20), ARM with or without
vision loss (RR 1.01, 95% CI 0.86 to 1.20) or advanced ARM (RR 0.97, 95% CI 0.69 to 1.37) (Table 45).
This remained the case after excluding cases diagnosed during the first 2 or 5 years of follow-up.
Christen and colleagues 2010412 included women from the Women’s Health Study who did not have a
diagnosis of AMD at recruitment. With 10 years of follow-up there were fewer cases of visually significant
AMD in those randomised to vitamin E and aspirin on alternate days than those given placebo, but the
difference was not statistically significant (RR 0.93, 95% CI 0.72 to 1.19) (see Table 45). The incidence of
advanced AMD was not significantly different between groups (RR 1.13, 95% CI 0.67 to 1.92), nor was
the incidence of all AMD with or without vision loss (RR 0.90, 95% CI 0.77 to 1.06).
Taylor and colleagues 2002399 included healthy volunteers aged 55–80 years. The 4-year incidences of
early AMD were similar between those randomised to high-dose vitamin E (500 IU daily) and those treated
with placebo, with RR 1.05 (95% CI 0.60 to 1.61) (see Table 45). Results for late AMD, incidence of drusen
and progression of AMD were similar between groups RR 1.36 (95% CI 0.67 to 2.77) for progression. The
study reported that there was a significantly lower incidence of hypopigmentation in those taking vitamin E,
but the data reported show a non-significant effect. No difference in BCVA was found (data not presented
by the study). Quality of life was assessed using the visual function (VF-14) scale and it was stated that there
were no differences between groups, but no data were presented.
Teikari and colleagues 1998397 compared the incidence of ARM among a subgroup of participants in a
Finnish RCT on lung cancer prevention. Men who were ≥ 65 years and smoked at least five cigarettes a
day were randomised to receive alpha-tocopherol, beta-carotene, alpha-tocopherol + beta-carotene or
placebo. After approximately 6 years, no differences in the incidence of AMD were found among groups,
RR for alpha-tocopherol 1.13 (95% CI 0.8 to 1.59) and 1.04 (95% CI 0.74 to 1.47) for beta-carotene (see
Table 45) and there was no association between the supplements and prevalence of ARM after controlling
for potential risk factors.
Christen and colleagues 2014410 included healthy male physicians from a cancer and cardiovascular
prevention study (the Physicians Health Study II) who were not diagnosed with AMD. After 11.2 years
of follow-up there was no significant difference between groups in cases of visually significant AMD
(HR 1.19, 95% CI 0.94 to 1.50) or cases of advanced AMD (HR 1.22, 95% CI 0.88 to 1.70). However,
the number of cases with total AMD with or without vision loss was significantly higher in those given
multivitamins (HR 1.22, 95% CI 1.03 to 1.44).
Cangemi 2007411 compared one arm of their RCT, which compared MCS with sham microstimulation
(abandoned because of lack of effect), with the placebo arm of another study.186 As both arms of the
original study received nutritional supplements, it is not clear why only the patients in the sham arm were
included in this study. It was really a before-and-after study with no local controls. Participants in Cangemi
2007411 had at least one eye with dry AMD (> 10 large soft drusen of 63 µm in diameter, within 3000 µm
of the fovea centre) and BCVA in the study eyes of 20/32 to 20/125 inclusive (ETDRS). After 6 months of a
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TABLE 45 Results of antioxidant vitamin studies
Christen et al., 2007398
RCT; unclear ROB Beta-carotene, N= 10,585 Placebo, N= 10,557 RRa (95% CI)
Visually significant ARM, n 162 170 0.96 (0.78 to 1.20)
ARM with or without vision loss, n 275 274 1.01 (0.86 to 1.20)
Advanced ARM, n 63 66 0.97 (0.69 to 1.37)
Christen et al., 2010412
RCT; unclear ROB Vitamin E, N= 19,697 Placebo, N= 19,724 p-value
Visually significant AMD, n cases 117 128 0.54
Advanced AMD, n cases 29 26 0.65
All AMD ± vision loss, n cases 280 313 0.20
Taylor et al., 2002399
RCT; unclear ROB Vitamin E, N= 587 Placebo, N= 592 RR (95% CI)
4-year incidence of early AMD (%)
Photographsb 8.6 8.1 1.05 (0.69 to 1.61)
Clinical gradingc 7 7 1.12 (0.66 to 1.9)
Incidence of late AMD (%)
Photographs 0.8 0.6 1.36 (0.67 to 2.77)
Clinical grading 1 1 1.00 (NA)
Incidence of drusen at 4 years (%)
Soft intermediate 19 18 1.05 (0.80 to 1.39)
Soft distinct 6 6 1.05 (0.60 to 1.82)
Soft indistinct 2 2 1.03 (0.77 to 1.38)
Progression of AMD (%) at 4 years
Photographs 19 18 1.09 (0.84 to 1.42)
Clinical grading 7.9 6.0 1.31 (0.83 to 2.07)
Teikari et al., 1998397
RCT; unclear ROB
Alpha-tocopherol,
N= 237
Beta-carotene,
N= 234
Alpha-tocopherol+
beta-carotene,
N= 257
Placebo,
N= 213 p-value
ARM overall incidence (%) 31.6 29.1 28.4 24.9 0.468
ARM classd, n
No ARM 162 166 184 160
I 65 64 64 46
II 2 2 6 6
III 6 2 2 0
IV 2 – 1 1
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nutritional supplement containing vitamins A, C and E, zinc, copper, taurine, EPA fatty acid, DHA fatty
acid, lutein and zeaxanthin (with sham microstimulation), VA was reported to have improved from baseline
by 0.5 ETDRS lines (p = 0.045; see Table 45) compared with a deterioration in the placebo arm of the
other study (no statistical comparison). BCVA improved in 56.7% of participants. There was little change in
other outcomes, including contrast sensitivity and NEIVFQ-25 (see Report Supplementary Material 5).
Because of the mixture of vitamins, metals, fatty acids and lutein given, it is not possible to say which
ingredient had the reported effect.
Adverse events
Four papers (Christen and colleagues 2010,412 Christen and colleagues 2007,398 Teikari and colleagues,397
Christen and colleagues 2014410) did not report AEs.
Taylor and colleagues 2002399 found no serious AEs. Ocular AEs occurred in 18% of participants in the
vitamin E group and 15% in the placebo group, not a significant difference. Cangemi 2007411 reported
that there were no significant systemic or ocular AEs related to the nutritional supplement.
Summary
The Huang et al.394 review concluded that AMD is associated with elevated homocysteine levels and
decreased vitamin B12 levels. Four additional studies (Christen 2015,406
,413 Merle 2016407 and Gopinath
2013408) were identified that assessed homocysteine levels, folic acid and B vitamins: one RCT (Christen
2009406) and three good-quality cohort studies (Christen 2015,413 Merle 2016,407 Gopinath 2013408) were
identified that assessed homocysteine levels, folic acid and B vitamins. The results from the primary studies
suggest an association with AMD and lower intake of B vitamins or reduced serum B12 levels. Results for
the effect of folic acid were inconsistent.
The Evans review357 concluded that people with AMD, or early signs of the disease, may experience some
benefit from taking supplements as used in the AREDS trial, but that current evidence does not support
the use of antioxidant vitamin supplements to prevent AMD. Four large RCTs found no beneficial effect of
beta-carotene or vitamin E/alpha-tocopherol in healthy individuals. One large RCT found higher total AMD
in people given multivitamins. It may be that, as in category 1 in the AREDS trial, the rates of progression
over the durations observed are too low to show any effect.
Ginkgo biloba extract
Ginkgo biloba extract is a popular herbal medicine, claimed by its advocates to be of benefit in a very wide
range of diseases.
TABLE 45 Results of antioxidant vitamin studies (continued )
Christen et al., 2014410
RCT; unclear ROB Multivitamin, N= 7111 Placebo, N= 7122 p-value
Visually significant AMD, n cases 152 129 0.15
Total AMD ± vision loss, n cases 294 244 0.02
Advanced AMD, n cases 79 65 0.23
FQ, fair quality; ROB, risk of bias.
a Adjusted for aspirin assignment (beta-carotene arm only received low-dose aspirin, 325 mg every other day before
being terminated).
b Soft distinct or soft indistinct or pigment changes (hyperpigmentation or hypopigmentation).
c Large/soft drusen or non-geographical RPE atrophy.
d I= dry maculopathy, with hard drusen and/or pigmentary changes, II = soft macular drusen, III = disciform degeneration,
IV=GA.
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A Cochrane review by Evans 2013414 found only two trials. One compared ginkgo extract with placebo but
had only 10 patients per arm followed for 6 months. In both groups, vision was report to improve but the
ginkgo group was reported to have improved more. The other trial compared two doses of ginkgo and
found no significant differences.
There is insufficient evidence for the use of ginkgo biloba in AMD.
HESA-A
HESA is described as a ‘natural drug’ but is a mixture of ingredients. A study by Ahmadi and colleagues415
from Iran included 140 participants in the HESA-A group and 140 in the placebo group. Details were sparse
and risk of bias could not be assessed. Treatment with a twice daily oral tablet (25 mg/kg) containing
‘herbal-marine’ elements (including calcium 43.79%, diphosphorus pentoxide 6.63% and 24 other
ingredients including various trace elements) or placebo (no details) lasted for 4 weeks with follow-up at
6 months. The study had an unclear risk of selection bias (see Report Supplementary Material 5). Participants
were aged 69 years, on average, and 42–45% were male. Baseline BCVA was 1.7 logMAR. The funding
source for the study was not reported.
Ahmadi and colleagues415 included people with a clinical diagnosis of wet or dry AMD but no breakdown
is given. At 1 month, BCVA was reported to have improved in the HESA-A group and a statistically
significant difference was reported between groups. The study reported that VA improved in 100% of
participants in the treatment group after 4 weeks, sustained to 6 months but that no effect on BCVA was
seen in the control group. No other outcomes were reported. Improvement was not defined and no data
were presented.
Saffron
Saffron is the dried red stigma of Crocus sativus and contains a large number of compounds, including the
carotenoids crocetin and zeaxanthin.
Quantity and quality of research
Reviews
Two non-systematic reviews of saffron use were identified. Milajerdi et al. 2015416 concluded that saffron
was effective in a very wide range of diseases. The studies they included for saffron in AMD were by
Falsini 2010417 and Marangoni 2013,418 described below. The other review by Bisti and colleagues 2014419
reviewed their own studies (including Falsini 2010417 and Marangoni 2013,418 in both of which Bisti is
an author).
Broadhead et al.359 also reviewed saffron use as part of a wider review of nutritional interventions in AMD,
but concluded its value was unproven. However they have a trial under way, reported below.
Studies
Six studies were included. Three were from the same group in Italy: one crossover RCT by Falsini et al.
2010,417 a before-and-after study by Piccardi et al.420 and a cohort study by Marangoni et al.418 A total of
87 participants were included in the studies, all of whom received saffron.
The other three studies were RCTs by Lashay et al.421 2016 from Tehran, Riazi et al.422 2017 from Tehran
(different hospitals) and Broadhead et al.423 2016 from Australia. The Broadhead study is available only as a
conference abstract.
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In the Falsini RCT, saffron 20 mg or placebo were given for 90 days and then after a 15-day wash out
participants received the alternate treatment for 90 days. Follow-up was immediate. In the before-and-after
study participants received saffron (dose not reported) for 14 months and were followed up 1 month later,
and in the cohort study saffron 20 mg was given for an average of 11 months and follow-up was immediate.
The Falsini RCT417 had an unclear risk of selection bias, the before-and-after study by Piccardi420 appeared to
be of good quality, and the cohort study418 to be poor quality. Mean age was 65–69 years across study
groups, and around 46–55% of participants were men. Baseline VA was reported by two of the studies
(see Report Supplementary Material 5).417,420
Falsini and colleagues417 included people with bilateral early AMD and a BCVA at least 0.3 in the study
eye (typically the eye with the best VA was selected as the study eye). After 90 days the mean VA was
significantly better with saffron than placebo (Table 46). It is unclear whether or not this analysis accounts for
the crossover appropriately. The VA was reported to have increased by 1 line in 80% and was unchanged in
20% of people treated with saffron. In the placebo group 100% were unchanged (see Table 46). The main
outcome measure was flicker sensitivity.
In a before-and-after study, Piccardi and colleagues420 included people with bilateral early AMD and BCVA
at least 0.5 in the study eye. After 14 months of treatment, mean VA improved by 2 Snellen lines compared
with baseline values (VA 0.75 to 0.9; p < 0.01) (see Table 46). The primary outcome of the study was focal
electroretinogram (fERG), which did not change during the study.
Marangoni and colleagues180 included people with bilateral early AMD and BCVA at least 0.5 in the study
eye. Although VA was assessed as a secondary outcome, no data were reported. The primary outcome of
the study, fERG, was reported to have improved significantly during the study compared with baseline
values (see Report Supplementary Material 5).
TABLE 46 Results of saffron studies
Falsini et al., 2010417
RCT; unclear ROB Saffron, n= 25 Placebo, n= 25 p-value
Mean Snellen VA after 90 days (SD) 0.80 (SD 0.20) 0.72 (SD 0.24) p< 0.01
VA (%)
Increase by 1 line 80 0
Unchanged 20 100
Piccardi et al., 2012420
B+A; GQ Saffron, n= 29 p-value
Mean VA Baseline: 0.75
15 months: 0.9
p < 0.01 versus baseline
Riazi 2017
RCT; unclear ROB Saffron, n= 29 Controls, n= 25
Mean BVCA baseline logMAR 0.46 (SD 0.41) 0.62 (SD 0.54)
Mean BCVA at 12 weeks logMAR 0.41 (SD 0.41) 0.65 (SD 054); p = 0.001
Change 0.05 + 0.03
B+ A, before and after; GQ, good quality; ROB, risk of bias.
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Adverse events
All three of the studies reported no AEs.
Lashay et al.421 randomised patients with both wet and dry AMD, but we are interested only in the 30 with
dry AMD. Only 16 completed the study. No definition or details of dry AMD are given. The trial appeared
to be of fair quality using the Cochrane risk-of-bias scale (four criteria low risk, unclear for allocation
concealment). The outcomes were retinal sensitivity by ERG and macular thickness by OCT. The paper
reports that VA was not improved but no data are provided.
Riazi et al.422 included only patients with dry AMD and assigned them to 50 mg saffron daily or placebo
capsules. The risk of bias in unclear due to lack of detail. After 3 months, improvements in VA and
contrast sensitivity were reported in the saffron group but not in the controls.
Details of the trial by Broadhead and colleagues423 are too sparse to assess quality. It is reported as a
double-blinded crossover trial in 100 people with non-advanced AMD. Saffron supplement (20 mg/day)
or placebo was given for 3 months, followed by crossover for another 3 months. The abstract reports that
saffron improved mean BCVA by 0.69 letters, which is not of clinical significance. The authors suggest that
longer-term studies may show greater effect.
Summary
Two non-systematic reviews, four small studies and one abstract for a larger but short-term trial, were
identified. The Falsini crossover RCT417 of uncertain risk of selection bias reported that VA was better with
saffron treatment after 90 days. After 14 months of treatment with saffron, the Piccardi420 before-and-after
study of good quality reported a significant increase in VA. Two studies did not report VA outcomes. No
adverse effects of saffron supplementation were recorded. Three studies and one of the reviews were from
the same centre.
Overall, the evidence suggests a potential for benefit but further evidence is required. An important point
made by Bisti and colleagues419 in their review is that the content of saffron may vary depending on source.
Curcumin
Curcumin is the main component of turmeric, the spice used in Indian cooking. A review by Pescosolido
2014424 stated ‘It has been demonstrated that curcumin has beneficial effects on several ocular diseases
such as . . . age-related macular degeneration . . .’. This review produced no evidence at all that this was
the case and almost all the studies reviewed were at a basic science level.
A few other studies have been published but all are at the basic science stage, for example using RPE
cells425 or rat models of light-induced retinal degeneration.426 There is no evidence at present to support
the use of turmeric products in AMD.
Zinc
Reviews
One high-quality systematic review by Vishwanathan and colleagues 2013427 was identified so we did not
go back to the primary studies. Vishwanathan and colleagues 2013427 included 10 studies: four RCTs, four
prospective cohort studies and two retrospective cohort studies. Outcomes were incidence of any AMD,
early AMD and late AMD, BCVA, progression to GA. The review concluded that the current evidence on
zinc intake for the prevention of AMD is inconclusive. The authors state that zinc treatment may be
effective in preventing progression to advanced AMD but zinc alone may not be sufficient to produce
clinically meaningful changes in VA. Recommendations for research were that evaluations of different
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forms of zinc supplementation (e.g. zinc oxide vs. zinc sulphate vs. zinc monocysteine) are required
because bioavailability varies. The AREDS 1 trial used 80 mg of zinc oxide, AREDS 2 used 25 mg, Newsome
1988342 used zinc sulphate 100 mg, Newsome 2008428 used zinc monocysteine 25 mg twice daily, and Stur
1996429 used 200 mg of zinc sulphate. The Vishwanathan review was written before the AREDS 2 results
were available.
Zinc was also mentioned in several non-systematic reviews310,322 of multiple interventions for dry AMD but
these referred to the Vishwanathan review or the AREDS trial papers so did not add anything.
Studies
No published studies not covered by the Vishwanathan and colleagues 2013427 review were identified.
Summary: zinc
One good-quality systematic review concluded that there is inconclusive evidence for the use of zinc to
prevent AMD but that it may be effective in prevention of progression to advanced AMD. It is included for
this purpose in the AREDS 2 formula.
Chapter summary
There are many studies of nutritional supplements but some are too small and of too short duration, or are
of combinations of compounds, making it difficult to assess the relative contributions of each. Supplements
used include lutein and zeaxanthin, in combination or individually, or combined with a variety of other
minerals and/or vitamins, the omega-3 fatty acids DHA and EPA, olive oil, folate acid, various vitamins,
ginkgo biloba, turmeric, saffron and zinc.
The strongest evidence is for the AREDS 2 supplement, which contains:
500 mg vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, 25 mg zinc, 2 mg copper.
There is currently insufficient evidence to recommend any other nutritional supplements, although saffron
extracts show promise and might justify further research. The combination of folic acid and vitamins B6 and
B12 may also be worth further research, perhaps in people with early AMD. Olive oil may be protective as
part of a healthy diet – the evidence is not on use as a supplement.
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Chapter 7 Discussion and research needs
There were two aims for this review. The first was to provide an up-to-date systematic review oftreatments for dry AMD and STGD. The second and more important aim was to identify treatments
that were sufficiently promising for the NIHR programmes (HTA and EME) to consider commissioning
primary research.
Statement of principal findings: dry age-related macular degeneration
Physical treatments
l Newer forms of laser treatment show promise but a large trial, the LEAD trial from a world centre of
excellence in Melbourne is ongoing (anticipated completion date June 2018), so we suggest waiting for
their results.
l Implantable telescopic lenses also show promise, but a NIHR EME study is under way (MIRROR) in
advanced AMD.
l There is insufficient good-quality evidence to recommend use of, or further research in, acupuncture,
MCS or ozone.
l There is some evidence on rheopheresis, but the largest trial showed no benefit, most studies reporting
positive results were small with only modest effect sizes and mostly uncertain risks of bias, and treatment
would be inconvenient to elderly patients. So we do not see rheopheresis as a research priority.
l The evidence for the use of blue-light-filtering IOLs after cataract extraction is currently insufficient to
justify their routine use, but further research is currently under way.
Cells
l One small before-and-after study and one very small case series of cell (RPE) transplantation was
identified. Improvements in VA were found in over half of treated eyes.
l The evidence base is still very sparse, but this seems a promising development, and further research is
under way.
Drug treatments
l We think that there is sufficient evidence to justify a trial of a potent statin, such as atorvastatin
80 mg daily.
l Fenretinide is a visual cycle inhibitor, which may reduce the deposition of lipofuscin. We found one
trial, with an unclear risk of bias and run and written up by the manufacturer’s staff, which had mixed
results. Progression of GA was little different overall, but was a bit lower in the subgroup that achieved
greater serum RBP levels. However progression to wet AMD was halved by fenretinide. There were
higher rates of AEs with fenretinide. Overall, we think a trial in early dry AMD may be justified, but the
roughly 20% drop-out rates in the active drug arms should be noted.
l An impressively large retrospective study from the USA found that people taking L-dopa were less likely
to develop AMD, and that if they did develop it, it was about 7 years later than among people not taking
L-dopa. Further research is needed, perhaps using the large UK general practice-based databases, THIN
and CPRD, in order to assess whether a trial assessing its use in treating AMD could be justified.
l The current evidence on lampalizumab suggests benefit, but very large trials are under way (sponsored
by the manufacturer), so no new research is indicated meantime.
l There is a little evidence of benefit from glatarimer acetate, but with only some shrinkage of drusen in
two studies which had unclear risks of bias. The evidence is too sparse to justify NIHR research at
present. Future trials can be left to the manufacturer if deemed worthwhile.
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l One small study reported benefit from prednisolone but it scored poorly on quality assessment so there
is insufficient evidence to justify its use. Systemic steroids have adverse effects so if steroids were to be
used, a topical one would seem better. The results of a trial of an implanted steroid, fluocinolone
(NCT00008515), are awaited.
l For nine drugs, there was some evidence showing no or very little benefit, or even harm, so we do not
recommend further consideration. They are alprostadil, eculizumab, dorzolomide, OT 551 eye drops,
sirolimus, tandospirone, trimetazidine, visaline and emixustat.
Nutrients
l There are many studies of nutritional supplements but some are too small, of poor quality, of too short
duration, or are of combinations of compounds, making it difficult to assess the relative contributions
of each. Supplements used include lutein and zeaxanthin, in combination or individually, or combined
with a variety of other minerals and/or vitamins, the omega-3 fatty acids DHA and EPA, olive oil, folate
acid, various vitamins, ginkgo biloba, curcumin (from turmeric), saffron and zinc.
l The first AREDS trial showed benefit in category 3 and 4 patients, which persisted for 7 years, with a
modest but useful slowing of progression, which could mean that 30% of people expected to progress
to advanced AMD over a 5-year period, would not. The trial did not have enough power to confirm, or
not, effects in categories 1 and 2.
l The AREDS 2 trial showed that beta-carotene should be replaced by lutein and zeaxanthin, and that
the dose of zinc could be reduced.
l We therefore think that there is good evidence that the AREDS 2 supplement should be used for
patients meeting the AREDS 3 and 4 categories.
l Saffron extracts have been reported to show some benefits in VA and might justify further research.
l There is currently insufficient evidence to recommend any other nutritional supplements.
Statement of principal findings: Stargardt disease
The evidence on treatments for STGD is sparse. We found only one randomised trial with a control group
(microstimulation), and it had only 12 patients and an unclear risk of bias. Most studies tested interventions
with no comparison group, most were far too short term, and the quality of some studies was poor. There
has been very little research into the treatment of STGD compared with AMD.
At present, the most promising treatments for STGD appear to be;
l Prevention of lipofuscin accumulation. Several drugs may have potential, including fenretinide, deuterated
vitamin A (ALK-001) and emixustat. Early trials of ALK-001 and emixustat are under way. Fenretinide has
shown promise in dry AMD and we think a trial in STGD may be justified. A vignette has been written for
the HTA programme.
l Gene therapy is at an early stage, but a study (StarGen NCT01736592) is under way in Oregon and Paris.
l Cell transplantation to replace the RPE has been tried in one small study in only nine people with
STGD, but looks promising. Further research is already under way.
There are three other possible interventions that seem worth further research. One is light reduction,
as reported in the very small trial by Teussink et al.,122 where progression in the light-protected eye was
reported to be less in four of the five participants. Second, there is a plausible rationale for the benefits of
lutein and zeaxanthin supplementation to protect the macula (perhaps especially the fovea) but insufficient
evidence. The small Aleman study114 was too short term. Scripsema and colleagues341 have pointed out
that after supplementation with lutein and zeaxanthin, serum levels rise quickly, but macular pigment
concentration increases over several months, and visual function may take a year or two to reach
statistically significant changes.
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The evidence for the third comes so far only from animal work, where fenofibrate appears to have some
activity as a visual cycle inhibitor. Fenofibrate is an old, cheap and safe drug used for lipid-lowering, but is
currently being trialled in diabetic retinopathy where it has shown some benefit in past studies.
Strengths and limitations
The strengths of this review come from the thorough searches, updated with weekly auto-alerts (to
December 2017, so including the period of editorial review and allowing late updating), the rigorous
systematic review methods used, including quality assessment of included studies, data extraction using
predefined forms, checking of data extractions and reporting using structured tables.
Expert ophthalmological input was available within the team. Our links with the Macular Society research
team fostered awareness and our panel of patient advisers met three times to hear and comment on drafts
of the review.
The limitations came from the poor quality of much of the evidence. Many studies were too small and of
poor quality. Durations were often very short and too short to capture effects on vision. Many studies used
VA as their main outcome despite not having sufficient duration to observe changes.
The AREDS trials have been criticised for recruiting a well-educated and well-nourished group, who might
not be representative of the general population (of the USA). However, their diets would have tended to
reduce their risk of progression, which means that the AREDS trial may have underestimated the benefits
of the supplement. The AREDS 1 supplement has been assessed as cost-effective in both the USA430
and Singapore.431
Two other limitations in the evidence need to be mentioned. First, many of the studies are case series with
no controls. Spontaneous improvement in VA can occur, as patients learn to use remaining retina more
effectively. Sunness432 reported that 5 out of 48 worse-seeing eyes improved in patients with bilateral GA.
Second, publication bias is a likely problem but we have been unable to assess this formally. Prenner and
colleagues433 found that half of the interventional trials registered on ClinicalTrials.gov had not been
published ≥ 2 years after completion.
Earlier detection for clinical trials
As argued in the Chapter 1, VA is a late manifestation of AMD, and future studies should aim to detect,
and intervene in, AMD earlier. Many people with early and intermediate (large drusen) AMD have no
symptoms, and others with symptoms may attribute them to ageing. This implies that they would have to
be found by screening. One option suggested by Chew and Schachat434 would be to detect people with
drusen using the digital photographs taken for screening for diabetic retinopathy. Unfortunately, that would
capture only those with diabetes and their retinopathy might require treated, which would complicate any
AMD trials. Another option, being provided by one optometry practice in Scotland, is screening during
annual eye tests, using both fundus photographs (and measurement of MPOD – although photographs are
sufficient to identify people with drusen).435 A network of screening practices could identify sufficient people
for dry AMD trials.
However, work from the USA suggests that AMD is being missed in primary eye care, by both optometrists
and ophthalmologists. Neely and colleagues436 examined 644 people aged ≥ 60 years who had been
recorded as having normal maculae at their most recent dilated eye examination. They obtained three-field
colour fundus photographs and found that 25% of people had some evidence of AMD. Of these, 69%
had early and 31% had intermediate (large drusen) AMD.
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Outcome measures
If we recruit people with early AMD (i.e. with drusen + RPE changes but no GA) to clinical trials, most are
going to be asymptomatic in terms of central visual loss and, in most, vision is going to be good. Therefore,
VA will not, in short-term follow-up, be a suitable outcome measure. Nor will GA, because enlargement of
areas of GA will occur slowly, although GA could be an outcome over longer periods, with the right imaging
technology. As Schaal and colleagues437 state: ‘The major disadvantage of using GA is that significant
irreversible disease progression has already occurred’.
It will be necessary to look for reducing or preventing functional deterioration, such as changes in drusen
number or volume (although with the caveat that resolution of drusen may be due to developing GA),
preventing or reducing the development of reduced signal on AF (conventional 488 nm AF, 787 nm
near-infrared AF), or lack of reduction/disorganisation of the IS/OS layer on OCT, or more sensitive
measures such as macular function as measured by microperimetry (including using dense grids on
microperimetry to more precisely determine macular function). Rod function is one of the earliest
abnormalities detected in people who will later develop GA in AMD. Both photopic and scotopic vision
need to be considered.
There appear to be subtypes of drusen as described by OCT that may have different prognostic significance.
Veerappan and colleagues438 describe subtypes of drusen that predict progression to GA but not to
wet AMD.
The appearances of GA on FAF (autoflorescence and fundus photography) also reveal subtypes of GA with
different prognoses. Schmitz-Valckenberg and colleagues76 from the Geographic Atrophy Progression
Study found more rapid growth in areas of GA in patients with multifocal atrophic spots than in those
with unifocal spots.
Dark adaptation may also be an early sign of developing AMD. Several studies have reported that dark
adaptation may be impaired in AMD before BCVA is affected. Owsley et al.439 assessed rod-mediated
dark adaptation in 325 people with no AMD and followed them up 3 years later. Those who had
abnormal dark adaptation at baseline were twice as likely to have developed AMD. Alvarez et al.440
reported that dark adaptation time measured by rod intercept time, increased over 2 years in eyes with
AMD (with bilateral large drusen or more advanced AMD), but not in control eyes or in eyes without large
drusen at baseline. They used the AdaptDx device (Maculogix, Middletown, PA, USA), which is said to take
only 5 minutes.441 Diaz and colleagues442 also reported that rod function was different between patients
with early AMD (grades 2–3) and normal eyes, whereas BCVA was not. Another study from the same
group443 described a digital dark adaptometer as providing a rapid and easy way of assessing progression
in dry AMD, with high sensitivity and specificity in a study of 20 patients (ARED 2–4) and 20 normal
controls. Lastly, Planas and colleagues444 compared patients with drusen with healthy controls, and found
worse dark adaptation in the patients, especially those with RPD. Therefore, dark adaptation appears to be
a quick test for monitoring early AMD, which is feasible in routine clinics.
Research under way in Northern Ireland shows that measuring the ability of people with AMD to see in
the dark could provide evidence of deteriorating vision earlier than the tests usually used in Ophthalmology
clinics. (Beirne R, University of Ulster, 2014).
We also need outcome measures that matter to people with AMD, such as being able to drive, reading
speed, VA for both close and distant vision, and contrast sensitivity.
Kimel and colleagues445 emphasise the importance of reading for people with GA, and note that some
people may have good BCVA, but have problems with reading. They have developed the functional
reading independence index, which will be used in the trials of lampalizumab, mentioned in Chapter 5,
Complement inhibitors.
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A recent systematic review of biomarkers by Kersten and colleagues446 considered a very large number
of possible biomarkers but concluded that few were likely to be useful. They also noted the potential
of ‘hypothesis-free’ studies (i.e. those that measure lots of possible compounds rather than looking at
specific ones where there may be a reason to suspect a link with AMD). An example of these was reported
by Lains et al.447 who studied 878 compounds and found that 87 metabolites differed between people
with AMD and those without.
Wittes and Downs448 provide a useful review of the types of outcome measures in AMD and their relative
advantages and disadvantages. They classify outcomes as:
l continuous measures, such as VA over time
l success or failure, such as proportions losing < 10 letters, or having no change over time
l proportions requiring retreatment or alternative treatments
l characteristics of the disease such as drusen volume.
They make several points worth considering. One is that using a continuous variable, such as mean VA,
requires a smaller sample size, but will conceal the distribution of results and individual success or failure.
To provide estimates of proportions requires a much larger sample size, but is clinically more useful.
Similarly in STGD, AF, macular sensitivity determined by microperimetry and VA are useful measures of
progression, but may not capture all the functional effects.449 One useful outcome in STGD is reading
speed. Murro and colleagues450 found that reading speed was a strong determinant of quality of life
(measured by the NEIVFQ-25).
One area where further research would be useful is in strengthening the links between early intermediate
changes and longer-term visual outcomes. We argued that intermediate outcomes can be accepted if
there is good evidence that they are strong predictors of later visual outcomes. However, some evidence
comes from cross-sectional studies showing correlations, but we need more longitudinal studies showing
that early intermediate outcomes predict later visual ones. As noted in the STGD chapter, this may require
studies of long duration. There may be a place for population-based registries here.
Research priorities for National Institute for Health Research programmes
We think that at present the interventions where the NIHR programmes might consider primary studies are:
l Fenretinide for STGD, and possibly for dry AMD, because it appears to reduce the accumulation
of lipofuscin.
l High-potency statins for AMD. We have inconclusive evidence from the trial by Guymer et al.283 of
simvastatin 40 mg but more promising results from an uncontrolled case series by Vavvas et al.286 of
atorvastatin 80 mg.
l Lutein and zeaxanthin supplements for STGD, based on theoretical reasoning rather than results from
intervention studies.
l Screening for early asymptomatic AMD in order to provide recruits for trials at earlier stages.
Cell transplantation and gene therapy both look promising. Research is under way but it would be good if
it could be accelerated. However, such research might, at present, lie more within the remit of the MRC
than NIHR.
As noted earlier, there is good evidence that the AREDS 2 supplement is worthwhile in AREDS categories 3
and 4, but not in categories 1 and 2. Absence of evidence in categories 1 and 2 is because the AREDS trial
DOI: 10.3310/hta22270 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 27
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
lacked power to observe changes, because progression was (luckily) too slow to detect significant changes
in the timescale of the trial. That raises two options for people in categories 1 and 2:
l extrapolate from later stages, assume the AREDS 2 supplement will be effective, and advocate
routine use
l mount a large trial comparing the AREDS 2 supplement with a normal diet.
The first option would do no harm, and probably much good, but we cannot claim it to be evidence-based
at present. The second would mean a long delay before people got what would probably be an effective
treatment, and there might be ethical and recruitment problems.
In STGD, filtering of light by contact lenses looked promising in the one small study122 but it seems unlikely
that the HTA programme would regard that as a sufficient basis for commissioning a large trial. That raises
the question of who would fund a pilot study to see if there was enough evidence of efficacy to warrant a
HTA trial.
The same might apply to saffron supplements in dry AMD, perhaps trialled against lutein and zeaxanthin,
using MPOD as the intermediate outcome.
In any research, the outcomes should include functional changes that are important to patients, as well as
morphological changes.
Prevention of age-related macular degeneration
It would be better if we could prevent or at least reduce AMD. Consideration of that topic is outside the
remit of this review, but there is good evidence that healthier lifestyles – avoiding smoking, physical
activity, healthy diets – can reduce the incidence, with a combination of lifestyle choices best.451
A recent systematic review by McGuinness and colleagues452 of physical activity and AMD found slight
protection against early AMD (OR 0.92, 95% CI 0.86 to 0.98) but a greater effect for late AMD (OR 0.59,
95% CI 0.49 to 0.72). The amount of activity in some studies was low, with just a few hours of small to
moderate level of activity per week.
A recent Cochrane review453 concluded that there is, as yet, no evidence that taking supplements of
vitamin E, beta-carotene, vitamin C or the multivitamin product Centrum (Pfizer Consumer Healthcare,
New York, NY, USA), will prevent or postpone AMD.
Sources of advice
We have noted a large number of internet sites that offer information on AMD. Some provide reliable
information, but many do not. Some are seriously misleading, making extravagant claims for treatments
without a good evidence base.
One potential source of advice could be optometrists. Two studies have tried to find out what advice
optometrists and ophthalmologist give to people at risk of, or who have, AMD. The response rates by
ophthalmologists were very poor and could provide no useful data. Lawrenson and Evans454 got response
rates of 16% from optometrists and 6% from ophthalmologists. About 60% of respondents gave advice,
such as to eat leafy green vegetables and oily fish, and in people with advanced AMD in one eye and early in
the other, supplements were recommended, but only a minority recommended evidence-based supplements.
There may be considerable selection bias with responders being more likely than non-responders to
give advice.
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A survey in Sweden by Martin455 got a better response from optometrists (40%) but an equally poor
response from ophthalmologists (5%). Over half of the optometrists would recommend macular
carotenoids but not the full AREDS formula.
Conclusions
There are some promising developments in dry AMD, but research studies are already under way in some
of these, and we suggest waiting for their results. We have suggested some topics where the NIHR
programmes might consider primary research.
In STGD, there are fewer developments. Research is under way in some. Research into visual cycle inhibitors
is under way but we have found no trials of fenretinide and we think a HTA trial may be justified.
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Appendix 1 Methods
Quality assessment approach
We assessed the methodological quality of the included studies using recommended criteria. For RCTs and
CCTs we used the Cochrane Handbook risk-of-bias criteria.456 The Cochrane risk-of-bias assessment criteria
looks at the extent to which the design of a study and how that study is conducted is likely to prevent bias
(error) in the results. The tool covers six possible biases (selection bias, performance bias, detection bias,
attrition bias, reporting bias and other bias) that have been shown to reflect the main mechanisms for
bias in RCTs (Higgins 2011457). These six biases are assessed by at least seven questions relating to the
generation of the allocation sequence, concealment of the allocation sequence, blinding of participants
and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting and
other threats to validity. In this review the assessment of performance bias, detection bias and attrition bias
was evaluated separately for outcomes that were considered to be objective (e.g. BCVA) and subjective
(e.g. quality-of-life measures). Each criteria is assigned a judgement of ‘high,’ ‘low’ or ‘unclear’ risk of bias.
Narrative descriptions are also used to provide reasons for a particular judgement. In the review we used
the risk of selection bias (generation and concealment of the allocation sequence) to establish the overall
risk of bias for each study.
For non-randomised studies we used tools developed by the NIH NHLBI for a systematic review of
cardiovascular risk.458 The tools were developed by methodologists using quality assessment methods and
concepts, and using other tools developed by groups such as Cochrane and the UK CRD. The tools focus
on concepts including biases (selection, performance, detection and attrition), confounding, power and
strengths of associations between treatments and outcomes. There are different tools for each major type
of study; in this review we used the tools for cohort studies (two groups), before-and-after studies (one
group), case–control studies (two group studies looking at associations) and case series studies. Specific
guidance notes are provided for each tool. Each question is assigned a response of ‘yes’, ‘no’, ‘cannot
determine’, ‘not reported’ or ‘not applicable’. The study is then assessed for overall quality (good, fair,
poor) based on the responses to the individual questions, where a good study has the least risk of bias,
and results are considered to be valid; a fair study is susceptible to some bias but this is not deemed
sufficient to invalidate the results; and a poor study indicates that the study is at a significant risk of bias.
Quality scoring involved an element of judgement, because some criteria may be more important than
others, and because some criteria may be assessed as not applicable, not reported or cannot determine,
but as a rough rule of thumb we used the number of ‘yes’ responses:
l for before-and-after studies, with 10 questions, good 8–10, fair 5–7, poor < 5
l for cohort studies with 14 questions, good 10–14, fair 7–9, poor < 7
l for case control studies with 12 questions, good 10–12, fair 7–9, poor < 7
l for case series with 9 questions, good 8–9, fair 5–7, poor < 5.
Quality criteria were applied by one reviewer and checked by a second reviewer, with disagreement
resolved by discussion.
Quantity of evidence
We included 108 primary studies (Table 47). A total of 104 studies were predominantly on people with
(or at risk of) dry AMD and four studies were on people with STGD. Of the 104 dry AMD studies, there
were 26 of pharmacological treatments, 30 in physical therapies, three of cell transplants and 45 of
nutritional supplements. In the four studies in STGD there were two physical therapies and two nutritional
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TABLE 47 Studies and interventions included in the systematic review
Primary reference Intervention(s)
STGD
Aleman et al., 2007114 Lutein
Querques et al., 2010125 Nutritional supplements
Röck et al. 2013121 Electrotherapy
Teussink et al., 2015122 Light protection
Dry AMD
Physical therapies
Krenn et al., 2008152 Acupuncture
Pipis et al., 2015162 Blue-light filters
Lavric & Pompe 2014164 Blue-light filters
Nagai et al., 2015163 Blue-light filters
Chong et al., 2011 (abstract)165 Blue-light filters
Blaha et al., 2013179 Haemopheresis
Studnicˇka et al. 2013180 Haemopheresis
Klingel et al., 2010181 Haemopheresis
Koss et al., 2009175 Haemopheresis
Pulido et al., 2006174 Haemopheresis
Rencová et al., 2015177 Haemopheresis
Brunner et al., 2000170 Haemopheresis
Swartz and Rabetoy 1999178 Haemopheresis
Figueroa et al., 1997239 Laser photocoagulation
Guymer et al., 2014232 Laser
Ivandic et al., 2008237 Laser
Luttrull et al., 201696 Laser
Huang et al., 2011223 Laser
Prahs et al., 2010236 Laser
Merry et al., 2016238 Photobiomodulation
Shinoda et al., 2008199 Microcurrent
Chaikin et al., 2015198 Microcurrent
Kondrot et al., 201597 Microcurrent
Kondrot et al., 2002208 Microcurrent
Anastassiou et al., 2013196 Microcurrent
Michael et al., 1993204 Microcurrent
Borrelli et al. 2012248 Oxygen ozone-therapy
Bocci et al., 2011244 Ozone
Hudson et al., 2006250 Telescopes
Qureshi et al., 2015254 Telescopes
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TABLE 47 Studies and interventions included in the systematic review (continued )
Primary reference Intervention(s)
Cell transplant technologies
Schwartz et al., 2015123 RPE transplant
Song et al., 2015271 Stem cell transplant
Ho et al., 2017276 Cell transplants
Pharmacological therapies
Augustin et al. 2013325 Alprostadil
Ladewig et al., 2005326 Alprostadil
Remky et al., 2005328 Dorzolamide
Yehoshua et al., 2014323 Eculizumab
Dugal et al., 2015308 Emixustat
Mata et al., 2013144 Fenretide
Landa et al., 2011330 Glatiramer acetate
Brilliant et al., 2016324 L-dopa
Zhang et al., 2011273 NT-501
Wong et al., 201092 Topical OT-551
Vojnikovic´ et al., 2008334 Prednisolone
Gallego-Pinazo et al., 2011338 Ranibizumab
Petrou et al., 201594 Sirolimus
Wong et al., 2013332 Sirolimus
Maguire et al., 2009293 Statins
Al-Holou 2015291 Statins
Barbosa et al., 2014294 Statins
Vavvas et al., 2016286 Statins
McGwin et al., 2003295 Statins
VanderBeek et al., 2013296 Statins
Kaiserman et al., 2009297 Statins
Fong et al., 2010298 Statins
Etminan et al., 2008285 Statins + ACE inhibitor
Jaffe et al., 2015190 Tandospirone
Cohen et al., 2012335 Trimetazidine
Kaiser et al., 1995336 Visaline
Nutritional supplements
AREDS 132 Antioxidants and zinc
AREDS 2348 Antioxidants, carotenoids and fatty acids
Berrow et al., 2013362 Lutein
Murray et al., 2013363 Lutein
Weigert et al., 2011364 Lutein, lutein + zeaxanthin
Ma et al., 2012a366 Lutein, zeaxanthin
continued
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TABLE 47 Studies and interventions included in the systematic review (continued )
Primary reference Intervention(s)
Huang et al., 2015a192 Lutein, zeaxanthin
Kelly et al., 2014372 Lutein, zeaxanthin
Kelly et al., 2017378 Lutein eggs
Richer et al., 2011367 Lutein, zeaxanthin
Akuffo et al., 2015368 Lutein, zeaxanthin
Peng et al., 2016369 Lutein, zeaxanthin
Wu et al., 2015370 Lutein, zeaxanthin
Trieschmann et al., 2007373 Lutein, zeaxanthin
Arnold et al., 2013371 Lutein, zeaxanthin, long-chain PUFA
Robman et al., 2007374 Lutein, zeaxanthin
Vishwanathan et al., 2009376 Eggs (lutein, zeaxanthin)
Olk et al., 2015375 Triple therapy, zeaxanthin
Beatty et al., 2013354 Lutein, zeaxanthin + others
Bartlett et al., 2007377 Lutein, antioxidants
Richer et al. 2004379 Lutein + carotenoids, antioxidants, vitamins, minerals
Dawczynski et al., 2013380 Lutein, zeaxanthin, omega-3
García-Layana et al., 2013381 Lutein and DHA
Wolf-Schnurrbusch et al., 2015365 Lutein, omega
Piermarocchi et al., 2012382 Lutein, zeaxanthin
Reynolds et al., 2013402 Omega-3
Feher et al., 2005400 Antioxidant and fatty acid
Souied et al., 2013393 DHA
Tao et al., 2016401 Alpha lipoic acid
Cougnard-Grégoire et al., 2016403 Olive oil
Christen et al., 2009406 Vitamin B6, B12, folate
Merle et al., 2016407 Folate and vitamin B12
Gopinath et al., 2013408 Serum homocysteine, folate and vitamin B12
Christen et al., 2007398 Beta-carotene
Christen et al., 2010412 Vitamin E
Christen et al., 2014410 Multivitamins
Cangemi et al., 2007411 Antioxidant and omega 3
Taylor et al., 2002399 Vitamin E
Teikari et al., 1998397 Antioxidants
Ahmadi et al., 2009415 HESA-A
Riazi et al., 2017422 Saffron
Lashay et al., 2016421 Saffron
Piccardi et al., 2012420 Saffron
Falsini et al., 2010417 Saffron
Marangoni et al., 2013418 Saffron
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supplements. Two studies had subgroups of people with dry AMD and STGD,97,98 making a total of six
studies in STGD (see Table 47).
Summary overview of the study characteristics can be seen in Report Supplementary Material 6. There
was a range of study designs, with 60 RCTs and CCTs, 24 cohort studies and cross-sectional studies,
13 single-arm before-and-after studies, 5 case–control studies and 6 case series. Many studies had small
sample sizes, the durations of intervention and follow-up were often short, and there were differences in
the outcomes reported. Further details are provided in Chapters 2–7. Baseline characteristics of participants
are summarised in Report Supplementary Material 6. There was generally poor reporting of baseline
characteristics across the studies. The risk of bias of RCTs and CCTs and quality of non-randomised studies
are summarised in Report Supplementary Material 6. The overall quality of each study are reported within
the results chapters of this report.
Review methods
Inclusion and exclusion criteria
Participants
l People with a confirmed diagnosis of dry AMD or STGD.
Interventions
l Any interventions which aim to preserve or restore vision in dry AMD or STGD.
Clinical experts were asked to identify treatments in development to ensure that all potential treatments
were included in the review.
Exclusions: to avoid overlap we excluded studies on some interventions being reviewed in the NICE guideline
process (e.g. smoking cessation, diagnostic technologies, monitoring and review, and rehabilitation support).
Outcomes
Primary outcomes were those that matter to patients and included:
l visual acuity
l contrast sensitivity
l macular sensitivity
l adverse effects of treatment
l adherence to treatment
l reading speed
l ability to drive
l health-related quality of life
l progression of disease.
Although visual outcomes were preferred, because progression of dry AMD is slow we also included
secondary outcomes where there was good evidence that they are strong predictors of subsequent visual
outcomes. Secondary outcomes that were potentially eligible included:
l rod function (may not correlate with VA as central VA, as measured using VA charts, but depends on
foveal function, and the fovea is cone rich. Rod function is one of the earliest abnormalities detected in
people who will later develop GA in AMD)
l macular pigment density
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l macular function as measured by microperimetry
l RPE thickness
l AF
l drusen volume.
Design
l Randomised controlled trials.
l Controlled clinical trials with a concurrent control group.
l Observational studies.
Exclusions: we excluded observational studies with < 10 participants (or eyes) with the exception in studies
for STGD and studies in stem cell treatments.
Systematic reviews and literature reviews that were identified by the searches were assessed for quality and
summarised if they met quality criteria. Where there was a good-quality systematic review we did not
review the primary studies. Reviews were also used as a source for identifying primary studies.
Study selection and data extraction
Studies were selected for inclusion through a two-stage process using predefined and explicit criteria.
Titles and abstracts from the full literature search results were screened independently by two reviewers
to identify all citations that appeared likely to have met the inclusion criteria. Full manuscripts of relevant
studies were then retrieved and assessed for eligibility by one reviewer and checked by a second reviewer.
Studies published as abstracts or conference presentations were only included if sufficient details were
presented to allow an appraisal of the methodology and the assessment of results to be undertaken. As
far as possible, full papers or abstracts describing the same study were linked together, with the article
reporting key outcomes designated as the primary publication.
Data were extracted by one reviewer using a standard data extraction form and checked by a second
reviewer. At each stage, any disagreements between reviewers were resolved by consensus or if necessary
by arbitration by a third reviewer.
Method of data synthesis
Studies were synthesised through a narrative review with tabulation of results of included studies. Formal
synthesis through meta-analysis was not possible because studies were not of sufficient quality and were
heterogeneous in terms of participant characteristics, outcomes and study design.
Search strategies
MEDLINE, EMBASE, Web of Science and The Cochrane Library were searched from 2005 to 13 July 2017
for reviews, journal articles and meeting abstracts. Searches were limited to English language only.
Initial searches of all databases were undertaken in June 2016 and updated searches were run in
June 2017 to check for any articles added in the previous year. The ARVO website was also searched
for meeting abstracts.
References of reviews were checked for relevant studies and clinical experts were also consulted for any
other relevant literature.
After removal of duplicate articles and screening out obviously irrelevant articles on the basis of their titles,
the titles and abstracts of 7948 articles were screened for inclusion by two reviewers (PR, GH) and checked
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by a third (NW). The full texts of 398 articles were obtained for further screening and checking of
references and 112 articles were included in the final report.
ClinicalTrials.gov, the WHO search portal and UK Clinical Trials gateway were searched for ongoing and
recently completed clinical trials.
MEDLINE
1. (age related macular degeneration or age related maculopathy or AMD or ARMD or stargardt* or
geographic atrophy).tw.
2. (therap* or intervention* or treatment* or prevent* or delay* or restore or preserve or trial).tw.
3. (telescop* or retinal implant* or intra-ocular lens* or intraocular lens* or IOLs).tw.
4. 2 or 3
5. 1 and 4
6. (age and macular degeneration).m_titl.
7. (ARMD or AMD or stargardt* or geographic atrophy).m_titl.
8. 6 or 7
9. (dry adj3 (age-related macular degeneration or ARMD or AMD)).tw.
10. ((early or intermediate) adj3 (age-related macular degeneration or ARMD or AMD)).tw.
11. ((nonexudative or non-exudative) adj3 (age-related macular degeneration or AMD or ARMD)).tw.
12. ((non-neovascular or nonneovascular) adj3 (age-related macular degeneration or ARMD or AMD)).tw
13. ((varying or various or different) adj3 (age-related macular degeneration or ARMD or AMD)).tw.
14. geographic atrophy.tw.
15. (atrophic adj3 (age related macular degeneration or AMD or ARMD)).tw.
16. stargardt*.mp.
17. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 5 or 8 or 17
19. limit 18 to yr=‘2005 -Current’
20. (comment or letter or editorial).pt.
21. 19 not 20
22. limit 21 to english language
Years searched: Ovid MEDLINE(R) 1946 to June Week 4 2016, Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations July 01, 2016.
Updated search: Ovid MEDLINE(R) 1946 to June Week 4 2017; Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations July 12, 2017
EMBASE
1. (age related macular degeneration or age related maculopathy or AMD or ARMD or stargardt* or
geographic atrophy).tw.
2. (therap* or intervention* or treat* or prevent* or delay* or restore or preserve or trial).tw.
3. (telescop* or retinal implant* or intra-ocular lens* or intraocular lens* or IOLs).tw.
4. 2 or 3
5. 1 and 4
6. (age and macular degeneration).m_titl.
7. (ARMD or AMD or stargardt* or geographic atrophy).m_titl.
8. 6 or 7
9. (dry adj2 (age-related macular degeneration or ARMD or AMD)).tw.
10. ((early or intermediate) adj2 (age-related macular degeneration or ARMD or AMD)).tw.
11. ((nonexudative or non-exudative) adj2 (age-related macular degeneration or AMD or ARMD)).tw.
12. ((non-neovascular or nonneovascular) adj2 (age-related macular degeneration or ARMD or AMD)).tw.
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13. ((varying or various or different) adj2 (age-related macular degeneration or ARMD or AMD)).tw.
14. geographic atrophy.tw.
15. (atrophic adj3 (age related macular degeneration or AMD or ARMD)).tw.
16. stargardt*.tw.
17. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 5 or 8 or 17
19. exp geographic atrophy/
20. exp age related macular degeneration/
21. exp Stargardt disease/
22. 19 or 20 or 21
23. 2 and 22
24. 18 or 23
25. limit 24 to yr=‘2005 -Current’
26. (comment or letter or editorial).pt.
27. (neovascular or neo-vascular or wet or exudative or ranibizumab or bevacizumab or aflibercept).m_titl.
28. 26 or 27
29. 25 not 28
Years searched: OVID EMBASE 1974 to 2016 Week 27; updated search from 2016 to 2017 Week 28.
Web of Science
TITLE: (age related macular degeneration or age related maculopathy or stargardt* or geographic atrophy)
AND TOPIC: (therap* or intervention* or treat* or prevent* or delay* or restore or progression or
telescop* or retinal implant* or intra-ocular lens* or intraocular lens* or IOLs)
Years searched: 2005 to 5 July 2016; updated search: 2016 to 13 July 2017.
The Cochrane Library
Searched the Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials.
Search terms:
age related macular degeneration or age related maculopathy or stargardt* or geographic atrophy in
Record Title AND therap* or intervention* or treat* or prevent* or delay* or restore or progression or
telescop* or retinal implant* or intra-ocular lens* or intraocular lens* or IOLs in Title, Abstract, Keywords
Dates searched: June 2016 and updated in July 2017.
Clinical trials and ongoing studies
Searched ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) and UK Clinical
Trials gateway.
Terms used: ‘age related macular degeneration’ or ‘geographic atrophy’ or AMD or ‘stargardt’
or ‘stargardt’s’.
Searched in June 2016 and updated searches in December 2016 and July 2017.
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FIGURE 2 The PRISMA flow diagram.
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